Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34000.0 | 2015-10-05 00:00:00 UTC | Novartis' (NVS) Sandoz Files for Enbrel Biosimilar in the U.S. | ABT | https://www.nasdaq.com/articles/novartis-nvs-sandoz-files-for-enbrel-biosimilar-in-the-u.s.-2015-10-05 | nan | nan | NovartisNVS announced that the FDA has accepted its generic arm, Sandoz's Biologics License Application (BLA) for its proposed biosimilar to Amgen's AMGN blockbuster drug, Enbrel (etanercept).
The application was approved under the 351 (k) pathway. Enbrel, a tumor necrosis factor alpha (TNF-alpha) inhibitor, is approved in the U.S. for moderately to severely active rheumatoid arthritis (RA), chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis.
Sandoz is seeking approval for all approved indications. We note that Sandoz continues to advance its portfolio of biosimilars. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen. Zarxio became the first FDA-approved biosimilar to b | NovartisNVS announced that the FDA has accepted its generic arm, Sandoz's Biologics License Application (BLA) for its proposed biosimilar to Amgen's AMGN blockbuster drug, Enbrel (etanercept). Enbrel, a tumor necrosis factor alpha (TNF-alpha) inhibitor, is approved in the U.S. for moderately to severely active rheumatoid arthritis (RA), chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen. | NovartisNVS announced that the FDA has accepted its generic arm, Sandoz's Biologics License Application (BLA) for its proposed biosimilar to Amgen's AMGN blockbuster drug, Enbrel (etanercept). The application was approved under the 351 (k) pathway. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen. | NovartisNVS announced that the FDA has accepted its generic arm, Sandoz's Biologics License Application (BLA) for its proposed biosimilar to Amgen's AMGN blockbuster drug, Enbrel (etanercept). Enbrel, a tumor necrosis factor alpha (TNF-alpha) inhibitor, is approved in the U.S. for moderately to severely active rheumatoid arthritis (RA), chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen. | The application was approved under the 351 (k) pathway. Enbrel, a tumor necrosis factor alpha (TNF-alpha) inhibitor, is approved in the U.S. for moderately to severely active rheumatoid arthritis (RA), chronic moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis. Last month, the division launched Zarxio in the U.S., the biosimilar version of Amgen's another blockbuster drug, Neupogen. |
34001.0 | 2015-10-02 00:00:00 UTC | Notable ETF Outflow Detected - VIG, ABT, LMT, TXN | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-vig-abt-lmt-txn-2015-10-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $143.7 million dollar outflow -- that's a 0.8% decrease week over week (from 249,326,912 to 247,376,912). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $143.7 million dollar outflow -- that's a 0.8% decrease week over week (from 249,326,912 to 247,376,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Lockheed Martin Corp. (Symbol: LMT) is down about 1.1%, and Texas Instruments Inc. (Symbol: TXN) is lower by about 2.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $143.7 million dollar outflow -- that's a 0.8% decrease week over week (from 249,326,912 to 247,376,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $73.03. |
34002.0 | 2015-10-01 00:00:00 UTC | Novartis Announces Positive Data on Arthritis Drug Cosentyx | ABT | https://www.nasdaq.com/articles/novartis-announces-positive-data-on-arthritis-drug-cosentyx-2015-10-01 | nan | nan | NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis.
The results were published in the New England Journal of Medicine .
The multi-center, randomized, placebo-controlled phase III study was conducted to evaluate the efficacy of Cosentyx in IL-17A inhibition in patients suffering from psoriatic arthritis. The study met its primary endpoint as Cosentyx demonstrated a 20% reduction in the American College of Rheumatology response criteria (ACR 20) at the end of week 24. The study showed that treatment with Cosentyx resulted in rapid and significant clinical improvements versus placebo.
Moreover, Cosentyx met all secondary endpoints, including improvements in skin and joint diseases, and joint structural damage progression. It was seen that approximately half of the patients in both Cosentyx-treated dose groups (150-mg and 75-mg) achieved an ACR 20 response as compared to only 17.3% in the placebo arm.
We remind investors that Cosentyx (at a dose of 300 mg) was approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients in Jan 2015. The drug was also approved in the U.S. as a treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy (light therapy).
Novartis made regulatory submissions across the world for the indication of psoriatic arthritis and ankylosing spondylitis. A potential label expansion of the drug will further boost its growth prospects.
We also note that Novartis had undertaken a series of actions to reorganize its portfolio in 2014 in order to focus on its core businesses of pharmaceuticals, eye care and generics. However, Novartis is expected to face headwinds this year in the form of generic competition for some products as well as negative currency movement.
Novartis currently carries a Zacks Rank #4 (Sell). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The multi-center, randomized, placebo-controlled phase III study was conducted to evaluate the efficacy of Cosentyx in IL-17A inhibition in patients suffering from psoriatic arthritis. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . We remind investors that Cosentyx (at a dose of 300 mg) was approved in Europe as a first-line systemic treatment of moderate-to-severe plaque psoriasis in adult patients in Jan 2015. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. | Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . NovartisNVS announced results from a phase III study, FUTURE 1, on Cosentyx for the treatment of psoriatic arthritis. |
34003.0 | 2015-10-01 00:00:00 UTC | Celsion Begins Patient Enrollment in Ovarian Cancer Study | ABT | https://www.nasdaq.com/articles/celsion-begins-patient-enrollment-in-ovarian-cancer-study-2015-10-01 | nan | nan | Celsion CorporationCLSN announced that it has enrolled the first patient in a phase Ib dose escalating clinical trial, OVATION.
The study will combine GEN-1, with the standard-of-care for the treatment of newly-diagnosed patients suffering from ovarian cancer, who will undergo neoadjuvant chemotherapy. GEN-1 is Celsion's DNA-based immunotherapy.
The study is being conducted to identify a safe, tolerable and therapeutically active dose of GEN-1 by recruiting and maximizing an immune response.
The trial will enroll three to six patients per dose level, and evaluate safety and efficacy of the therapy. It will also determine an optimal dose for a follow-on phase I/II study combining GEN-1 with Avastin and Doxil.
Moreover, the study aims to assess how cytokine-based compounds such as GEN-1 directly affects ovarian cancer cells and the tumor microenvironment in newly diagnosed patients.
Celsion plans to initiate the trial in two additional sites in the coming months. Interim results from the study are expected in the fourth quarter of 2015. Additionally, Celsion expects to continue the study into the first half of 2015 with higher doses of GEN-1.
Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer.
Meanwhile, GEN-1 also showed preclinical activity in glioblastoma multiforme (brain cancer). Consequently, Celsion plans to initiate a phase I study.
We note that Celsion's lead program, ThermoDox, is currently in a phase III study for primary liver cancer and a phase II study for recurrent chest wall breast cancer.
Celsion currently carries a Zacks Rank #2 (Buy). Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry the same rank as Celsion.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CELSION CORP (CLSN): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Celsion CorporationCLSN announced that it has enrolled the first patient in a phase Ib dose escalating clinical trial, OVATION. | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer. | Click to get this free report CELSION CORP (CLSN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably placed stocks in the health care sector include Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Earlier, Celsion had reported positive safety and encouraging results from a phase I study with GEN-1, when given as monotherapy in patients with peritoneally metastasized ovarian cancer and in combination with PEGylated doxorubicin in patients suffering from platinum-resistant ovarian cancer. |
34004.0 | 2015-09-30 00:00:00 UTC | Roche Presents Positive Data on Respiratory Drug Esbriet | ABT | https://www.nasdaq.com/articles/roche-presents-positive-data-on-respiratory-drug-esbriet-2015-09-30 | nan | nan | RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. Data was presented at the European Respiratory Society congress in Amsterdam.
The results showed a 38% reduction in risk of death in patients suffering from IPF, who continued treatment with Esbriet for two years as compared with placebo.
The results reinforced the efficacy of Esbriet in reducing the risk of death in the long run in IPF patients. At the end of one year, the study had shown a 48%reduction in the risk of mortality after treatment with Esbriet.
Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet.
We remind investors that Roche had added Esbriet to its respiratory portfolio following the acquisition of InterMune in Sep 2014. Esbriet was approved by the FDA in 2014 for the treatment of IPF. The drug was approved in Europe in 2011.
Roche's respiratory portfolio includes Xolair for severe asthma, Pulmozyme for cystic fibrosis, and Esbriet. The company also has a pipeline candidate - lebrikizumab - in phase III for severe uncontrolled asthma and targets IL-13. We are encouraged by Roche's efforts to broaden its drug portfolio beyond oncology.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . RocheRHHBY announced positive data on idiopathic pulmonary fibrosis (IPF) drug, Esbriet from two phase III studies - ASCEND and CAPACITY. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Moreover, an ad-hoc analysis of the pooled data from ASCEND and CAPACITY showed that patients, who were hospitalized within the first six months of treatment, showed reduced risk of disease progression or death by more than two-thirds at one year on continued treatment with Esbriet. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked health care stocks are Abbott Laboratories ABT , AbbVie Inc. ABBV and Novo Nordisk A/S NVO . Esbriet was approved by the FDA in 2014 for the treatment of IPF. |
34005.0 | 2015-09-28 00:00:00 UTC | AbbVie Updates on Viekirax and Rheumatoid Arthritis Pipeline | ABT | https://www.nasdaq.com/articles/abbvie-updates-on-viekirax-and-rheumatoid-arthritis-pipeline-2015-09-28 | nan | nan | AbbVie Inc.ABBV announced a series of regulatory/pipeline updates. The company's Viekirax has been approved by the Japanese Ministry of Health, Labour and Welfare as a new interferon and ribavirin-free treatment option for patients suffering from chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis. Viekirax (with or without ribavirin) is already approved in Europe in combination with Exviera for the treatment of GT1 chronic HCV patients, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. Additionally, Viekirax is approved in the EU for use with ribavirin in genotype 4 chronic hepatitis C patients.
Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. Both studies evaluated patients suffering from moderate-to-severe rheumatoid arthritis, who responded inadequately to prior anti-TNF (TNF-IR) or methotrexate (MTX-IR) treatment, respectively. The primary endpoint of both studies was the percentage of patients achieving an ACR20 response after 12 weeks of treatment.
AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. In the TNF-inadequate responder population, ACR20 responses were up to 73%, while that in the MTX-inadequate responder population was up to 82%. The company intends to advance the once-daily formulation of ABT-494 to phase III studies for the treatment of rheumatoid arthritis by 2015 end.
AbbVie is also evaluating ABT-494 in a phase II study for the treatment of Crohn's disease.
Meanwhile, following a thorough review of available data, AbbVie decided not to exercise its right to in-license a JAK1 inhibitor, filgotinib, from Galapagos NV GLPG and terminated its agreement with the company for the development of filgotinib. Galapagos will advance filgotinib to phase III development for rheumatoid arthritis in early 2016.
AbbVie currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
GALAPAGOS -ADR (GLPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. The company intends to advance the once-daily formulation of ABT-494 to phase III studies for the treatment of rheumatoid arthritis by 2015 end. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GALAPAGOS -ADR (GLPG): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. | Additionally, the company announced positive results from two double-blind, placebo-controlled, dose-ranging phase II studies (BALANCE-I and BALANCE-II) on its rheumatoid arthritis candidate, ABT-494. AbbVie stated that both studies achieved impressive levels of ACR20 at week 12 across all doses of ABT-494, except the lowest dose in the BALANCE-II study. The company intends to advance the once-daily formulation of ABT-494 to phase III studies for the treatment of rheumatoid arthritis by 2015 end. |
34006.0 | 2015-09-28 00:00:00 UTC | Novo Nordisk's Tresiba & Ryzodeg Gain Entry into the U.S. | ABT | https://www.nasdaq.com/articles/novo-nordisks-tresiba-ryzodeg-gain-entry-into-the-u.s.-2015-09-28 | nan | nan | Novo NordiskNVO announced that Tresiba and Ryzodeg 70/30 have gained the long-awaited FDA approval for the treatment of diabetes mellitus in adults.
Novo Nordisk intends to launch Tresiba in the U.S. during the first quarter of 2016. The drug will be available in the FlexTouch device in two formulations enabling maximum doses of 80 units and 160 units per injection.
We remind investors that on Mar 26, 2015, Novo Nordisk had announced its decision to submit results from a pre-specified interim analysis of a cardiovascular outcomes study, DEVOTE, to the FDA as part of a Class II resubmission of the new drug applications (NDAs) for Tresiba and Ryzodeg. The DEVOTE study is being conducted per requirements mentioned in a complete response letter served by the FDA related to Tresiba and Ryzodeg in Feb 2013. The study is expected to be complete by mid-2016.
Novo Nordisk said that in order to preserve integrity of the DEVOTE study the company has maintained a small team, which enjoys access to data from the study.
Meanwhile, Novo Nordisk has submitted an NDA for Xultophy to the FDA. The company is looking to get it approved in the U.S. for the treatment of type II diabetes. While Tresiba and Ryzodeg are already approved for the treatment of type I and type II diabetes in Europe and Japan, Xultophy is approved in the EU for the treatment of type II diabetes mellitus in adults.
Additionally, Novo Nordisk announced encouraging headline results from the second phase IIIa study (SUSTAIN 3) on its once-weekly GLP-1 analogue, semaglutide. The study showed that patients treated with semaglutide (1.0 mg) achieved a statistically significant and superior improvement of 1.5% in HbA1c compared to a 0.9% improvement in HbA1c in patients receiving a once-weekly dose of AstraZeneca's AZN Bydureon (2.0 mg) from a mean baseline HbA1c of 8.4%.
Novo Nordisk carries a Zacks Rank #2 (Buy). Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . Both carry the same Zacks Rank as Novo Nordisk.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that on Mar 26, 2015, Novo Nordisk had announced its decision to submit results from a pre-specified interim analysis of a cardiovascular outcomes study, DEVOTE, to the FDA as part of a Class II resubmission of the new drug applications (NDAs) for Tresiba and Ryzodeg. | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . We remind investors that on Mar 26, 2015, Novo Nordisk had announced its decision to submit results from a pre-specified interim analysis of a cardiovascular outcomes study, DEVOTE, to the FDA as part of a Class II resubmission of the new drug applications (NDAs) for Tresiba and Ryzodeg. | Other well-ranked stocks in the health care sector include Abbott Laboratories ABT and Eli Lilly and Company LLY . Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Novo NordiskNVO announced that Tresiba and Ryzodeg 70/30 have gained the long-awaited FDA approval for the treatment of diabetes mellitus in adults. |
34007.0 | 2015-09-24 00:00:00 UTC | Noteworthy ETF Inflows: VIG, ABT, LMT, MON | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vig-abt-lmt-mon-2015-09-24 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 247,926,838 to 249,326,912). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 247,926,838 to 249,326,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 1.6%, Lockheed Martin Corp. (Symbol: LMT) is off about 1.3%, and Monsanto Co. (Symbol: MON) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 247,926,838 to 249,326,912). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $72.83. |
34008.0 | 2015-09-21 00:00:00 UTC | 10 Stocks That Even the Pope Could Love | ABT | https://www.nasdaq.com/articles/10-stocks-even-pope-could-love-2015-09-21 | nan | nan | Comfort the sick; feed and clothe the poor; provide shelter for the homeless. Pope Francis, who begins his first visit to the U.S. on September 22, has focused on issues of social justice since being named to the Catholic Church's top slot in 2013. But even before Francis became pope, several mutual funds applied the teachings of the church to their selection of stocks and bonds. In light of the pope's visit, we've taken a look at the stock holdings of three Catholic values fund families--Ave Maria, LKCM Aquinas and Epiphany FFV (FFV stands for Faith and Family Values)--which all base their investment choices on the ecumenical constraints of the church. That means barring investments in companies that facilitate abortions or produce pornography, among other things.
Even with these exclusions, Catholic values funds have plenty of companies to choose from. So we took a look at their top holdings in search of attractive stocks. Here are 10 that savvy investors--and even the pope--could love. (Share prices and related figures are as of September 18.)
Health care
Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). AbbVie is best known for its blockbuster autoimmune drug, Humira, which is used to treat arthritis, Crohn's disease and psoriasis. The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. But analysts say that Humira won't be easy to replicate and, in any case, AbbVie has an impressive list of new medications, treating everything from fibroid tumors to hepatitis C and leukemia, working their way through its labs. Thanks in part to the recent pullback--the stock has dropped 13% since mid-July--the shares sell for just 13 times estimated year-ahead earnings. Plus, the stock yields a healthy 3.3%. By comparison, Standard & Poor's 500-stock index sells for 16 times estimated year-ahead profits and yields 2.2%. UBS analyst Marc Goodman rates AbbVie a buy, with a one-year price target of $81.
AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. When Abbott spun off its brand-name drug enterprise in AbbVie, it kept its generic pharmaceutical and medical device businesses, which have continued to grow rapidly. Because of the strong dollar, Abbott expects earnings to dip slightly this year. But analysts see profits rebounding by 11.5% next year. The stock trades for 19 times estimated year-ahead earnings and yields 2.2%. William Blair analyst Margaret Kaczor believes the company's profit estimates are conservative and that the stock is likely to outperform the market over the next year.
St. Jude Medical ( STJ , $67.31), which makes heart devices, is among the top holdings of the Ave Maria Catholic Values Fund ( AVEMX ). St. Jude, fresh off a restructuring aimed at consolidating its manufacturing and supply-chain operations, is expected to post flat earnings in 2015, then see profits rise by 9% next year. But what makes the shares especially compelling, says William Blair analyst Ben Andrew, is St. Jude's planned $3.4 billion purchase of Thoratec, a company that makes medical devices designed for patients with advanced heart failure. Andrew says the deal gives St. Jude entrée to a business with annual sales of $1 billion. That will boost St. Jude's revenues, he says, and revive the stock, which has slumped 13% since mid-July.
Other well-regarded health care stocks that find a place in these ecumenical funds include CVS Health ( CVS , $99.03), which runs drugstores and provides pharmacy-benefits management services; CVS's benefits management rival Express Scripts ( ESRX , $83.92); and medical testing giant Laboratory Corp. of America ( LH , $119.40).
Food and clothing
Coca-Cola Corp. ( KO ) and Costco ( COST ) are key holdings in the Epiphany funds, but the shares are tough to recommend at today's prices. Coke and Costco shares sell for 19 and 26 times projected year-ahead earnings, respectively. But neither company's earnings are expanding quickly enough to justify those P/E ratios. On the surface, Yum Brands ( YUM ), $80.15), which owns the KFC, Pizza Hut and Taco Bell restaurant chains, also looks expensive, trading at 21 times estimated year-ahead earnings. But the stock looks more defensible in light of analyst projections that Yum will deliver double-digit-percentage earnings gains this year and next. Yum is a big player in China, which accounts for 52% of its annual revenues. UBS analyst Keith Siegner says Yum's sales in China are picking up despite the country's slowing economy, and he thinks the stock could reach $116 within a year.
The Ave Maria Growth and Rising Dividend funds own shares in cut-rate clothing retailer Ross Stores ( ROST , $49.12). The stock, which is down about 13% since midAugust, is now reasonably priced, says William Blair analyst Daniel Hofkin. Investors are worried about Ross's rising inventory levels and relatively modest earnings projections. But Hofkin says that Ross boosted inventory this summer because it was able to get closeout merchandise at bargain prices. The company has a long history of successfully unloading its opportunistic buys. Indeed, Hofkin expects the rising inventory level to simply lead to stronger sales in coming quarters.
Housing
The stocks of home-improvement retailers Home Depot ( HD , $115.12) and Lowe's ( LOW , $68.19) are owned by the Aquinas Growth and Ave Maria Rising Dividend funds, respectively. Although the stocks aren't cheap--Home Depot sells for 20 times year-ahead earnings, while Lowe's sells for 19 times projected earnings--UBS analyst Michael Lasser says both are attractive because the companies are experiencing growth spurts. Analysts on average expect Home Depot's earnings to increase 16% in the fiscal year that ends in January and 15% in the following fiscal year, and they project that Lowe's earnings will rise by 22% in the January 2016 fiscal year and 20% the following year.
See Also: 10 Stocks for Socially Conscious Investors
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. Health care Spun off from Abbott Labs in January 2013, drugmaker AbbVie (symbol ABBV , $61.22) is owned by two of the three fund companies that specialize in Catholic causes: LKCM's Aquinas Growth ( AQEGX ) and Epiphany FFV ( EPVNX ). The stock, which has climbed 74% since AbbVie began trading as a separate entity, has hit a rough patch lately, partly due to worries that the company could lose protection for some of its Humira patents next year. | AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. In light of the pope's visit, we've taken a look at the stock holdings of three Catholic values fund families--Ave Maria, LKCM Aquinas and Epiphany FFV (FFV stands for Faith and Family Values)--which all base their investment choices on the ecumenical constraints of the church. Housing The stocks of home-improvement retailers Home Depot ( HD , $115.12) and Lowe's ( LOW , $68.19) are owned by the Aquinas Growth and Ave Maria Rising Dividend funds, respectively. | AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. In light of the pope's visit, we've taken a look at the stock holdings of three Catholic values fund families--Ave Maria, LKCM Aquinas and Epiphany FFV (FFV stands for Faith and Family Values)--which all base their investment choices on the ecumenical constraints of the church. Although the stocks aren't cheap--Home Depot sells for 20 times year-ahead earnings, while Lowe's sells for 19 times projected earnings--UBS analyst Michael Lasser says both are attractive because the companies are experiencing growth spurts. | AbbVie's former parent, Abbott Labs ( ABT , $43.33) is a top holding in both Ave Maria Growth ( AVEGX ) and Ave Maria Rising Dividend ( AVEDX ) funds. By comparison, Standard & Poor's 500-stock index sells for 16 times estimated year-ahead profits and yields 2.2%. The stock trades for 19 times estimated year-ahead earnings and yields 2.2%. |
34009.0 | 2015-09-17 00:00:00 UTC | Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG | ABT | https://www.nasdaq.com/articles/daily-dividend-report-orcl-abt-dhr-ben-bxp-apa-ess-slg-2015-09-17 | nan | nan | Oracle Corporation ( ORCL ) declared a quarterly cash dividend of $0.15 per share of outstanding common stock. This dividend will be paid to stockholders of record as of the close of business on October 14, 2015, with a payment date of October 28, 2015.
Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. This marks the 367th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Nov. 15, 2015, to shareholders of record at the close of business on Oct. 15, 2015.
Danaher Corporation ( DHR ) has approved a regular quarterly dividend of $0.135 per share payable on October 30, 2015 to holders of record on September 25, 2015.
Agilent Technologies ( A ) that a quarterly dividend of 10 cents per share of common stock will be paid on Oct. 21, 2015, to all shareholders of record as of the close of business on Sept. 29, 2015.
Franklin Resources ( BEN ) announced a quarterly cash dividend in the amount of $0.15 per share payable on October 15, 2015 to stockholders of record holding shares of common stock at the close of business on September 30, 2015. The quarterly dividend of $0.15 per share is equivalent to the dividend paid for the prior quarter and represents a 25% increase over the quarterly dividend paid for the same quarter last year.
Boston Properties (BXP) declared a regular quarterly cash dividend of $0.65 per share of common stock for the period July 1, 2015 to September 30, 2015 payable on October 30, 2015 to shareholders of record as of the close of business on September 30, 2015.
Apache (APA) has declared regular cash dividends on the company's common shares. The dividend on common shares of 25 cents per share is payable on Nov. 23, 2015, to stockholders of record on Oct. 22, 2015.
Essex Property Trust (ESS) has declared a regular quarterly cash dividend of $1.44 per common share payable October 15, 2015 to shareholders of record as of September 30, 2015.
SL Green Realty (SLG) has declared a quarterly dividend of $0.60 per share of common stock. The dividend is payable on October 15, 2015 to shareholders of record at the close of business on September 30, 2015.
VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Danaher Corporation ( DHR ) has approved a regular quarterly dividend of $0.135 per share payable on October 30, 2015 to holders of record on September 25, 2015. | VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Boston Properties (BXP) declared a regular quarterly cash dividend of $0.65 per share of common stock for the period July 1, 2015 to September 30, 2015 payable on October 30, 2015 to shareholders of record as of the close of business on September 30, 2015. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Franklin Resources ( BEN ) announced a quarterly cash dividend in the amount of $0.15 per share payable on October 15, 2015 to stockholders of record holding shares of common stock at the close of business on September 30, 2015. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ORCL, ABT, DHR, A, BEN, BXP, APA, ESS, SLG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Oracle Corporation ( ORCL ) declared a quarterly cash dividend of $0.15 per share of outstanding common stock. |
34010.0 | 2015-09-17 00:00:00 UTC | Thursday's ETF with Unusual Volume: IHI | ABT | https://www.nasdaq.com/articles/thursdays-etf-unusual-volume-ihi-2015-09-17 | nan | nan | The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. Shares of IHI were up about 1% on the day.
Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. Nevro ( NVRO ) is the component faring the best Thursday, higher by about 11.2% on the day, while Cynosure ( CYNO ) is lagging other components of the iShares U.S. Medical Devices ETF, trading lower by about 1.1%.
VIDEO: Thursday's ETF with Unusual Volume: IHI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. Nevro ( NVRO ) is the component faring the best Thursday, higher by about 11.2% on the day, while Cynosure ( CYNO ) is lagging other components of the iShares U.S. Medical Devices ETF, trading lower by about 1.1%. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. Nevro ( NVRO ) is the component faring the best Thursday, higher by about 11.2% on the day, while Cynosure ( CYNO ) is lagging other components of the iShares U.S. Medical Devices ETF, trading lower by about 1.1%. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. VIDEO: Thursday's ETF with Unusual Volume: IHI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Thursday were Boston Scientific ( BSX ), trading up about 0.9% with over 3.1 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 1.5% on volume of over 2.6 million shares. The iShares U.S. Medical Devices ETF ( IHI ) is seeing unusually high volume in afternoon trading Thursday, with over 978,000 shares traded versus three month average volume of about 77,000. Shares of IHI were up about 1% on the day. |
34011.0 | 2015-09-16 00:00:00 UTC | VIG, ABT, GD, FDX: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/vig-abt-gd-fdx-large-outflows-detected-etf-2015-09-16 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $56.6 million dollar outflow -- that's a 0.3% decrease week over week (from 248,676,439 to 247,926,838). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $56.6 million dollar outflow -- that's a 0.3% decrease week over week (from 248,676,439 to 247,926,838). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, General Dynamics Corp. (Symbol: GD) is down about 0.3%, and FedEx Corp (Symbol: FDX) is lower by about 3.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $56.6 million dollar outflow -- that's a 0.3% decrease week over week (from 248,676,439 to 247,926,838). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $47.70 per share, with $83.28 as the 52 week high point - that compares with a last trade of $75.72. |
34012.0 | 2015-09-04 00:00:00 UTC | Why September's Volatility Is a Huge Opportunity for Options Trading | ABT | https://www.nasdaq.com/articles/why-septembers-volatility-huge-opportunity-options-trading-2015-09-04 | nan | nan | MoneyMorning.com Report - The last few weeks of trading have been tough to say the least. After the crash on Aug. 24 that sucked trillions from the markets in a matter of minutes, the markets clawed their way back and held their own for about a week. Then, just two days ago, they fell again, this time dropping by 3%.
It's no secret that I think this volatility will continue, at least in the short term, and the best way to weather the storm is to make sure you've got options in your portfolio.
Today, I'm going to tell you about the different kinds of volatility and how they affect the markets generally and options specifically. Then I'm going to give you a road map to deal with the volatility that I see continuing for the next few months, including a few of my favorite options trading strategies.
Let's get started...
Two Kinds of Volatility
There are two kinds of volatility that traders talk about with regard to options: statistical volatility and implied volatility. Statistical volatility (SV), also referred to as historical volatility, doesn't have much of an impact on options, but there are a few ways options traders can use it to their advantage, as you'll see in a moment.
SV is measured by the prior price moves of a stock, ETF , or any underlying security. It is typically calculated by measuring one day's closing price against the next.
It is usually shown as the standard deviation of the security's daily returns over a look-back period. It is usually an annualized number regardless of the length of that period.
When looking at options, SV can be used to compare one underlying with the other. For example, if one stock has a higher SV than the other, that would indicate a stock with more telling price moves over a given time period.
Statistical volatility has its place, but it is implied volatility (IV) that options traders are most focused on because of its impact on options pricing.
IV is a way to see what the markets expect the future volatility in the price of the stock will be between now and a particular option's expiration.
In a sense, IV is a byproduct of the option pricing model. It cannot be calculated, but once the other components are - such as short-term interest rates, time until expiry, strike, price, etc. - then the implied volatility can be assessed.
Implied volatility can be charted, so you don't have to worry about crunching all this data - your brokerage might even have it available online for you.
The list below shows stocks and their one-year IV rankings. That allows us to look at the one-year high and the one-year low, and see if a stock is currently at one extreme or the other, or somewhere in between.
You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. In fact, three of the top four stocks are in the same boat.
Here's How to Play Volatility
Increased statistical volatility is great for us as options traders because, as I've said before, one of the biggest detriments to an options trader is a stock that does not move.
But as long as this current volatility continues, finding stocks that move enough for us to profit on our options is going to be a snap.
So we're going to continue buying calls and puts and using our "loophole" trades to take advantage of statistical volatility.
Here's another way you can use statistical volatility: Measure a stock's SV versus an At the Money (ATM) option's implied volatility.
If the difference between the stock's SV and the option's IV is significant (let's say the stock's SV is 25% while the option's IV is 70%), the numbers could be telling you the markets expect something to happen that may move that stock significantly, like an upcoming earnings announcement or pending FDA approval for one of its drugs.
Implied volatility can be a bit trickier to navigate, but here are a few strategies to keep in mind.
What to do in periods of high implied volatility: If you have a situation where the IV is high relative to its past IV, it would be wise to pass on buying options and look for an option strategy where you can sell that option with high IV.
Credit Spreads: This is another loophole strategy, very similar to the debit spreads I have recommended in the past. In this trade, however, we receive a net credit for entering the position, and we're looking for the spreads to narrow or expire for profit.
Covered Calls: This strategy involves buying the stock and waiting for it to hit a resistance point. If that resistance point coincides with a spike in IV, and if the At the Money or just slightly Out of the Money options have a high IV, you can write calls against the stock and wait for an "IV crush" or a reversion to the mean (when IV falls). Then you can buy back those options, pocket the difference, keep the stock, and repeat the process again.
What to do in periods of low implied volatility: Periods of low IV are a great time to buy options. Here's a quick strategy to take advantage of cheaper options.
Play the "Volatility Rush" on Earnings
First, take a look at the IV about a week or two before earnings. If it's low, you can pick up options on the cheap in anticipation of a "volatility rush" heading into the earnings announcement.
Then, as earnings draws near and the IV gets its rush and the value of the option increases, you can sell for a profit a day or two before the earnings announcement (to avoid the risk of a strong gap against them post earnings). This way you're not playing the earnings announcement, but rather the pre-earnings IV rush.
Here's Your Trading Lesson Summary:
The volatility we've seen in the markets lately isn't going anywhere. For the next few months, it's going to present us with plenty of profit opportunities. Here's what you need to know:
Statistical volatility, also known as historical volatility, measures the price movement of a given security. Implied volatility is what the markets expect the future volatility will be.
Statistical volatility can be used to pinpoint stocks that move in price so we can target the best options.
Implied volatility is an important component of options prices. Investors should buy options during periods of low IV and sell options during periods of high IV.
Follow us on Twitter @moneymorning.
The "Three Cs" of Risk:Pundits have all sorts of theories as to what's driving the recent market chaos. Let them speculate. These are the three main drivers of the volatility we're seeing now.Understand what they are, and you'll come out on top...
To get full access to all Money Morning content including our latest Premium Report, "How to Make 2015 Your Wealthiest Year Ever," click here
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience - for free . Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.
Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. Then I'm going to give you a road map to deal with the volatility that I see continuing for the next few months, including a few of my favorite options trading strategies. Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. | You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. If the difference between the stock's SV and the option's IV is significant (let's say the stock's SV is 25% while the option's IV is 70%), the numbers could be telling you the markets expect something to happen that may move that stock significantly, like an upcoming earnings announcement or pending FDA approval for one of its drugs. What to do in periods of low implied volatility: Periods of low IV are a great time to buy options. | You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. Let's get started... Two Kinds of Volatility There are two kinds of volatility that traders talk about with regard to options: statistical volatility and implied volatility. If the difference between the stock's SV and the option's IV is significant (let's say the stock's SV is 25% while the option's IV is 70%), the numbers could be telling you the markets expect something to happen that may move that stock significantly, like an upcoming earnings announcement or pending FDA approval for one of its drugs. | You can see Abbott Laboratories ( ABT ) is currently at the high range of its one-year IV. IV is a way to see what the markets expect the future volatility in the price of the stock will be between now and a particular option's expiration. So we're going to continue buying calls and puts and using our "loophole" trades to take advantage of statistical volatility. |
34013.0 | 2015-08-27 00:00:00 UTC | Edwards Completes CardiAQ Buyout, Resolves FORTIS Issue | ABT | https://www.nasdaq.com/articles/edwards-completes-cardiaq-buyout-resolves-fortis-issue-2015-08-27 | nan | nan | Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of percutaneous mitral heart valve replacement system.
This news comes close on the heels of Edwards' peer Medtronic plc's MDT announcement of its plan to foray into the billion dollar transcatheter mitral valve replacement (TMVR) market through the acquisition of California-based medical device startup - Twelve, Inc.
As far as the financial terms of the deal are concerned, $350 million of the total $400 million purchase price has been paid in cash. The remaining amount will be paid once CardiAQ's mitral valve replacement system wins a European regulatory milestone.
The acquisition reflects Edwards' efforts to revolutionize the treatment of cardiac patients with mitral valve disorders, who at the moment, are not adequately served. This is in sync with the company's primary strategy to create valuable therapies that transform patient care. Edwards expects this acquisition to be slightly dilutive to its earnings per share in 2015.
Post-acquisition, the corporations believe their skilled expertise and valued experience in heart valve construction will jointly facilitate significant advancement in their respective mitral valve replacement systems - the FORTIS and CardiAQ systems.
The CardiAQ system, which incorporates multiple delivery approaches with a single valve, is a promising mitral valve technology that has already won the U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval to conduct an early feasibility study of upto 20 patients. Meanwhile, a CE Mark study for this system is in the cards in Europe.
With transcatheter aortic valve replacement (TAVR) having already made a name for itself, cardiology has shifted focus toward the next major frontier in interventional structural heart technology - transcatheter mitral valve repair (TMVR). Notably, mitral regurgitation is a common disease that affects over 4 million Americans - nearly one in 10 people aged 75 and older.
With the global cardiac prosthetic market estimated to grow at a CAGR of 8.41% over the period 2014-2019, we expect Edwards to capture a larger share of this market potential, effectively backed by the CardiAQ buyout.
On the other hand, the clinical program, aimed at estimating the efficiency of Edwards' FORTIS mitral valve system, had been briefly suspended in May this year. However, in what can be deemed an encouraging update, Edwards recently completed its review and has incorporated protocol revisions related to patient selection, post procedural drug regimens and enhanced imaging surveillance following the procedures. The company also received the FDA approval to proceed with the early feasibility study.
Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. The company recently announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. Separately, Abbott also invested in Cephea Valve Technologies to develop a catheter-based mitral valve replacement therapy and secured an option to buy the company outright on a future date.
None of the mitral valve technologies of any of these medical device makers are currently available for sale in any country. We believe, once these technologies get their commercial go-ahead, these companies will be in a position to capture a considerable share of this huge market potential.
Currently, Edwards retains a Zacks Rank #3 (Hold). A better-ranked medical product stock is ICU Medical, Inc. ICUI with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. This news comes close on the heels of Edwards' peer Medtronic plc's MDT announcement of its plan to foray into the billion dollar transcatheter mitral valve replacement (TMVR) market through the acquisition of California-based medical device startup - Twelve, Inc. As far as the financial terms of the deal are concerned, $350 million of the total $400 million purchase price has been paid in cash. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of percutaneous mitral heart valve replacement system. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of percutaneous mitral heart valve replacement system. | Apart from Edwards and Medtronic, Abbott Laboratories ABT has also entered the TMVR market. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of percutaneous mitral heart valve replacement system. |
34014.0 | 2015-08-27 00:00:00 UTC | U.S. Stocks Seek to Continue Recovery | ABT | https://www.nasdaq.com/articles/us-stocks-seek-continue-recovery-2015-08-27 | nan | nan | U.S. stock futures were heading for another bullish open despite a stronger-than-expected upward revision to second quarter GDP that could put a September rate hike back on the table. Fueled by Wednesday's record rally on Wall Street, coupled with intervention efforts by the Chinese government, the Dow Jones Industrial Average was expected to open as much as 200 points higher.
Led by consumer spending, the economy grew at an annual pace of 3.7%, revised from 2.3% initially and beating the estimated revision to 3.2%. Price components remained relatively unchanged including the price deflator which was revised to 2.1% from 2.0%.
Also, initial jobless claims declined 6,000 to 271,000 for the week ended August 22, slightly above the estimated 270,000.
Today's remaining data includes the July pending home sales index (expected +1.0%), and the Kansas City Fed manufacturing index (expected -4.0 from July's -7.0).
Investors poured back into riskier assets overnight, encouraged by yesterday's remark from New York Fed Governor William | U.S. stock futures were heading for another bullish open despite a stronger-than-expected upward revision to second quarter GDP that could put a September rate hike back on the table. Fueled by Wednesday's record rally on Wall Street, coupled with intervention efforts by the Chinese government, the Dow Jones Industrial Average was expected to open as much as 200 points higher. Investors poured back into riskier assets overnight, encouraged by yesterday's remark from New York Fed Governor William | Led by consumer spending, the economy grew at an annual pace of 3.7%, revised from 2.3% initially and beating the estimated revision to 3.2%. Price components remained relatively unchanged including the price deflator which was revised to 2.1% from 2.0%. Today's remaining data includes the July pending home sales index (expected +1.0%), and the Kansas City Fed manufacturing index (expected -4.0 from July's -7.0). | U.S. stock futures were heading for another bullish open despite a stronger-than-expected upward revision to second quarter GDP that could put a September rate hike back on the table. Led by consumer spending, the economy grew at an annual pace of 3.7%, revised from 2.3% initially and beating the estimated revision to 3.2%. Today's remaining data includes the July pending home sales index (expected +1.0%), and the Kansas City Fed manufacturing index (expected -4.0 from July's -7.0). | U.S. stock futures were heading for another bullish open despite a stronger-than-expected upward revision to second quarter GDP that could put a September rate hike back on the table. Fueled by Wednesday's record rally on Wall Street, coupled with intervention efforts by the Chinese government, the Dow Jones Industrial Average was expected to open as much as 200 points higher. Led by consumer spending, the economy grew at an annual pace of 3.7%, revised from 2.3% initially and beating the estimated revision to 3.2%. |
34015.0 | 2015-08-27 00:00:00 UTC | Pre-Market Most Active for Aug 27, 2015 : STJ, AAPL, THOR, BAC, XIV, SDRL, RDS/B, QQQ, FB, NFLX, ABT, DB | ABT | https://www.nasdaq.com/articles/pre-market-most-active-aug-27-2015-stj-aapl-thor-bac-xiv-sdrl-rdsb-qqq-fb-nflx-abt-db-2015 | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 45.81 to 4,265.41. The total Pre-Market volume is currently 10,352,943 shares traded.
The following are the most active stocks for the pre-market session :
St. Jude Medical, Inc. ( STJ ) is +3.02 at $72.36, with 3,091,697 shares traded. As reported by Zacks, the current mean recommendation for STJ is in the "buy range".
Apple Inc. ( AAPL ) is +2.05 at $111.74, with 997,728 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Tho | The following are the most active stocks for the pre-market session : St. Jude Medical, Inc. ( STJ ) is +3.02 at $72.36, with 3,091,697 shares traded. As reported by Zacks, the current mean recommendation for STJ is in the "buy range". As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | The total Pre-Market volume is currently 10,352,943 shares traded. As reported by Zacks, the current mean recommendation for STJ is in the "buy range". As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | The total Pre-Market volume is currently 10,352,943 shares traded. The following are the most active stocks for the pre-market session : St. Jude Medical, Inc. ( STJ ) is +3.02 at $72.36, with 3,091,697 shares traded. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | The NASDAQ 100 Pre-Market Indicator is up 45.81 to 4,265.41. The following are the most active stocks for the pre-market session : St. Jude Medical, Inc. ( STJ ) is +3.02 at $72.36, with 3,091,697 shares traded. Apple Inc. ( AAPL ) is +2.05 at $111.74, with 997,728 shares traded. |
34016.0 | 2015-08-26 00:00:00 UTC | Will Medtronic's Twelve Buy Expedite Growth in Mitral Valves? | ABT | https://www.nasdaq.com/articles/will-medtronics-twelve-buy-expedite-growth-in-mitral-valves-2015-08-26 | nan | nan | In an attempt to enter the billion dollar transcatheter mitral valve replacement (TMVR) market, Medtronic plcMDT recently agreed to purchase California-based medical device startup - Twelve, Inc. - for a total cash-and debt-free amount of $458 million. The transaction is expected to close in Oct 2015.
Notably, Twelve was formed through the twelfth spin-off by premier medical device incubator, The Foundry. Twelve is focused on developing a TMVR device that is yet to be commercialized.
On closure of the deal, Medtronic will pay $408 million to Twelve and the remaining $50 million will be payed once Twelve's TMVR device wins CE Mark approval in Europe. Medtronic will incorporate Twelve's TMVR device as part of its Coronary & Structural Heart division within the Cardiac and Vascular Group.
Mitral valve regurgitation, a heart valve disorder characterized by backflow of blood, affected roughly 1.7% of the entire U.S. population in 2014 - comprising the largest segment of the total U.S. population suffering from heart valve-related disorders.
Twelve's TMVR technology has been designed to treat inoperable patients suffering from mitral valve regurgitation. Post-acquisition, Medtronic believes this promising TMVR device, which incorporates a novel technology, will act as a significant growth opportunity for the company. This, in turn, will facilitate Medtronic's expansion in the TMVR space.
Management at Medtronic expects this buyout to meet the company's long-term financial metrics. Further, Medtronic expects the net impact from this deal to be neutral to earnings as the company intends to offset the dilutive impact of the transaction.
If we delve deeper into the TMVR market, we may note that currently, there exists no single approved TMVR device to treat mitral valve regurgitation. No doubt, an array ofmedical device developers, such as Medtronic, is currently targeting to make an impactful foray into this relatively underpenetrated market.
With this aim in view, in July 2015, Edwards Lifesciences Corp. EW agreed to buy CardiAQ Valve Technologies - a privately held medical device developer of percutaneous mitral heart valve replacement system - for $400 million.
Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. Separately, Abbott also invested in Cephea Valve Technologies to develop a catheter-based mitral valve replacement therapy and secured an option to buy the company outright ona future date.
According to marketing analytics firm GlobalData, the compound annual growth rate (CAGR) for transcatheter aortic valve replacement (TAVR) market will increase 19.7% from 2013 to more than $3 billion in 2020. Since the TMVR patient population is almost four times the TAVR patient population, there is no doubt that the TMVR market will be worth more than the TAVR market.
We expect that the Twelve buyout will enable Medtronic to capture a considerable share of this huge market potential. However, since other medical device majors (as mentioned above) are also targeting to invade this market, how fast Medtronic manages to get the approval for the TMVR device is the crucial point.
Currently, Medtronic carries a Zacks Rank #4 (Sell), while both Edwards Lifesciences and Abbott retain a Zacks Rank #3 (Hold). Abetter-ranked medical product stock is ICU Medical, Inc. ICUI , with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
EDWARDS LIFESCI (EW): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. In an attempt to enter the billion dollar transcatheter mitral valve replacement (TMVR) market, Medtronic plcMDT recently agreed to purchase California-based medical device startup - Twelve, Inc. - for a total cash-and debt-free amount of $458 million. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. In an attempt to enter the billion dollar transcatheter mitral valve replacement (TMVR) market, Medtronic plcMDT recently agreed to purchase California-based medical device startup - Twelve, Inc. - for a total cash-and debt-free amount of $458 million. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. In an attempt to enter the billion dollar transcatheter mitral valve replacement (TMVR) market, Medtronic plcMDT recently agreed to purchase California-based medical device startup - Twelve, Inc. - for a total cash-and debt-free amount of $458 million. | Following suit, Abbott Laboratories ABT announced that it will acquire the remaining equities of Minnesota-based Tendyne (those that it already did not own), which is focused on developing minimally invasive mitral valve replacement therapies, for a total price of $250 million. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report EDWARDS LIFESCI (EW): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ICU MEDICAL INC (ICUI): Free Stock Analysis Report To read this article on Zacks.com click here. Twelve's TMVR technology has been designed to treat inoperable patients suffering from mitral valve regurgitation. |
34017.0 | 2015-08-25 00:00:00 UTC | Abbott Laboratories (ABT) Plunges: Stock Falls by 7.3% | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-plunges%3A-stock-falls-by-7.3-2015-08-25 | nan | nan | Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month.
The pharmaceuticals company has seen a mixed track record when it comes to current year estimate revisions over the past few weeks (3 increases, 1 decrease), and the consensus for earnings hasn't been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
Abbott Laboratories currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.
A better-ranked stock in the same sector is Eli Lilly and Company ( LLY ), which currently carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Is ABT going up? Or down? Predict to see what others think:
Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month. Click to get this free report >> Is ABT going up? | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month. | Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month. | Abbott Laboratories ( ABT ) saw a big move last session, as the company's shares fell by over 7% on the day. This continues the recent downtrend for ABT, as the stock is now down over nearly 14% over the past one month. Click to get this free report >> Is ABT going up? |
34018.0 | 2015-08-21 00:00:00 UTC | ABT Dividend Yield Pushes Past 2% | ABT | https://www.nasdaq.com/articles/abt-dividend-yield-pushes-past-2-2015-08-21 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF ( SPY ) back on 12/31/1999 - you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. According to the ETF Finder at ETF Channel, ABT makes up 9.32% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 1.7% on the day Friday.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Friday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.50 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. |
34019.0 | 2015-08-17 00:00:00 UTC | KemPharm (KMPH) Posts Wider-Than-Expected Loss in Q2 | ABT | https://www.nasdaq.com/articles/kempharm-kmph-posts-wider-than-expected-loss-in-q2-2015-08-17 | nan | nan | KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP).
Concurrently, the company reported a second-quarter 2015 loss of 55 cents per share, wider than the Zacks Consensus Estimate of 47 cents, but narrower than the year ago-loss of $1.57.
The company did not generate any revenue in the reported quarter.
Research and development expenses were $2.8 million, up 61.4% year over year.
General and administrative expenses were $3.2 million, up 139.7% from the year-ago quarter.
Pipeline Update
KemPharm is working on the development of its pipeline. The company's most advanced candidate, KP201, in combination with acetaminophen (KP201/APAP) is being developed for the treatment of acute moderate-to-moderately severe pain.
KemPharm announced positive data from the first intranasal human abuse liability study (KP201.A03). In the study, KP201 led to a 36% reduction in peak hydrocodone exposure, delayed the time to achieve peak exposure by an hour and led to a significant decrease in total exposure to hydrocodone released from KP201 compared to hydrocodone bitartrate, especially in the early time points that are typically associated with increased drug-liking and abuse. Additionally, KP201 significantly lowered drug-liking and pupil-dilation difficulty of snorting compared to hydrocodone bitartrate.
Meanwhile, the second intranasal human abuse liability study (KP201.A02) designed to evaluate the pharmacokinetics and drug likability of KP201/APAP compared to Norco is ongoing with data expected in the third quarter of 2015.
Additionally, the human abuse liability program includes three studies designed to evaluate the tamper resistance of KP201/APAP. The company intends to submit a new drug application for KP201/APAP to the FDA in the fourth quarter of 2015.
We expect investor focus to remain on pipeline updates from the company.
KemPharm carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . While Valeant holds a Zacks Rank #1 (Strong Buy), Eli Lilly and Abbott carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
KEMPHARM INC (KMPH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KEMPHARM INC (KMPH): Free Stock Analysis Report To read this article on Zacks.com click here. KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP). | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KEMPHARM INC (KMPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP). | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KEMPHARM INC (KMPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP). | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report KEMPHARM INC (KMPH): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Valeant Pharmaceuticals International, Inc. VRX , Eli Lilly and Company LLY and Abbott Laboratories ABT . KemPharm, Inc. 's KMPH shares gained 25.9% after the company reported positive data from an intranasal human abuse liability study on KP201 in combination with acetaminophen (KP201/APAP). |
34020.0 | 2015-08-17 00:00:00 UTC | Roche's (RHHBY) Lung Cancer Drug Meets Primary Endpoint | ABT | https://www.nasdaq.com/articles/roches-rhhby-lung-cancer-drug-meets-primary-endpoint-2015-08-17 | nan | nan | Roche HoldingRHHBY announced encouraging data from an open-label, multi-centre, single-arm pivotal phase II study (BIRCH), which evaluated the safety and efficacy of its investigational cancer immunotherapy, atezolizumab (MPDL3280A, anti-PDL1).
Atezolizumab met its primary endpoint in the study by shrinking the tumor size in patients suffering from locally advanced or metastatic PD-L1 expressing non-small cell lung cancer (NSCLC). Additionally, the study showed a correlation between the amount of PD-L1 expressed by a patient's cancer and their response to atezolizumab treatment.
Atezolizumab enjoys Breakthrough Therapy status for the treatment of patients suffering from PD-L1 expressing NSCLC, whose disease progressed during or after undergoing standard treatments including platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease. Breakthrough Therapy designation is generally granted to candidates, which are believed to have the potential to treat serious diseases, so as to expedite its development and review process.
We note that atezolizumab is currently being evaluated in seven phase III studies - either alone or in combination with other therapies - for the treatment of patients suffering from early and advanced stages of lung cancer. Additionally, there are 11 phase III studies (ongoing or planned) on atezolizumab for several types of cancers including lung, kidney, breast and bladder cancers.
According to Roche, lung cancer is the leading cause of cancer-related death across the world with 1.59 million people dying of the disease every year. Moreover, NSCLC, which is the most prevalent type of lung cancer, accounts for approximately 85% of all cases of the disease.
Meanwhile, Merck & Co. Inc. MRK is looking to get its anti-PD-1 therapy, Keytruda, approved in the U.S. for the treatment of advanced NSCLC in patients whose disease progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK-genomic tumor aberrations (if present). A response from the FDA is expected by Oct 2, 2015.
Roche carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Roche HoldingRHHBY announced encouraging data from an open-label, multi-centre, single-arm pivotal phase II study (BIRCH), which evaluated the safety and efficacy of its investigational cancer immunotherapy, atezolizumab (MPDL3280A, anti-PDL1). | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Atezolizumab enjoys Breakthrough Therapy status for the treatment of patients suffering from PD-L1 expressing NSCLC, whose disease progressed during or after undergoing standard treatments including platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Atezolizumab enjoys Breakthrough Therapy status for the treatment of patients suffering from PD-L1 expressing NSCLC, whose disease progressed during or after undergoing standard treatments including platinum-based chemotherapy and appropriate targeted therapy for EGFR mutation-positive or ALK-positive disease. | Some better-ranked stocks in the health care sector are Eli Lilly and Company LLY and Abbott Laboratories ABT . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the study showed a correlation between the amount of PD-L1 expressed by a patient's cancer and their response to atezolizumab treatment. |
34021.0 | 2015-08-14 00:00:00 UTC | After Hours Most Active for Aug 14, 2015 : CMCSA, DFS, QQQ, ABT, BAX, DG, PRU, AAPL, BAC, TERP, MU, SIRI | ABT | https://www.nasdaq.com/articles/after-hours-most-active-aug-14-2015-cmcsa-dfs-qqq-abt-bax-dg-pru-aapl-bac-terp-mu-siri | nan | nan | The NASDAQ 100 After Hours Indicator is up .71 to 4,531.45. The total After hours volume is currently 19,609,415 shares traded.
The following are the most active stocks for the after hours session :
Comcast Corporation ( CMCSA ) is unchanged at $58.88, with 1,551,837 shares traded. As reported by Zacks, the current mean recommendation for CMCSA is in the "buy range".
Discover Financial Services ( DFS ) is unchanged at $55.97, with 1,138,706 shares traded. Over the last four weeks they have had 7 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2015. The consensus EPS forecast is $1.34. As reported by Zacks, the current mean recommendation for DFS is in the "buy range".
PowerShares QQQ Trust, Series 1 ( QQQ ) is unchanged at $110.51, with 1,020,821 shares traded. This represents a 22.46% increase from its 52 Week Low.
Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2015. The consensus EPS forecast is $0.63. As reported by Zacks, the current mean recommendation for ABT is in the "buy range".
Baxter International Inc. ( BAX ) is unchanged at $40.90, with 912,033 shares traded. BAX's current last sale is 102.25% of the target price of $40.
Dollar General Corporation ( DG ) is unchanged at $79.23, with 801,754 shares traded. As reported by Zacks, the current mean recommendation for DG is in the "buy range".
Prudential Financial, Inc. ( PRU ) is unchanged at $90.10, with 739,936 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $2.47. As reported by Zacks, the current mean recommendation for PRU is in the "buy range".
Apple Inc. ( AAPL ) is unchanged at $115.96, with 689,602 shares traded. Over the last four weeks they have had 8 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $1.88. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Bank of America Corporation ( BAC ) is -0.05 at $17.65, with 599,575 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. The consensus EPS forecast is $0.36. As reported by Zacks, the current mean recommendation for BAC is in the "buy range".
TerraForm Power, Inc. ( TERP ) is -0.0025 at $25.50, with 503,514 shares traded. As reported by Zacks, the current mean recommendation for TERP is in the "buy range".
Micron Technology, Inc. ( MU ) is +0.04 at $16.99, with 476,803 shares traded., following a 52-week high recorded in today's regular session.
Sirius XM Holdings Inc. ( SIRI ) is -0.03 at $3.91, with 466,510 shares traded. As reported by Zacks, the current mean recommendation for SIRI is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Comcast Corporation ( CMCSA ) is unchanged at $58.88, with 1,551,837 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Comcast Corporation ( CMCSA ) is unchanged at $58.88, with 1,551,837 shares traded. | Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2015. | Abbott Laboratories ( ABT ) is unchanged at $50.23, with 976,181 shares traded. As reported by Zacks, the current mean recommendation for ABT is in the "buy range". The following are the most active stocks for the after hours session : Comcast Corporation ( CMCSA ) is unchanged at $58.88, with 1,551,837 shares traded. |
34022.0 | 2015-08-11 00:00:00 UTC | The Zacks Analyst Blog Highlights: Bayer AG, Abbott Laboratories, Xtant Medical Holdings, RTI Surgical, Cogentix Medical and Synergetics USA - Press Releases | ABT | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-bayer-ag-abbott-laboratories-xtant-medical-holdings-rti | nan | nan | For Immediate Release
Chicago, IL - August 11, 2015 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .
Here are highlights from Monday's Analyst Blog:
4 Hot Med-Instrument Stocks to Buy
Investors interested in the Medical Devices industry generally keep themselves busy analyzing existing trends - like longer life expectancies, mergers and acquisitions, emerging market opportunities, increased regulatory scrutiny and health care reforms. However, here are some of the emerging trends that one should also take into account, as these might eventually transform the prospects of industry.
Add to it, the overall favorable Zacks Industry Rank (#52 for medical products and #81 for medical instruments - both of which indicate a positive outlook) makes it a favorable space to bet on.
Home medical devices market evolves: Of late, self-health care (of course with growing awareness) has become one of the driving forces within the home medical devices market. A recent report published in mddionline.com states that the global home healthcare market will reach $303.6 billion by 2020, up over 70% from $176.1 billion in 2013. Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others.
3D printing reforming personalized care: The global medical 3D printing market (dental, medical prosthetic, orthopedic and surgical instruments) is estimated to reach $983.2 million by 2020 with an impressive CAGR of 20.3%, per Meticulous Research. Companies those are likely to rule this market include Stratasys Ltd and 3D Systems, Inc.
Mobile applications gaining popularity: At present more than 500 million smartphone users worldwide sport health-related apps on their mobile devices and the number is projected to climb to more than 1.7 billion by 2018. This indicates enormous opportunity in this segment.
In Vitro Diagnostics to dominate: According to a survey by EvaluateMedTech World Preview, in vitro diagnostics (IVD) is expected to emerge as the sector leader by 2020 (14% of the total medical device market) with sales of $71.6 billion reflecting annual growth of 6.1%. Roche Holding AG is expected to lead this space with a 17% market share and sales of $12.20 billion by 2020.
Such evolving trends, however, do not lead to the conclusion that emerging markets are losing their sheen. While economists are not naturally enthusiastic about the near-term prospects of currently troubled nations like Brazil, Russia and China, the appointment of promising political groups in India and Indonesia ensures that reform tops the economic agenda of both these countries. Per a 'Fortune' report by Ian Bremmer, along with Malaysia, these two nations are blessed with less socio-political conflict now.
4 Growth Stocks Under $10 to Buy Now
Amid such dynamic trends, if you are looking to ramp up the returns from your portfolio, we have handpicked four top-ranked growth stocks from the medical instruments space. Thanks to our new style score system, we have been able to identify these stocks. Moreover, all these stocks currently trade under $10.
Our research shows that stocks with Growth Style Scores of 'A' or 'B' when combined with a Zacks Rank #1 (Strong Buy) or 2 (Buy) offer the best investment opportunities in the growth investing space.
Xtant Medical Holdings, Inc. ( BONE ) provides biologics products to domestic and international markets. Investors can look forward to the company's recent purchase of spinal surgery product maker X-spine Systems which is going to perfectly complement Xtant Medical's leading orthobiologics portfolio.
BONE holds a Zacks Rank #2 (Buy) and has a Growth Style Score of 'B'. The company has expected earnings growth rate of 60.9% for the next quarter.
RTI Surgical Inc. ( RTIX ) is a surgical implant company offering safe biologic, metal and synthetic implants that find use in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures.
RTIX holds a Zacks Rank #2 (Buy) and has a Growth Style Score of 'A'. The company has an expected earnings growth rate of 93.9% for the current year. In the past one month, the Zacks Consensus Estimate for the current year has moved 25% higher.
Cogentix Medical, Inc. ( CGNT ) provides products for flexible endoscopy with advanced product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath technology.
CGNT carries a Zacks Rank #2 and has a Growth Style Score of 'A'. The company has an expected earnings growth rate of 53.3% for the next quarter.
Synergetics USA, Inc. ( SURG ) is a supplier of precision surgical devices with focus on ophthalmology and neurosurgery. We are looking forward to the company's early renewal of its supply agreement with Stryker Corporation which will extend through Mar 2019.
SURG holds a Zacks Rank #2 and has a Growth Style Score of 'A'. The company's expected earnings growth rate of 14.3% for the current year compares favorably with the S&P growth rate of 5.5%. In addition, the Zacks Consensus Estimate for the current year has seen an upward revision of 33.3% over the last 2 months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today . Find out What is happening in the stock market today on zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
XTANT MEDICAL (BONE): Free Stock Analysis Report
RTI SURGICAL (RTIX): Free Stock Analysis Report
COGENTIX MEDICL (CGNT): Free Stock Analysis Report
SYNERGETICS USA (SURG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report XTANT MEDICAL (BONE): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report To read this article on Zacks.com click here. | Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report XTANT MEDICAL (BONE): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report To read this article on Zacks.com click here. Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report XTANT MEDICAL (BONE): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others. | Stocks recently featured in the blog include the Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ), Xtant Medical Holdings, Inc. ( BONE ), RTI Surgical Inc. ( RTIX ), Cogentix Medical, Inc. ( CGNT ) and Synergetics USA, Inc. ( SURG ). Some of the bigger players in this niche are Bayer AG ( BAYRY ), Abbott Laboratories ( ABT ) and Cardinal Health among others. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report XTANT MEDICAL (BONE): Free Stock Analysis Report RTI SURGICAL (RTIX): Free Stock Analysis Report COGENTIX MEDICL (CGNT): Free Stock Analysis Report SYNERGETICS USA (SURG): Free Stock Analysis Report To read this article on Zacks.com click here. |
34023.0 | 2015-08-07 00:00:00 UTC | IYH, MDT, LLY, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iyh-mdt-lly-abt-large-outflows-detected-etf-2015-08-07 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $88.4 million dollar outflow -- that's a 3.3% decrease week over week (from 16,500,000 to 15,950,000). Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $88.4 million dollar outflow -- that's a 3.3% decrease week over week (from 16,500,000 to 15,950,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83. | Among the largest underlying components of IYH, in trading today Medtronic PLC (Symbol: MDT) is down about 0.7%, Eli Lilly & Co. (Symbol: LLY) is off about 2.4%, and Abbott Laboratories (Symbol: ABT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $88.4 million dollar outflow -- that's a 3.3% decrease week over week (from 16,500,000 to 15,950,000). For a complete list of holdings, visit the IYH Holdings page » The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $124.28 per share, with $164.98 as the 52 week high point - that compares with a last trade of $158.83. |
34024.0 | 2015-08-06 00:00:00 UTC | Mylan Beats on Q2 Earnings, Revenues In Line, Guidance Up - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-beats-on-q2-earnings-revenues-in-line-guidance-up-analyst-blog-2015-08-06 | nan | nan | Mylan 's MYL second-quarter 2015 earnings (excluding special items) of 91 cents per share beat the Zacks Consensus Estimate of 87 cents. Earnings increased 32% from the year-ago quarter driven by higher revenues.
Mylan Inc. - Earnings Surprise | FindTheBest
Revenues climbed 29% (36% on a constant currency basis) to $2.4 billion, in line with the Zacks Consensus Estimate. Mylan recorded year-over-year growth on the back of solid revenue growth at the Generics segment. Specialty segment also performed well. Foreign currency exchange rates negatively impacted revenues by $127 million in the second quarter of 2015.
Second Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 34% to $2.1 billion. Segmental third-party net sales grew 27% to $937.4 million in North America. New product launches, acquisitions and favorable pricing aided revenues.
Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Third party net sales from rest of the world rose 38% to $546.7 million. Segmental performance improved on the back of acquisitions, new product launches in Australia and Japan and increased sales of its antiretroviral products.
Third-party net sales at the Specialty segment jumped 5% to $301.9 million. Specialty segment sales were boosted by strong performance of its flagship product - EpiPen Auto-Injector - for severe allergic reactions. Sales of the product improved on increased volume.
Adjusted gross margin during the second quarter of 2015 expanded to 54% from 50% in the year-ago quarter on the back of new product introductions and net sales from acquisitions.
2015 Outlook Raised
Mylan raised its 2015 guidance. The company expects adjusted earnings per share in the range of $4.15 to $4.35 (previous guidance: $4.00 to $4.30). The Zacks Consensus Estimate for 2015 earnings is at $4.16.
Our Take
Mylan's second-quarter earnings were better than expected. We are encouraged by strong sales at the Generics segment. However, we remain concerned about the company's Specialty segment sales. The company expects to face generic competition for EpiPen Auto-Injector in the second half of 2015. Meanwhile, Mylan remains committed to acquiring Perrigo Company PRGO . The company has received the European regulatory approval to move forward with its proposed buyout. Investor focus is expected to remain on Mylan-Perrigo updates in the near term.
Mylan holds a Zacks Rank #3 (Hold). Ligand Pharmaceuticals Incorporated LGND is a well-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan Inc. - Earnings Surprise | FindTheBest Revenues climbed 29% (36% on a constant currency basis) to $2.4 billion, in line with the Zacks Consensus Estimate. | Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Second Quarter in Details Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 34% to $2.1 billion. | Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Second Quarter in Details Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 34% to $2.1 billion. | Third-party net sales from the European market increased 44% to $571 million driven by net sales from the acquisition of Abbott's ABT non-U.S. developed markets branded generics business and new product sales, partially offset by unfavorable currency translations. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects adjusted earnings per share in the range of $4.15 to $4.35 (previous guidance: $4.00 to $4.30). |
34025.0 | 2015-07-31 00:00:00 UTC | Will Zoetis (ZTS) Pull a Surprise this Earnings Season? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-zoetis-zts-pull-a-surprise-this-earnings-season-analyst-blog-2015-07-31 | nan | nan | Zoetis Inc.ZTS is scheduled to report second-quarter 2015 results before the opening bell on Aug 4. Last quarter, the company posted a positive earnings surprise of 10.81%. The company has recorded positive earnings surprises in three of the four trailing quarters with an average beat of 7.54%. Let's see how things are shaping up for this announcement.
Factors at Play this Quarter
Zoetis' robust and diversified product portfolio should help support revenues. The company's livestock segment should continue to do well. Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business.
However, foreign currency movements can prove to be a threat this quarter. The company has announced comprehensive operational efficiency initiatives, which are expected to generate cost savings of approximately $300 million by 2017. The company plans to modify its supply network, including plans to sell or exit 10 manufacturing sites over the long term and eliminate approximately 5,000 lower-revenue, lower-margin product stock keeping units. As a result of these initiatives, Zoetis expects to record restructuring charges and other one-time cash charges of $400-500 million, primarily by the end of 2016.
For 2015, excluding one-time items, earnings are expected to be in the range of $1.61 to $1.68 per share. The company expects revenues to be between $4.675 billion and $4.775 billion. We could see an update on the same along with the second-quarter results.
What Our Model Indicates
Our proven model does not conclusively show that Zoetis is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. That is not the case here as you will see below.
Zacks ESP : The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 38 cents per share.
Zacks Rank : Zoetis currently carries a Zacks Rank #2 (Buy). Although the company's Zacks Rank #2 enhances the predictive power of the ESP, the company's ESP of 0.00% makes a beat difficult to predict.
We caution against stocks with a Zacks Rank #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a few health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Momenta Pharmaceuticals Inc. MNTA has an Earnings ESP of + 74.36% and carries a Zacks Rank #3. The company is expected to release results on Aug 4.
The Earnings ESP for Immune Design Corp. IMDZ is +20.41% and it carries a Zacks Rank #3. The company is expected to release results on Aug 13.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MOMENTA PHARMA (MNTA): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
IMMUNE DESIGN (IMDZ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business. Click to get this free report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report IMMUNE DESIGN (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play this Quarter Zoetis' robust and diversified product portfolio should help support revenues. | Click to get this free report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report IMMUNE DESIGN (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business. Zacks Rank : Zoetis currently carries a Zacks Rank #2 (Buy). | Click to get this free report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report IMMUNE DESIGN (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. | Zoetis has acquired Abbott Laboratories' ABT animal health assets strengthening its pain and sedation product portfolio and diagnostic business. Click to get this free report MOMENTA PHARMA (MNTA): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report IMMUNE DESIGN (IMDZ): Free Stock Analysis Report To read this article on Zacks.com click here. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. |
34026.0 | 2015-07-28 00:00:00 UTC | Notable ETF Outflow Detected - UPRO, ABT, ABBV, ACN | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-upro-abt-abbv-acn-2015-07-28 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $66.8 million dollar outflow -- that's a 8.3% decrease week over week (from 12,100,000 to 11,100,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is up about 0.7%, and Accenture plc (Symbol: ACN) is higher by about 0.1%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $67.00. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
34027.0 | 2015-07-28 00:00:00 UTC | Merck Tops on Q2 Earnings & Revenues, Revises Outlook - Analyst Blog | ABT | https://www.nasdaq.com/articles/merck-tops-q2-earnings-revenues-revises-outlook-analyst-blog-2015-07-28 | nan | nan | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period.
Merck & Company Inc. - Earnings Surprise | FindTheBest
Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. While currency movement negatively impacted revenues by 7%, the divestiture of the Consumer Care business and other products impacted revenues by net 7%. This was partially offset by the Cubist acquisition.
The Quarter in Detail
Merck's Pharmaceutical segment | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period. Merck & Company Inc. - Earnings Surprise | FindTheBest Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. While currency movement negatively impacted revenues by 7%, the divestiture of the Consumer Care business and other products impacted revenues by net 7%. | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period. Merck & Company Inc. - Earnings Surprise | FindTheBest Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. While currency movement negatively impacted revenues by 7%, the divestiture of the Consumer Care business and other products impacted revenues by net 7%. | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period. Merck & Company Inc. - Earnings Surprise | FindTheBest Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. This was partially offset by the Cubist acquisition. | Merck & Co.MRK reported second quarter 2015 earnings of 86 cents per share, surpassing the Zacks Consensus Estimate of 80 cents and increasing 1.2% from the year-ago period. Merck & Company Inc. - Earnings Surprise | FindTheBest Revenues for the quarter declined 10.5% to $9.785 billion but were above the Zacks Consensus Estimate of $9.709 billion. While currency movement negatively impacted revenues by 7%, the divestiture of the Consumer Care business and other products impacted revenues by net 7%. |
34028.0 | 2015-07-23 00:00:00 UTC | Company News for July 23, 2015 - Corporate Summary | ABT | https://www.nasdaq.com/articles/company-news-for-july-23-2015-corporate-summary-2015-07-23 | nan | nan | • Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents
• Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78
• Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million
• Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
AMPHENOL CORP-A (APH): Free Stock Analysis Report
WHIRLPOOL CORP (WHR): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents • Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78 • Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million • Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report AMPHENOL CORP-A (APH): Free Stock Analysis Report WHIRLPOOL CORP (WHR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents • Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78 • Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million • Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report AMPHENOL CORP-A (APH): Free Stock Analysis Report WHIRLPOOL CORP (WHR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents • Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78 • Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million • Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report AMPHENOL CORP-A (APH): Free Stock Analysis Report WHIRLPOOL CORP (WHR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Abbott Laboratories's ( ABT ) shares gained 2.5% after announcing second quarter earnings per share of $0.52, beating the Zacks Consensus Estimate by a couple of cents • Shares of Thermo Fisher Scientific, Inc. ( TMO ) rose 2.6% after declaring second quarter adjusted earnings per share of $1.84, ahead of the Zacks Consensus Estimate of $1.78 • Amphenol Corporation's ( APH ) shares jumped 5% after reporting second quarter revenues of $1,351.5 million, higher than the Zacks Consensus Estimate of $1,347 million • Shares of Whirlpool Corp. ( WHR ) surged 7.3% after posting second quarter adjusted earnings per share of $2.70, outpacing the Zacks Consensus Estimate by 3 cents Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report AMPHENOL CORP-A (APH): Free Stock Analysis Report WHIRLPOOL CORP (WHR): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
34029.0 | 2015-07-22 00:00:00 UTC | Health Care Sector Update for 07/22/2015: STJ, THOR, ABT | ABT | https://www.nasdaq.com/articles/health-care-sector-update-07222015-stj-thor-abt-2015-07-22 | nan | nan | Health care stocks:Â
JNJ: -0.15%
PFE: flat
ABT: -1.04%
MRK: flat
AMGN: -1.04%
Health-care shares were mixed in pre-market trade Wednesday.
In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates.
Shares fell 1.7% to $48.92 in recent trade. The stock has a 52-week range of $39.28 - 50.47. The pharmaceutical company reported Q2 revenue of $5.17 billion, versus $5.06 billion in the same period last year. This was higher than the $5.15 billion Capital IQ consensus.
In other news, St. Jude Medical ( STJ ) said it has agreed to acquire Thoratec ( THOR ) for $63.5 per share in cash or a total $3.4 billion, a 40.1% premium over the medical device maker's volume-weighted average trading price in the 30 trading days to July 17.
THOR shares rose more than 9% in recent pre-market trade to $62.71, an all-time high if it holds into regular trading. The 52-week range is between $22.50 and $62.05. STJ was unchanged in recent pre-market trade, near the higher end of the 52-week range between $54.80 and $77.35.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates. In other news, St. Jude Medical ( STJ ) said it has agreed to acquire Thoratec ( THOR ) for $63.5 per share in cash or a total $3.4 billion, a 40.1% premium over the medical device maker's volume-weighted average trading price in the 30 trading days to July 17. STJ was unchanged in recent pre-market trade, near the higher end of the 52-week range between $54.80 and $77.35. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates. Health-care shares were mixed in pre-market trade Wednesday. | In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates. In other news, St. Jude Medical ( STJ ) said it has agreed to acquire Thoratec ( THOR ) for $63.5 per share in cash or a total $3.4 billion, a 40.1% premium over the medical device maker's volume-weighted average trading price in the 30 trading days to July 17. THOR shares rose more than 9% in recent pre-market trade to $62.71, an all-time high if it holds into regular trading. | In notable health-care stocks earnings this morning, Abbott Laboratories ( ABT ) was lower in pre-market trade Wednesday despite beating earnings estimates. Health-care shares were mixed in pre-market trade Wednesday. The stock has a 52-week range of $39.28 - 50.47. |
34030.0 | 2015-07-22 00:00:00 UTC | Abbott Laboratories (ABT) Beats on Q2 Earnings, Keeps View - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-beats-on-q2-earnings-keeps-view-analyst-blog-2015-07-22 | nan | nan | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents.
Abbott Labs generated sales of $5.2 billion in the second quarter of 2015, up 2.2% year over year (on a reported basis) and in line with the Zacks Consensus Estimate. Sales were impacted unfavorably by foreign exchange movements to the tune of 8.6% during the quarter.
Quarter in Detail
Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
EPD sales were up 31.3% to $977 million including the negative impact of 14.7% due to currency fluctuations. Sales in key emerging markets climbed 43.2% on an operational basis driven by growth in India, China and Columbia.
The Medical Devices business generated sales of $1.3 billion, down 6.1% year over year. Diabetes Care sales, Vascular business sales and Medical Optics business were down 5.6%, 5.3% and 8%, respectively. Sales in the Medical Optics business were affected by market dynamics in the cataract and refractive businesses. Abbott filed for Absorb GT1 in the U.S. and Japan. The company expects to file for its approval in China in the next few months.
The Nutrition business improved 0.8% year over year to $1.7 billion. Pediatric Nutrition sales were up slightly (0.1%). Growth was driven by double-digit growth in China and Latin America. However, Adult Nutrition sales were weak in the U.S. due to competitive and market dynamics, particularly in the institutional segment.
Diagnostics business sales decreased 1% year over year to $1.2 billion. Core Laboratory and Molecular sales decreased 2.3% and 0.3%, respectively, while Point-of-Care Diagnostics sales grew 9.8%. Molecular Diagnostics sales in the U.S. were affected by market dynamics in the oncology business and the planned scale down of the genetics business.
During this quarter, Abbott received FDA clearance for its first-of-its-kind handheld and whole blood point of care test, i-STAT Total β-hCG test. In addition, Abbott launched its wireless i-STAT handheld system in Europe.
2015 Outlook Reiterated
Abbott Labs continues to expect earnings per share in the range of $2.10 - $2.20 per share in 2015. The Zacks Consensus Estimate currently stands at $2.16, well within the projected range.
Our Take
Although the unfavorable impact of currency fluctuations continue to dampen revenues, Abbott Labs second-quarter results were impressive. The branded generics and global diagnostics businesses should drive growth in the coming quarters.
Abbott Labs currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Bayer BAYRY , Eli Lilly and Company LLY and Sanofi SNY . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. The Medical Devices business generated sales of $1.3 billion, down 6.1% year over year. | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.2 billion in the second quarter of 2015, up 2.2% year over year (on a reported basis) and in line with the Zacks Consensus Estimate. | Abbott LaboratoriesABT reported second-quarter 2015 earnings of 52 cents per share, up 6.12% year over year, beating the Zacks Consensus Estimate of 50 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.2 billion in the second quarter of 2015, up 2.2% year over year (on a reported basis) and in line with the Zacks Consensus Estimate. |
34031.0 | 2015-07-22 00:00:00 UTC | Abbott Labs (ABT) Beats on Earnings in Q2 - Tale of the Tape | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-earnings-in-q2-tale-of-the-tape-2015-07-22 | nan | nan | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. In Feb 2015, Abbott Labs completed the sale of its branded generics pharmaceuticals business in developed markets.
The pediatric nutrition business, along with the launch of new products in ex-U.S. market (Ensure in China) should continue to drive revenues. However, concerns remain regarding the performance of the adult nutrition business, which is facing competition in the U.S. and low demand at the institutional level.
However, unfavorable movement in foreign currency rates is affecting the top line adversely. In particular, sales in emerging markets have been hampered due to currency devaluation.
Abbott Labs has an impressive track record as the company beat estimates in the last four trailing quarters with an average positive earnings surprise of 6.38%.
Currently, Abbott Labs has a Zacks Rank #3 (Hold). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Abbott Labs beat on earnings in second-quarter 2015. Our consensus called for EPS of 50 cents per share, while the company reported EPS of 52 cents (from continuing operations excluding one-time items).
Revenue: Abbott Labs posted revenues of $5.2 billion, in line with our expectations.
Key Stats: Strong performance in branded generics, international nutrition and global diagnostics businesses positively impacted second-quarter results. The company reiterated its earnings guidance for 2015.
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Key Stats: Strong performance in branded generics, international nutrition and global diagnostics businesses positively impacted second-quarter results. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott Laboratories ( ABT ) is an Illinois-based company focused on bringing a diverse line of healthcare products to the market. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The pediatric nutrition business, along with the launch of new products in ex-U.S. market (Ensure in China) should continue to drive revenues. |
34032.0 | 2015-07-21 00:00:00 UTC | Dow Jones Industrial Average Today Drops 180 Points as IBM, UTX Slide | ABT | https://www.nasdaq.com/articles/dow-jones-industrial-average-today-drops-180-points-ibm-utx-slide-2015-07-21 | nan | nan | MoneyMorning.com Report - For July 21, 2015, here's how the Dow Jones Industrial Average did today, plus the topstock market news and stocks to watch based on today's market moves...
How Did the Stock Market Do Today?
Dow Jones: 17,919.29; -181.12;-1.00%
S&P 500: 2,119.21; -9.07;-0.43%
Nasdaq: 5,208.12; -10.74;-0.21%
The DJIA today fell nearly 1%, or 180 points, as revenue figures from large caps International Business Machines Corp. ( IBM ) and United Technologies Corp. ( UTX ) pulled down the index. The two stocks accounted for more than 100 points combined in the decline on the day. IBM shares slumped more than 6.2% on news that the company's revenue slipped for the 13th straight quarter. Meanwhile, United Technologies shares fell more than 7% after the company slashed its 2015 profit outlook.
The S&P 500 Volatility Index (VIX), the market's fear gauge, slipped 0.6%.
Top Stock Market News Today
What Pushed Down the Dow: The Dow Jones Industrial Average slipped below 18,000 after two large caps, IBM and UTX, weighed down the index on weak revenue and weak forward guidance, respectively. Shares of Verizon Communications Inc. ( VZ ) slumped more than 2.5%, dragging down the S&P 500 by seven points. The Nasdaq was down ahead of earnings reports from two of its largest companies, Apple Inc. (Nasdaq: AAPL) and Microsoft Corp. (Nasdaq: MSFT).
Oil Outlook: Oil prices were up marginally after hitting recent lows on supply concerns. WTI crude futures for September added 0.4% to hit $50.56 per barrel. Meanwhile, Brent oil prices added 0.6% to hit $57.03 per barrel.
On Tap Tomorrow: On Wednesday, investors will be keeping an eye on existing home sales and an update to domestic crude stocks from the U.S. Energy Information Administration. Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX).
Stocks to Watch: AAPL, HOG, TSLA, LXK
Stocks to Watch No. 1,AAPL: Shares of Apple Inc. (Nasdaq: AAPL) dipped ahead of its post-market earnings report on news that its App Store, Apple Music, iTunes Store, and some other services were offline during a three-hour outage. The company did not specify why its networks were down. The news comes after a rash of outages have affected airline companies, media publications, and even the operator of the New York Stock Exchange in recent weeks.
Stocks to Watch No. 2, HOG: Shares of Harley-Davidson Inc. (HOG) jumped nearly 5% after the company beat Wall Street earnings and revenue expectations. The company reported earnings of $1.44 per share and revenue of $1.82 billion. Despite the positive quarterly results, the company did report that its market share in the United States has fallen below 50%, as Japanese rivals are offering better competition and prices than in the past. Harley has refused to cut its prices but says it hopes to boost sales from a new roster of products it will introduce to the markets next month.
Stocks to Watch No.3, TSLA: Shares of Tesla Motors Inc. (Nasdaq: TSLA) slumped 5.5% after the company received a downgrade from "Neutral" to "Sell" from investment bank UBS Group AG (USA) (UBS). The bank said that it expects the company's storage and auto divisions to disappoint. UBS said it does not expect that the company will meet the target sales levels that it has set and that assumptions made for its production are "unlikely" to occur.
Stocks to Watch No.4, LXK: Shares of Lexmark International Inc. (LXK) slumped more than 20.2% after the company reported weak earnings and announced plans to slash 500 jobs. The printer manufacturer reported a second-quarter loss and slashed its 2015 revenue outlook. It also said that it will pause its stock buyback program for 18 to 24 months while it pays down credit costs associated with its $1 billion takeover of Kodak.
Stay informed on what's going on in the markets by following us on Twitter@moneymorning .
What Investors Must Know This Week
The Top Three High-Return Investments to Buy Today
Is Netflix Stock a Buy After Stock Split and Earnings Beat?
The Real Impact of the Iran Nuclear Deal on U.S. Oil Prices
To get full access to all Money Morning content including our latest Premium Report, "How to Make 2015 Your Wealthiest Year Ever," click here
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience - for free . Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.
Disclaimer: © 2015 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX). Nasdaq: 5,208.12; -10.74;-0.21% The DJIA today fell nearly 1%, or 180 points, as revenue figures from large caps International Business Machines Corp. ( IBM ) and United Technologies Corp. ( UTX ) pulled down the index. Our experts - who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV - deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. | Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX). Nasdaq: 5,208.12; -10.74;-0.21% The DJIA today fell nearly 1%, or 180 points, as revenue figures from large caps International Business Machines Corp. ( IBM ) and United Technologies Corp. ( UTX ) pulled down the index. Top Stock Market News Today What Pushed Down the Dow: The Dow Jones Industrial Average slipped below 18,000 after two large caps, IBM and UTX, weighed down the index on weak revenue and weak forward guidance, respectively. | Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX). MoneyMorning.com Report - For July 21, 2015, here's how the Dow Jones Industrial Average did today, plus the topstock market news and stocks to watch based on today's market moves... How Did the Stock Market Do Today? Stocks to Watch No.4, LXK: Shares of Lexmark International Inc. (LXK) slumped more than 20.2% after the company reported weak earnings and announced plans to slash 500 jobs. | Companies reporting earnings tomorrow include Abbott Laboratories ( ABT ), AutoNation Inc. ( AN ), Boeing Co. (BA), TheCheesecake Factory Inc. (Nasdaq: CAKE), Coca-Cola Co. (KO), Discover Financial Services (DFS), Las Vegas Sands Corp. (LVS), SanDisk Corp. (Nasdaq: SNDK), and Six Flags Entertainment Corp. (SIX). IBM shares slumped more than 6.2% on news that the company's revenue slipped for the 13th straight quarter. The Nasdaq was down ahead of earnings reports from two of its largest companies, Apple Inc. (Nasdaq: AAPL) and Microsoft Corp. (Nasdaq: MSFT). |
34033.0 | 2015-07-21 00:00:00 UTC | Pre-Market Earnings Report for July 22, 2015 : KO, BA, ABT, TMO, EMC, ITW, TEL, ARMH, STJ, NTRS, APH, CHKP | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-july-22-2015-ko-ba-abt-tmo-emc-itw-tel-armh-stj-ntrs-aph-chkp | nan | nan | The following companies are expected to report earnings prior to market open on 07/22/2015. Visit our Earnings Calendar for a full list of expected earnings releases.
Coca-Cola Company ( KO ) is reporting for the quarter ending June 30, 2015. The beverages company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.60. This value represents a 6.25% decrease compared to the same quarter last year. In the past year KO has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.63%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for KO is 20.69 vs. an industry ratio of 47.60.
Boeing Company ( BA ) is reporting for the quarter ending June 30, 2015. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $2.14. This value represents a 11.57% decrease compared to the same quarter last year. In the past year BA has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 8.84%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BA is 17.10 vs. an industry ratio of 16.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.50. This value represents a 7.41% decrease compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 11.9%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending June 30, 2015. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.78. This value represents a 3.49% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.24%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TMO is 18.55 vs. an industry ratio of -58.80, implying that they will have a higher earnings growth than their competitors in the same industry.
EMC Corporation ( EMC ) is reporting for the quarter ending June 30, 2015. The computer storage company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.31. This value represents a 6.06% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EMC is 16.77 vs. an industry ratio of -0.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Illinois Tool Works Inc. ( ITW ) is reporting for the quarter ending June 30, 2015. The machinery company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.28. This value represents a 5.79% increase compared to the same quarter last year. In the past year ITW has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 3.42%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ITW is 18.25 vs. an industry ratio of 18.60.
TE Connectivity Ltd. ( TEL ) is reporting for the quarter ending June 30, 2015. The electrical instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.88. This value represents a 12.00% decrease compared to the same quarter last year. TEL missed the consensus earnings per share in the 1st calendar quarter of 2015 by -8.08%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TEL is 16.91 vs. an industry ratio of 21.90.
ARM Holdings plc ( ARMH ) is reporting for the quarter ending June 30, 2015. The electric company company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.27. This value represents a 17.39% increase compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ARMH is 37.86 vs. an industry ratio of 0.90, implying that they will have a higher earnings growth than their competitors in the same industry.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending June 30, 2015. The medical products company's consensus earnings per share forecast from the 19 analysts that follow the stock is $0.99. This value represents a 2.94% decrease compared to the same quarter last year. In the past year STJ has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for STJ is 19.43 vs. an industry ratio of 65.90.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending June 30, 2015. The bank company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.96. This value represents a 10.34% increase compared to the same quarter last year. NTRS missed the consensus earnings per share in the 3rd calendar quarter of 2014 by -3.45%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for NTRS is 20.56 vs. an industry ratio of 14.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Amphenol Corporation ( APH ) is reporting for the quarter ending June 30, 2015. The electrical connectors company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.57. This value represents a 3.64% increase compared to the same quarter last year. In the past year APH has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for APH is 22.27 vs. an industry ratio of 17.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Check Point Software Technologies Ltd. ( CHKP ) is reporting for the quarter ending June 30, 2015. The computer software company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.87. This value represents a 7.41% increase compared to the same quarter last year. In the past year CHKP has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for CHKP is 21.10 vs. an industry ratio of 24.70.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 23.18 vs. an industry ratio of 14.90, implying that they will have a higher earnings growth than their competitors in the same industry. |
34034.0 | 2015-07-20 00:00:00 UTC | Will Abbott Laboratories (ABT) Miss Earnings This Season? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-abbott-laboratories-abt-miss-earnings-this-season-analyst-blog-2015-07-20 | nan | nan | Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22.
Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 6.38%. Let us see how things are shaping up for this announcement.
Factors Influencing Q2 Results
Although the pediatric nutrition business, along with the launch of new products in ex-U.S. market (Ensure in China), may help to drive revenues, concerns remain regarding the performance of the adult nutrition business, which is facing competition in the U.S. and low demand at the institutional level.
On its first-quarter call, the company had said that it expects mid-to-high single-digit growth in the global nutritional business in second-quarter 2015, driven by a continued double-digit operational sales growth in international nutrition. While the established pharmaceuticals division is expected to generate double-digit sales growth on an operational basis, the global medical optics business and global diagnostics business are expected to grow in mid-single digits.
Second-quarter earnings are expected in the range of 49 cents − 51 cents per share, reflecting double-digit growth.
However, the top line may be affected by the negative impact of currency fluctuation of above 8%. With operational sales growth in the low-double digits, the company expects to register sales in low single digits.
What Our Model Indicates
Our proven model does not conclusively shows that Abbott Labs is likely to beat on earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is pegged at 0.00%. This is because the Most Accurate estimate and the Zacks Consensus Estimate both stand at 50 cents.
Zacks Rank: Abbott Labs currently carries a Zacks Rank #3 (Hold). Although the company's Zacks Rank #3 enhances the predictive power of ESP, the company's ESP of 0.00% makes a surprise prediction difficult.
We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. AMGN has an earnings ESP of +1.65% and carries a Zacks Rank #3. The company is scheduled to release its second-quarter 2015 results on Jul 30.
Express Scripts Holding Company ESRX has an earnings ESP of +0.72% and carries a Zacks Rank #3. The company is scheduled to release its second-quarter 2015 results on Jul 28.
The Earnings ESP for Valeant Pharmaceuticals International, Inc. VRX is +0.41% and it carries a Zacks Rank #3. The company is scheduled to release second-quarter results on Jul 23.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs has an impressive track record with the company beating estimates in each of the trailing four quarters with an average earnings surprise of 6.38%. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22. Zacks Rank: Abbott Labs currently carries a Zacks Rank #3 (Hold). | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) to likely post an earnings beat. | Abbott LaboratoriesABT is scheduled to report second-quarter 2015 results before the opening bell on Jul 22. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing a negative estimate revision momentum. |
34035.0 | 2015-07-20 00:00:00 UTC | Strategy To YieldBoost Abbott Laboratories From 1.9% To 5.3% Using Options | ABT | https://www.nasdaq.com/articles/strategy-yieldboost-abbott-laboratories-19-53-using-options-2015-07-20 | nan | nan | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Any upside above $55 would be lost if the stock rises there and is called away, but ABT shares would have to climb 9.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 14.7% return from this trading level, in addition to any dividends collected before the stock was called.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.9% annualized dividend yield. Below is a chart showing ABT's trailing twelve month trading history, with the $55 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 covered call at the $55 strike gives good reward for the risk of having given away the upside beyond $55. ( Do most options expire worthless? This and six other common options myths debunked ). We calculate the trailing twelve month volatility for Abbott Laboratories (considering the last 251 trading day closing values as well as today's price of $50.18) to be 17%. For other call options contract ideas at the various different available expirations, visit the ABT Stock Options page of StockOptionsChannel.com. In mid-afternoon trading on Monday, the put volume among S&P 500 components was 769,808 contracts, with call volume at 1.35M, for a put:call ratio of 0.57 so far for the day. Compared to the long-term median put:call ratio of .65, that represents high call volume relative to puts; in other words, buyers are showing a preference for calls in options trading so far today. Find out which 15 call and put options traders are talking about today .
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is a chart showing ABT's trailing twelve month trading history, with the $55 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 covered call at the $55 strike gives good reward for the risk of having given away the upside beyond $55. Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Any upside above $55 would be lost if the stock rises there and is called away, but ABT shares would have to climb 9.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 14.7% return from this trading level, in addition to any dividends collected before the stock was called. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Any upside above $55 would be lost if the stock rises there and is called away, but ABT shares would have to climb 9.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 14.7% return from this trading level, in addition to any dividends collected before the stock was called. Below is a chart showing ABT's trailing twelve month trading history, with the $55 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 covered call at the $55 strike gives good reward for the risk of having given away the upside beyond $55. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Any upside above $55 would be lost if the stock rises there and is called away, but ABT shares would have to climb 9.7% from current levels for that to occur, meaning that in the scenario where the stock is called, the shareholder has earned a 14.7% return from this trading level, in addition to any dividends collected before the stock was called. In the case of Abbott Laboratories, looking at the dividend history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 1.9% annualized dividend yield. | Shareholders of Abbott Laboratories (Symbol: ABT) looking to boost their income beyond the stock's 1.9% annualized dividend yield can sell the January 2017 covered call at the $55 strike and collect the premium based on the $2.53 bid, which annualizes to an additional 3.4% rate of return against the current stock price (at Stock Options Channel we call this the YieldBoost ), for a total of 5.3% annualized rate in the scenario where the stock is not called away. Below is a chart showing ABT's trailing twelve month trading history, with the $55 strike highlighted in red: The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the January 2017 covered call at the $55 strike gives good reward for the risk of having given away the upside beyond $55. For other call options contract ideas at the various different available expirations, visit the ABT Stock Options page of StockOptionsChannel.com. |
34036.0 | 2015-07-13 00:00:00 UTC | Novo Nordisk Up on Positive Results from Diabetes Study - Analyst Blog | ABT | https://www.nasdaq.com/articles/novo-nordisk-up-on-positive-results-from-diabetes-study-analyst-blog-2015-07-13 | nan | nan | Novo Nordisk A/SNVO announced encouraging headline results from the first phase IIIa study (SUSTAIN1) on investigational once-weekly GLP-1 analogue, semaglutide. Shares were up 5.3% following the announcement.
SUSTAIN1 evaluated the efficacy and safety of semaglutide monotherapy (0.5 mg and 1.0 mg doses) for a treatment period of 30 weeks versus placebo in patients suffering from type II diabetes who were previously on diet and exercise. The study has met its primary objective showing that patients treated with 0.5 mg and 1.0 mg semaglutide achieved superior improvement in HbA1c (1.5% and 1.6%, respectively) from a mean baseline HbA1c of 8.1%, compared to no change in HbA1c in those receiving placebo. Novo Nordisk reported that 74% and 73% of the patients treated with 0.5 mg and 1.0 mg semaglutide, respectively, achieved the treatment target of HbA1c below 7% as set by the American Diabetes Association and the European Association for t | Novo Nordisk A/SNVO announced encouraging headline results from the first phase IIIa study (SUSTAIN1) on investigational once-weekly GLP-1 analogue, semaglutide. SUSTAIN1 evaluated the efficacy and safety of semaglutide monotherapy (0.5 mg and 1.0 mg doses) for a treatment period of 30 weeks versus placebo in patients suffering from type II diabetes who were previously on diet and exercise. The study has met its primary objective showing that patients treated with 0.5 mg and 1.0 mg semaglutide achieved superior improvement in HbA1c (1.5% and 1.6%, respectively) from a mean baseline HbA1c of 8.1%, compared to no change in HbA1c in those receiving placebo. | Novo Nordisk A/SNVO announced encouraging headline results from the first phase IIIa study (SUSTAIN1) on investigational once-weekly GLP-1 analogue, semaglutide. The study has met its primary objective showing that patients treated with 0.5 mg and 1.0 mg semaglutide achieved superior improvement in HbA1c (1.5% and 1.6%, respectively) from a mean baseline HbA1c of 8.1%, compared to no change in HbA1c in those receiving placebo. Novo Nordisk reported that 74% and 73% of the patients treated with 0.5 mg and 1.0 mg semaglutide, respectively, achieved the treatment target of HbA1c below 7% as set by the American Diabetes Association and the European Association for t | SUSTAIN1 evaluated the efficacy and safety of semaglutide monotherapy (0.5 mg and 1.0 mg doses) for a treatment period of 30 weeks versus placebo in patients suffering from type II diabetes who were previously on diet and exercise. The study has met its primary objective showing that patients treated with 0.5 mg and 1.0 mg semaglutide achieved superior improvement in HbA1c (1.5% and 1.6%, respectively) from a mean baseline HbA1c of 8.1%, compared to no change in HbA1c in those receiving placebo. Novo Nordisk reported that 74% and 73% of the patients treated with 0.5 mg and 1.0 mg semaglutide, respectively, achieved the treatment target of HbA1c below 7% as set by the American Diabetes Association and the European Association for t | Novo Nordisk A/SNVO announced encouraging headline results from the first phase IIIa study (SUSTAIN1) on investigational once-weekly GLP-1 analogue, semaglutide. Shares were up 5.3% following the announcement. SUSTAIN1 evaluated the efficacy and safety of semaglutide monotherapy (0.5 mg and 1.0 mg doses) for a treatment period of 30 weeks versus placebo in patients suffering from type II diabetes who were previously on diet and exercise. |
34037.0 | 2015-07-08 00:00:00 UTC | Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog | ABT | https://www.nasdaq.com/articles/novartis-heart-failure-drug-entresto-receives-fda-approval-analyst-blog-2015-07-08 | nan | nan | Novartis AGNVS announced that its heart failure drug Entresto (previously known as LCZ696) has received FDA approval.
Novartis stated that Entresto (twice-daily) is the first-in-class angiotensin receptor neprilysin inhibitor therapy approved for reducing strain on the failing heart. The drug can be used along with other heart failure treatments to reduce the risk of cardiovascular death and hospitalization in patients suffering from reduced ejection fraction heart failure, who are classified as NYHA class II-IV.
The company intends to start shipping the product in the U.S. in the next week.
Meanwhile, Entresto is under review in Canada, Switzerland and the EU. A response from the Committee for Medicinal Products for Human Use is expected later in 2015. Novartis estimated that upon potential approval around the world, estimated peak sales of the drug may exceed $5 billion for the treatment of reduced ejection fraction heart failure.
Additionally, Novartis is working on expanding Entresto's label and is evaluating the drug for preserved ejection fraction heart failure. Currently, the company is enrolling patients in the phase III registration study on Entresto with regulatory submission expected in or after 2019. Additionally, Tekturna is being developed in a phase III outcome study for chronic heart failure. The drug is expected to be submitted for review in this indication in 2016. Tekturna is already approved for the treatment of hypertension and lowering blood pressure.
According to an abstract published in Heart Disease and Stroke Statistics - 2015 Update: a Report from the American Heart Association , approximately 6 million people in the U.S. suffer from heart failure. Given that the reduced ejection fraction form accounts for nearly half of this population, we are pleased with the approval of Entresto in the U.S. It should boost the company's top line and help improve sales growth dynamics, going forward.
Novartis carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced that its heart failure drug Entresto (previously known as LCZ696) has received FDA approval. | Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The drug can be used along with other heart failure treatments to reduce the risk of cardiovascular death and hospitalization in patients suffering from reduced ejection fraction heart failure, who are classified as NYHA class II-IV. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . The drug can be used along with other heart failure treatments to reduce the risk of cardiovascular death and hospitalization in patients suffering from reduced ejection fraction heart failure, who are classified as NYHA class II-IV. | Some better-ranked stocks in the health care sector are Roche Holding RHHBY , Abbott Laboratories ABT and Johnson & Johnson JNJ . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The drug can be used along with other heart failure treatments to reduce the risk of cardiovascular death and hospitalization in patients suffering from reduced ejection fraction heart failure, who are classified as NYHA class II-IV. |
34038.0 | 2015-07-08 00:00:00 UTC | UPRO, MMM, ABT, ABBV: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/upro-mmm-abt-abbv-large-inflows-detected-etf-2015-07-08 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $139.9 million dollar inflow -- that's a 18.2% increase week over week in outstanding units (from 11,250,000 to 13,300,000). Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $66.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $139.9 million dollar inflow -- that's a 18.2% increase week over week in outstanding units (from 11,250,000 to 13,300,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $66.14. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $139.9 million dollar inflow -- that's a 18.2% increase week over week in outstanding units (from 11,250,000 to 13,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $66.14. | Among the largest underlying components of UPRO, in trading today 3M Co (Symbol: MMM) is down about 1.1%, Abbott Laboratories (Symbol: ABT) is down about 0.4%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $139.9 million dollar inflow -- that's a 18.2% increase week over week in outstanding units (from 11,250,000 to 13,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $66.14. |
34039.0 | 2015-07-01 00:00:00 UTC | Aeterna Zentaris' Endometrial Cancer Study Fully Enrolled - Analyst Blog | ABT | https://www.nasdaq.com/articles/aeterna-zentaris-endometrial-cancer-study-fully-enrolled-analyst-blog-2015-07-01 | nan | nan | Aeterna Zentaris Inc.AEZS announced that it has completed patient enrolment (n=500) in the open-label, randomized-controlled phase III ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study on its oncology candidate zoptarelin doxorubicin. The company said that patient enrolment in this study was completed earlier than expected.
The study is being conducted under the FDA's Special Protocol Assessment and compares the efficacy and safety of zoptarelin doxorubicin to doxorubicin alone for the treatment of advanced, recurrent or metastatic endometrial cancer. The primary efficacy endpoint of the study is improvement in overall survival.
We note that the first interim analysis of the study was conducted in Apr 2015, when the IDMC recommended continuation of the study. Aeterna Zentaris expects the second interim analysis to be conducted in the fourth quarter of 2015 at approximately 192 events. The study should be completed by the end of 2016 with the final analysis planned at 384 events.
Currently, Aeterna Zentaris is working on its commercialization plans for zoptarelin doxorubicin for advanced, recurrent or metastatic endometrial cancer. The company is actively establishing deals with other companies for zoptarelin doxorubicin's commercialization in regions where the company will be unable to sell the product (if approved). Aeterna Zentaris owns worldwide rights to zoptarelin doxorubicin except in China (including Hong Kong and Macau) where the company out-licensed the rights to Sinopharm A-Think Pharmaceuticals.
Meanwhile, zoptarelin doxorubicin is also being evaluated in an investigator-initiated phase II study for prostate cancer. Aeterna Zentaris stated that subject to the success of the ZoptEC program, the company will plan the development of therapies for ovarian, prostate and triple-negative breast cancers.
Aeterna Zentaris carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
AETERNA ZENTARS (AEZS): Free Stock Analysis Report
AVALANCHE BIOT (AAVL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Aeterna Zentaris is working on its commercialization plans for zoptarelin doxorubicin for advanced, recurrent or metastatic endometrial cancer. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . Currently, Aeterna Zentaris is working on its commercialization plans for zoptarelin doxorubicin for advanced, recurrent or metastatic endometrial cancer. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . Aeterna Zentaris Inc.AEZS announced that it has completed patient enrolment (n=500) in the open-label, randomized-controlled phase III ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) study on its oncology candidate zoptarelin doxorubicin. | Some better-ranked stocks in the health care sector are Avalanche Biotechnologies, Inc. AAVL , Abbott Laboratories ABT and Roche Holding AG RHHBY . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Aeterna Zentaris is working on its commercialization plans for zoptarelin doxorubicin for advanced, recurrent or metastatic endometrial cancer. |
34040.0 | 2015-06-30 00:00:00 UTC | Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog | ABT | https://www.nasdaq.com/articles/roches-multiple-sclerosis-studies-meet-primary-endpoint-analyst-blog-2015-06-30 | nan | nan | Roche Holding AGRHHBY announced that two randomized, double-blind, double-dummy, multi-centre phase III studies (OPERA I and OPERA II) evaluating the efficacy and safety of ocrelizumab (600 mg intravenous infusion) have met their primary and major secondary endpoints. Both studies compared ocrelizumab to Merck KGaA MKGAF /Pfizer's PFE Rebif for the treatment of people suffering from relapsing multiple sclerosis.
The primary endpoint in both studies measured ocrelizumab's ability to reduce the annualized relapse rate over a period of two years compared to Rebif. Apart from meeting this endpoint, ocrelizumab led to a significant reduction in the progression of clinical disability and the number of lesions in the brain (measured by MRI) compared to Rebif.
Roche intends to submit these data for review to regulatory authorities in the U.S. and EU in the first quarter of 2016.
Meanwhile, the company is conducting additional analyses on OPERA I and OPERA II with detailed data expected to be presented at an upcoming medical congress.
We note that the phase III development program for ocrelizumab includes three studies - OPERA I, OPERA II studies and ORATORIO (a randomized, double-blind, global multi-centre, placebo-controlled study in people with primary progressive multiple sclerosis). Roche intends to announce results from ORATORIO later this year.
We note that the market for multiple sclerosis is already crowded with several drugs including Tecfidera, Tysabri and Gilenya, among others.
Roche carries a Zacks Rank #2 (Buy). Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Both studies compared ocrelizumab to Merck KGaA MKGAF /Pfizer's PFE Rebif for the treatment of people suffering from relapsing multiple sclerosis. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche. Roche Holding AGRHHBY announced that two randomized, double-blind, double-dummy, multi-centre phase III studies (OPERA I and OPERA II) evaluating the efficacy and safety of ocrelizumab (600 mg intravenous infusion) have met their primary and major secondary endpoints. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche. Roche Holding AGRHHBY announced that two randomized, double-blind, double-dummy, multi-centre phase III studies (OPERA I and OPERA II) evaluating the efficacy and safety of ocrelizumab (600 mg intravenous infusion) have met their primary and major secondary endpoints. | Another well-ranked stock in the health care sector is Abbott Laboratories ABT , carrying the same Zacks Rank as Roche. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. The primary endpoint in both studies measured ocrelizumab's ability to reduce the annualized relapse rate over a period of two years compared to Rebif. |
34041.0 | 2015-06-30 00:00:00 UTC | Intercept Pharmaceuticals Files for OCA in U.S. and Europe - Analyst Blog | ABT | https://www.nasdaq.com/articles/intercept-pharmaceuticals-files-for-oca-in-u.s.-and-europe-analyst-blog-2015-06-30 | nan | nan | Intercept Pharmaceuticals, Inc.ICPT announced that it has achieved two important regulatory milestones related to its lead candidate, obeticholic acid (OCA).
The company has completed submitting a rolling new drug application with the FDA (initiated in Dec 2014) for an accelerated approval for OCA for the above indication. Additionally, the company's marketing authorization application for the candidate has been accepted for review for the same indication by the European Medicines Agency.
We note that Intercept Pharma is looking to get OCA (in combination with ursodeoxycholic acid (UDCA)) approved for the treatment of primary biliary cirrhosis (PBC) in patients who respond inadequately to UDCA or as monotherapy in those unable to tolerate UDCA.
According to Intercept Pharma, PBC is the second-leading cause of liver transplant among women in the U.S. and affects roughly 1 in 1,000 patients over the age of 40. In Europe, 50% of liver transplants due to cholestatic diseases and 6% of all liver transplants are associated to PBC. Given that UDCA is the only approved treatment for PBC, and majority of patients undergoing UDCA therapy experience persistent elevations in serum marker alkaline phosphatase beyond the upper limit of normal, the company believes that there is a critical need for new treatments for PBC.
We note that OCA enjoys both orphan drug and fast track designation for PBC in the U.S. In Europe it enjoys orphan drug status for PBC. In Dec 2014, Intercept Pharma commenced a phase IIIb confirmatory clinical outcomes study on OCA for PBC as per the FDA's accelerated approval regulations. This study will enroll about 350 patients suffering from advanced PBC and is expected to be completed on a post-marketing basis.
We are pleased with the company's efforts to develop and commercialize its lead candidate. If approved, OCA stands to gain a large share of the PBC market. We expect investor focus to remain on regulatory updates from the company.
Meanwhile, Intercept Pharma is evaluating OCA for other chronic liver diseases including nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis and biliary atresia. The company intends to initiate a double-blind, placebo-controlled phase III study on OCA for NASH in the third quarter of 2015.
Intercept Pharma carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . While Gilead holds a Zacks Rank #1 (Strong Buy), J&J and Abbott carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
INTERCEPT PHARM (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. The company has completed submitting a rolling new drug application with the FDA (initiated in Dec 2014) for an accelerated approval for OCA for the above indication. | Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. While Gilead holds a Zacks Rank #1 (Strong Buy), J&J and Abbott carry a Zacks Rank #2 (Buy). | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . We note that Intercept Pharma is looking to get OCA (in combination with ursodeoxycholic acid (UDCA)) approved for the treatment of primary biliary cirrhosis (PBC) in patients who respond inadequately to UDCA or as monotherapy in those unable to tolerate UDCA. | Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Gilead Sciences Inc. GILD , Johnson & Johnson JNJ and Abbott Laboratories ABT . The company has completed submitting a rolling new drug application with the FDA (initiated in Dec 2014) for an accelerated approval for OCA for the above indication. |
34042.0 | 2015-06-29 00:00:00 UTC | Noteworthy ETF Outflows: JKD, ABBV, USB, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-jkd-abbv-usb-abt-2015-06-29 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Morningstar Large-Cap ETF (Symbol: JKD) where we have detected an approximate $55.4 million dollar outflow -- that's a 7.9% decrease week over week (from 5,700,000 to 5,250,000). Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average:
Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Morningstar Large-Cap ETF (Symbol: JKD) where we have detected an approximate $55.4 million dollar outflow -- that's a 7.9% decrease week over week (from 5,700,000 to 5,250,000). For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. | Among the largest underlying components of JKD, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.9%, U.S. Bancorp (Symbol: USB) is off about 1.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the JKD Holdings page » The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $107.81 per share, with $126.28 as the 52 week high point - that compares with a last trade of $122.10. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
34043.0 | 2015-06-29 00:00:00 UTC | Better Dividend Stock: AbbVie or Johnson & Johnson? | ABT | https://www.nasdaq.com/articles/better-dividend-stock-abbvie-or-johnson-johnson-2015-06-29 | nan | nan | Dividend stocks are an essential part of a portfolio for investors focused on the long term. After all, these stocks can amplify gains tremendously when investors use them to purchase more shares through dividend reinvestment plans.
As we all have to make tough investing choices, though, it can be difficult to decide which dividend payers to buy, especially among top dogs such as AbbVie and Johnson & Johnson . These two healthcare companies have a well-earned reputation for increasing their dividends, as well as their top and bottom lines. So let's take a deeper look under the hood of these dividend aristocrats to suss out which stock offers the better long-term prospects.
AbbVie is pursuing a high-growth strategy
Unlike many of its peers in the large-cap dividend-stock universe, AbbVie is still very much a growth stock as well, reflecting management's strategy of producing double-digit revenue growth over the long term. Since being spun off from Abbott Laboratories in 2013, AbbVie has markedly outperformed the broader markets -- all the while increasing its dividend by a noteworthy 28%.
At current levels, AbbVie offers a dividend yield of 2.91%, making it a top dog among income-generating healthcare stocks. Unfortunately, there is some concern that this comparatively high yield might be unsustainable going forward. Because of the drugmaker's various investments in its clinical pipeline and product portfolio -- including its recent $21 billion acquisition of Pharmacyclics -- as a holistic strategy to stave off the pain of the loss of exclusivity for its flagship anti-inflammatory drug Humira in 2017, AbbVie's 12-month trailing payout ratio and cash flows have been heading in the wrong direction for a while now.
On the bright side, the company has been seeing stellar sales growth from multiple products, including Duodopa, Creon, Humira, and Synthroid. And the Pharmacyclics acquisition is expected to start boosting AbbVie's top and bottom lines starting in 2017. Management is also confident that it has a formidable defense in place against generic versions (that is, biosimilars) of Humira that could delay their eventual entry into the marketplace by several years, if not a decade. So there is a better than average chance that this somewhat disconcerting pattern between cash flow and the payout ratio could start to reverse course soon.
Johnson & Johnson has provided investors with decades of steady income and growth
Despite its massive market cap of $276 billion, J&J also has a long history of generating strong top- and bottom-line growth, as well as regularly increasing its dividend. Specifically, this healthcare stalwart has now posted 31 consecutive years of adjusted earnings growth and raised its dividend 53 years in a row.
In recent times, J&J's growth and rising cash flows have been driven almost exclusively by its red-hot pharmaceutical division. Last year, pharmaceutical sales jumped by 15% to $32.3 billion compared with 2013, while the company's medical-device and consumer-healthcare segments posted low-single-digit drop-offs in sales.
However, J&J's pharmaceutical sales are expected to tip this year for a couple of reasons. First off, the introduction of Gilead Sciences ' hepatitis C treatment Harvoni has basically made J&J's hep C drug, Olysio, obsolete. And then there's the threat of biosimilars to its arthritis blockbuster Remicade. Competitors in Europe are offering steep discounts of nearly 40% on their biosimilar, Remsima, which is apparently helping it to grab a larger share of the market than previously anticipated .
This dip in pharma sales looks like a temporary overhang, though, that shouldn't worry investors with a longer-term outlook. In the past five years, J&J has garnered the most new drug approvals with the Food and Drug Administration in the entire pharma industry, and its dominance should continue, with an estimated 12 novel drugs with blockbuster potential expected to come to market by 2019.
So which stock is the winner?
While AbbVie has trounced the broader markets since becoming an independent company, J&J has proved its ability to sustain top-notch value creation over multiple decades. That's why this is such a hard choice.
J&J nevertheless comes off as the winner because it simply has one of the best balance sheets in the industry, which has, in turn, given it the capability of funding numerous partnerships to bolster its clinical pipeline. AbbVie, by contrast, has taken on a lot of debt recently to fund the Pharmacyclics buyout, which could hamstring the drugmaker from pursuing additional deals down the line. Simply put, AbbVie has a far smaller margin of error on the clinical front than J&J to maintain its current levels of growth and dividend yield.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Better Dividend Stock: AbbVie or Johnson & Johnson? originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Because of the drugmaker's various investments in its clinical pipeline and product portfolio -- including its recent $21 billion acquisition of Pharmacyclics -- as a holistic strategy to stave off the pain of the loss of exclusivity for its flagship anti-inflammatory drug Humira in 2017, AbbVie's 12-month trailing payout ratio and cash flows have been heading in the wrong direction for a while now. Management is also confident that it has a formidable defense in place against generic versions (that is, biosimilars) of Humira that could delay their eventual entry into the marketplace by several years, if not a decade. Competitors in Europe are offering steep discounts of nearly 40% on their biosimilar, Remsima, which is apparently helping it to grab a larger share of the market than previously anticipated . | At current levels, AbbVie offers a dividend yield of 2.91%, making it a top dog among income-generating healthcare stocks. Because of the drugmaker's various investments in its clinical pipeline and product portfolio -- including its recent $21 billion acquisition of Pharmacyclics -- as a holistic strategy to stave off the pain of the loss of exclusivity for its flagship anti-inflammatory drug Humira in 2017, AbbVie's 12-month trailing payout ratio and cash flows have been heading in the wrong direction for a while now. And the Pharmacyclics acquisition is expected to start boosting AbbVie's top and bottom lines starting in 2017. | AbbVie is pursuing a high-growth strategy Unlike many of its peers in the large-cap dividend-stock universe, AbbVie is still very much a growth stock as well, reflecting management's strategy of producing double-digit revenue growth over the long term. Because of the drugmaker's various investments in its clinical pipeline and product portfolio -- including its recent $21 billion acquisition of Pharmacyclics -- as a holistic strategy to stave off the pain of the loss of exclusivity for its flagship anti-inflammatory drug Humira in 2017, AbbVie's 12-month trailing payout ratio and cash flows have been heading in the wrong direction for a while now. Johnson & Johnson has provided investors with decades of steady income and growth Despite its massive market cap of $276 billion, J&J also has a long history of generating strong top- and bottom-line growth, as well as regularly increasing its dividend. | At current levels, AbbVie offers a dividend yield of 2.91%, making it a top dog among income-generating healthcare stocks. So which stock is the winner? The Motley Fool recommends Gilead Sciences and Johnson & Johnson. |
34044.0 | 2015-06-29 00:00:00 UTC | Roche's Perjeta Recommended for Pre-Surgery Breast Cancer - Analyst Blog | ABT | https://www.nasdaq.com/articles/roches-perjeta-recommended-for-pre-surgery-breast-cancer-analyst-blog-2015-06-29 | nan | nan | Roche Holding AG 's RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence.
Roche stated that the CHMP's recommendation for Perjeta was the first of its kind in the neoadjuvant setting based on encouraging pathological complete response in a phase II study (NeoSphere) on the candidate.
According to the World Health Organization and other sources, approximately 100,000 people in Europe are diagnosed with HER2-positive breast cancer each year. However, an abstract published in the SEER Cancer Statistics Review reveals that the majority of breast cancer cases can be diagnosed at an early stage of the disease. In this context, Roche emphasized the necessity to bring promising treatments to the market for patients diagnosed with early-stage breast cancer.
We note that the European Commission generally takes the CHMP's recommendation into account during the approval process of a candidate. Given the CHMP's positive opinion, we believe there is high chance for the drug to gain approval as the neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer.
We note that Perjeta is already approved as a neoadjuvant treatment for HER2-positive early-stage breast cancer in the U.S.
Meanwhile, Roche is conducting a phase III study (APHINITY) on Perjeta in the adjuvant (post-surgery) setting. The company expects data from this study to provide additional insight into Perjeta's potential in the treatment of HER2-positive early-stage breast cancer.
Roche is one of the leading companies in the field of developing treatments for breast cancer. The company already has Herceptin, Perjeta and Kadcyla in its HER2-positive breast cancer franchise.
Roche carries a Zacks Rank #2 (Buy). Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . All these stocks carry the same Zacks Rank as Roche.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AG 's RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . Roche Holding AG 's RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . Roche Holding AG 's RHHBY Perjeta (in combination with Herceptin and chemotherapy) received positive opinion from the EU Committee for Medicinal Products for Human Use (CHMP) as a neoadjuvant (pre-surgery) treatment of patients suffering from HER2-positive, locally advanced, inflammatory or early-stage breast cancer who are at a high risk of recurrence. | Other well-ranked stocks in the health care sector are Novo Nordisk A/S NVO , Bayer AG BAYRY and Abbott Laboratories ABT . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Perjeta is already approved as a neoadjuvant treatment for HER2-positive early-stage breast cancer in the U.S. |
34045.0 | 2015-06-18 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2015-06-18 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #116 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 10.4%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34046.0 | 2015-06-17 00:00:00 UTC | Mylan Inks Deal with Pulmatrix for Respiratory Disease Drug - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-inks-deal-with-pulmatrix-for-respiratory-disease-drug-analyst-blog-2015-06-17 | nan | nan | MylanMYL has entered into an ex-U.S. development agreement with Pulmatrix PULM for the latter's respiratory disease candidate, PUR0200. PUR0200, a once-daily therapy in a capsule-based dry powder inhaler, is being evaluated for chronic obstructive pulmonary disease (COPD). PUR0200 contains a long-acting muscarinic agent (LAMA).
As per the terms of the agreement, Pulmatrix will undertake development responsibility and conduct pharmacokinetic study with collaborative support from Mylan. Currently, development is focused on pharmacokinetic bioequivalence in Europe. Mylan enjoys an option for PUR0200 ex-U.S. based on successful completion of the pharmacokinetic study. Financial terms of the agreement were not disclosed.
A currently available LAMA is Incruse Ellipta. As per IMS Health data, global sales of LAMA monotherapies for COPD were approximately $5 billion for the 12 months ending Dec 31, 2014. Out of this approximately $1.5 billion in sales were generated outside the U.S.
Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . We note that Abbott owns 14.5% of Mylan's outstanding shares and is the largest shareholder.
We remind investors that in Apr 2015, Mylan raised its offer to acquire Perrigo. As per the terms of the latest offer, Perrigo shareholders would receive $232.23 per share in a combination of cash and stock.
The acquisition of Perrigo will add a robust suite of store brand over-the-counter pharmaceutical products across several categories including analgesics, cough/cold/allergy/sinus, gastrointestinal and smoking cessation products to Mylan's portfolio. Perrigo also has a presence in nutritionals and generics among others.
Mylan carries a Zacks Rank #4 (Sell). Valeant Pharmaceuticals International, Inc. VRX is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the agreement, Pulmatrix will undertake development responsibility and conduct pharmacokinetic study with collaborative support from Mylan. | Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . Click to get this free report >> Want the latest recommendations from Zacks Investment Research? | Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. As per IMS Health data, global sales of LAMA monotherapies for COPD were approximately $5 billion for the 12 months ending Dec 31, 2014. | Meanwhile, Mylan announced that Abbott Laboratories ABT has said that it would support Mylan's offer to acquire Perrigo Company PRGO . Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the agreement, Pulmatrix will undertake development responsibility and conduct pharmacokinetic study with collaborative support from Mylan. |
34047.0 | 2015-06-12 00:00:00 UTC | Weekly Market Wrap: June 12, 2015 | ABT | https://www.nasdaq.com/articles/weekly-market-wrap-june-12-2015-2015-06-12 | nan | nan | The twenty-third full trading week of 2015 comes to a close with the Dow Jones and S&P 500 down and the NASDAQ composite lower on the day, in late afternoon trading.
Most actively traded stocks include Twitter ( TWTR ) down 0.36%, Bank of America (BAC) lower by 0.17% and Apple (AAPL) down 0.87%.
The S&P 500 and Dow are higher in the last five days of trading, while the NASDAQ is slightly lower over the period.
Crude oil futures are higher this week, trading at $60.10 per barrel on Friday afternoon.
And Gold futures are also higher this week, trading at $1180.20 an ounce this afternoon.
In economic news, the U.S. Census Bureau announced that April 2015 sales of merchant wholesalers, except manufacturers sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $448.3 billion, up 1.6
percent from the revised March level, but were down 3.3 percent from the April 2014 level. Total inventories of merchant wholesalers, except manufacturers sales branches and offices, after adjustment for seasonal variations but not for price changes, were $576.9 billion at the end of April, up 0.4 percent from the revised March level and were up 4.5 percent from the April 2014 level.
In the week ending June 6, the advance figure for seasonally adjusted initial claims was 279,000, an increase of 2,000 from the previous week's revised level. The previous week's level was revised up by 1,000 from 276,000 to 277,000. The 4-week moving average was 278,750, an increase of 3,750 from the previous week's revised average. The previous week's average was revised up by 250 from 274,750 to 275,000.
The Producer Price Index for final demand rose 0.5 percent in May, seasonally adjusted, the U.S. Bureau of Labor Statistics reported. Final demand prices fell 0.4 percent in April and
advanced 0.2 percent in March. On an unadjusted basis, the final demand index declined 1.1
percent for the 12 months ended in May, the fourth straight 12-month decrease.
In May, the increase in the final demand index can be traced to prices for final demand goods, which rose 1.3 percent. The index for final demand services was unchanged.
Within intermediate demand, prices for processed goods climbed 1.0 percent, the index for
unprocessed goods jumped 3.3 percent, and prices for services fell 0.5 percent.
In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. The cash dividend is payable Aug. 15, 2015, to shareholders of record at the close of business on July 15, 2015.
Philip Morris International ( PM ) declared a regular quarterly dividend of $1.00 per common share, payable on July 10, 2015, to shareholders of record as of June 25, 2015. The ex-dividend date is June 23, 2015.
United Technologies Corp.'s ( UTX ) declared, effective July 6, a dividend of 64 cents per common share payable Sept. 10 to shareowners of record at the close of business Aug. 14. The ex-dividend date is Aug. 12.
The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.21 per share payable September 3, 2015, to shareholders of record on August 13, 2015.
Caterpillar ( CAT ) voted to increase the quarterly cash dividend by 10 percent to seventy-seven cents ($0.77) per share of common stock, payable August 20, 2015, to stockholders of record at the close of business on July 20, 2015.
Target Corporation (TGT) has declared a quarterly dividend of 56 cents per common share, a 7.7 percent increase from the prior quarterly dividend of 52 cents. The dividend is payable Sept. 10, 2015, to shareholders of record at the close of business Aug. 19, 2015.
Microsoft announced that its board of directors declared a quarterly dividend of $0.31 per share. The dividend is payable September 10, 2015 to shareholders of record on August 20, 2015. The ex-dividend date will be August 18, 2015.
MasterCard declared a cash dividend of $0.16 per share, payable on August 10, 2015, to holders of record of its Class A common stock and Class B common stock as of July 9, 2015.
FedEx Corporation (FDX) declared a quarterly cash dividend of $0.25 per share on FedEx Corporation common stock. The dividend is payable July 2, 2015 to stockholders of record at the close of business on June 18, 2015.
This is the 'Weekly Market Wrap' for Friday June 12, 2015.
Please join us on Monday for the Week Ahead Market Report.
VIDEO: Weekly Market Wrap: June 12, 2015
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Philip Morris International ( PM ) declared a regular quarterly dividend of $1.00 per common share, payable on July 10, 2015, to shareholders of record as of June 25, 2015. United Technologies Corp.'s ( UTX ) declared, effective July 6, a dividend of 64 cents per common share payable Sept. 10 to shareowners of record at the close of business Aug. 14. | In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. In economic news, the U.S. Census Bureau announced that April 2015 sales of merchant wholesalers, except manufacturers sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $448.3 billion, up 1.6 percent from the revised March level, but were down 3.3 percent from the April 2014 level. Total inventories of merchant wholesalers, except manufacturers sales branches and offices, after adjustment for seasonal variations but not for price changes, were $576.9 billion at the end of April, up 0.4 percent from the revised March level and were up 4.5 percent from the April 2014 level. | In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Caterpillar ( CAT ) voted to increase the quarterly cash dividend by 10 percent to seventy-seven cents ($0.77) per share of common stock, payable August 20, 2015, to stockholders of record at the close of business on July 20, 2015. Target Corporation (TGT) has declared a quarterly dividend of 56 cents per common share, a 7.7 percent increase from the prior quarterly dividend of 52 cents. | In corporate dividend news, Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. The Producer Price Index for final demand rose 0.5 percent in May, seasonally adjusted, the U.S. Bureau of Labor Statistics reported. The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.21 per share payable September 3, 2015, to shareholders of record on August 13, 2015. |
34048.0 | 2015-06-12 00:00:00 UTC | Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO | ABT | https://www.nasdaq.com/articles/daily-dividend-report-abt-mjn-hst-rl-pf-ggg-tho-2015-06-12 | nan | nan | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. The cash dividend is payable Aug. 15, 2015, to shareholders of record at the close of business on July 15, 2015.
Mead Johnson Nutrition Company ( MJN ) has declared a regular quarterly dividend of $0.4125 per share for the quarter ending June 30, 2015. The dividend will be paid on July 2, 2015, to shareholders of record at close of business on June 22, 2015.
Host Hotels & Resorts ( HST ) authorized a regular quarterly cash dividend of $0.20 per share on the Company's common stock. The dividend is payable on July 15, 2015, to stockholders of record on June 30, 2015.
Ralph Lauren Corporation ( RL ) has declared a regular quarterly dividend of $0.50 per share on Ralph Lauren Corporation Common Stock. The dividend is payable on July 10, 2015 to shareholders of record at the close of business on June 26, 2015.
Pinnacle Foods ( PF ) has declared a quarterly cash dividend of $0.235 per share, payable on July 10, 2015 to all common stockholders of record at the close of business on June 24, 2015.
Graco (GGG) has declared a regular quarterly dividend of 30 cents per common share, payable on August 5, 2015, to shareholders of record at the close of business on July 20, 2015.
Thor Industries (THO) approved the payment of a regular quarterly dividend of $0.27 per share. The regular dividend is payable on July 10, 2015, to shareholders of record at the close of business on June 26, 2015.
VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Host Hotels & Resorts ( HST ) authorized a regular quarterly cash dividend of $0.20 per share on the Company's common stock. | VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Ralph Lauren Corporation ( RL ) has declared a regular quarterly dividend of $0.50 per share on Ralph Lauren Corporation Common Stock. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Pinnacle Foods ( PF ) has declared a quarterly cash dividend of $0.235 per share, payable on July 10, 2015 to all common stockholders of record at the close of business on June 24, 2015. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, MJN, HST, RL, PF, GGG, THO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Host Hotels & Resorts ( HST ) authorized a regular quarterly cash dividend of $0.20 per share on the Company's common stock. |
34049.0 | 2015-06-11 00:00:00 UTC | 3 Things AbbVie Inc.'s Management Wants You to Know | ABT | https://www.nasdaq.com/articles/3-things-abbvie-incs-management-wants-you-know-2015-06-11 | nan | nan | In January 2013, healthcare giant Abbott Laboratories made the decision to split itself into two separately traded public companies, keeping its original name and ticker and adding AbbVie to the investable universe.
While investors who held on to either company since the split have benefited, as both companies have outperformed the averages, AbbVie has really been a home-run investment and has more than doubled the S&P 500 's return over that time period.
On AbbVie's most recent quarterly investor conference call, CEO Rick Gonzalez had a lot of great information to share with investors. Here are three takeaways from the call that are worth knowing.
1. Pharmacyclics will be accretive by 2017
In March 2015, AbbVie made a huge $21 billion offer to acquire biopharmaceutical company Pharmacyclics in an effort to expand its presence in the oncology market and in particular to get its hands on cancer drug Imbruvica. The deal closed in May and should be a big driver of growth for the company in the years to come. A key benefit of the deal is that it will help to diversify Abbvie's revenue base away from its reliance on their blockbuster drug Humira, which is set to lose patent protection in the U.S. in December 2016 and in the EU in 2018. Here's what management had to say about how the Pharmacyclics deal will impact AbbVie's financial statements in the years to come:
2. Humira will drive cash flow for years to come
Blockbuster drug Humira was responsible for producing 63% of AbbVie's revenue in 2014. However, with the patent for Humira set to expire in the not-so-distant future, investors have lots of questions about what the impact to revenue and earnings will be when the patent officially expires. Amgen has already made it known that is they consider Humira to be a great candidate for a biosimilar, which is essentially a generic version of a biologic drug. Management, however, is confident that they have hundreds of patents related to the formulation, manufacturing, and indications of Humira, and they will use their intellectual property to defend Humira wherever they can.
3. Hepatitis C drug Viekira Pak will be a big contributor to revenue for the year
AbbVie recently launched a hepatitis C regimen, Viekira Pak, in the United States following FDA approval in mid-December. The drug faces some tough competition from Gilead Sciences ' blockbuster drugs Sovaldi and Harvoni, which may make it difficult for AbbVie's treatment to gain traction. First quarter results for Viekira Pak came in at $231 million worldwide, with only $138 million of that total coming from the U.S. Analysts were expecting sales of $236 million in the U.S. alone, so the drug appears to be off to slower-than-expected start.
Despite the disappointing early results, management actually remains very optimistic for Viekira Pak sales this year, forecasting well over blockbuster status by year end. Here's why:
Looking ahead, analysts see AbbVie continuing to grow its bottom line over the next five years by more than 14%, which makes the company's forward price-to-earnings multiple of 14 look quite reasonable. When you add in the company's generous dividend, which currently yields more than 3%, I'd say AbbVie looks like quite a compelling investment opportunity.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article 3 Things AbbVie Inc.'s Management Wants You to Know originally appeared on Fool.com.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In January 2013, healthcare giant Abbott Laboratories made the decision to split itself into two separately traded public companies, keeping its original name and ticker and adding AbbVie to the investable universe. A key benefit of the deal is that it will help to diversify Abbvie's revenue base away from its reliance on their blockbuster drug Humira, which is set to lose patent protection in the U.S. in December 2016 and in the EU in 2018. Here's why: Looking ahead, analysts see AbbVie continuing to grow its bottom line over the next five years by more than 14%, which makes the company's forward price-to-earnings multiple of 14 look quite reasonable. | Hepatitis C drug Viekira Pak will be a big contributor to revenue for the year AbbVie recently launched a hepatitis C regimen, Viekira Pak, in the United States following FDA approval in mid-December. The drug faces some tough competition from Gilead Sciences ' blockbuster drugs Sovaldi and Harvoni, which may make it difficult for AbbVie's treatment to gain traction. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On AbbVie's most recent quarterly investor conference call, CEO Rick Gonzalez had a lot of great information to share with investors. Humira will drive cash flow for years to come Blockbuster drug Humira was responsible for producing 63% of AbbVie's revenue in 2014. Hepatitis C drug Viekira Pak will be a big contributor to revenue for the year AbbVie recently launched a hepatitis C regimen, Viekira Pak, in the United States following FDA approval in mid-December. | Here's what management had to say about how the Pharmacyclics deal will impact AbbVie's financial statements in the years to come: 2. Humira will drive cash flow for years to come Blockbuster drug Humira was responsible for producing 63% of AbbVie's revenue in 2014. The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." |
34050.0 | 2015-06-01 00:00:00 UTC | Noteworthy ETF Inflows: UPRO, ABT, ACN, ADT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-upro-abt-acn-adt-2015-06-01 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $43.3 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 10,700,000 to 11,300,000). Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $70.78. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $43.3 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 10,700,000 to 11,300,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $70.78. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $43.3 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 10,700,000 to 11,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $70.78. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.3%, Accenture plc (Symbol: ACN) is down about 0.1%, and ADT Corp (Symbol: ADT) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $43.3 million dollar inflow -- that's a 5.6% increase week over week in outstanding units (from 10,700,000 to 11,300,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $45.74 per share, with $73.66 as the 52 week high point - that compares with a last trade of $70.78. |
34051.0 | 2015-05-12 00:00:00 UTC | 5 Largest Markets for Pharmaceuticals | ABT | https://www.nasdaq.com/articles/5-largest-markets-pharmaceuticals-2015-05-12 | nan | nan | Source: Flickr, Creative Commons.
If you're a biotech or Big Pharma company, your world is not only growing, it's standing on its head. According to the Institute for Healthcare Informatics, worldwide spending for prescription branded drugs and generic medicines will jump 30% from 2013-2018 -- a compound annual growth rate of over 5% -- leading to a jaw-dropping $1.3 trillion in annual global drug sales.
The market is also radically shifting position, with traditional strongholds, such as Japan and Europe, flipping over, and emerging markets, such as China, becoming the head. The result is that healthcare investors need a new strategy; they need a way to keep an eye on emerging markets so they aren't left in the lurch because they don't understand the true engines for growth in their holdings.
Here's a country-by-country look at what's really happening with global pharmaceuticals, focusing on the five largest markets for pharmaceuticals, based on sales, in 2013. .
No. 5: France: total pharmaceutical sales in 2013: $37.2 billion France has historically been a strong market for brand name drugs. In general, the culture highly values treatment with expensive medications, as seen by the fact that more than 90% of doctor visits in France end with prescriptions, a much higher rate than other countries.
France's market growth has plateaued however, due to restrictions on retail pharmacy margins and regulation of drug prices. IMS World Review Analyst reports that the French market for pharmaceuticals only grew 1% from 2012 to 2013, down from 4% the previous year. For the record, even at 1%, France is one of the few remaining European markets that is not declining. If you look at the breakdown the European Union as a whole, "growth" is -1%.
The shrinking of the EU market is a serious problem for Big Pharma. Not only is the EU an easy market to reach and understand, but Big Pharma's most innovative drugs, particularly pricey biologics, are skewed toward populations who can afford them, such as you find in many EU countries. For instance, expenditures on targeted oncology drugs increased exponentially in Europe over the past decade, making the EU now responsible for 40% of the overall market for these drugs. By contrast, emerging countries like China prioritize much less expensive drugs for public health diseases.
No. 4: Germany, total pharmaceutical sales in 2013: $45.8 billion
Germany is the leading pharmaceutical market in Europe, but its growth has also slowed to a crawl. The German drug sector is expected to expand at a modest 1.7% rate from 2015 to 2020, according to research and consulting firm GlobalData.
While Germany was once considered a "free price" market, that came to an end in 2011. A reform measure known as AMNOG took effect that year. AMNOG requires that pharma companies prove added benefits of their new products, or face very low reimbursement rates.
AMNOG also excludes some new drugs entirely. For instance, Gilead Sciences ' blockbuster idelalisib, known also as Zydelig, is approved in the U.S., but Germany's tougher regulators insisted "added benefit of idelalisib is not proven." In addition, some pharmaceutical companies are opting voluntarily not to provide their new products to Germany, in the face of needing to prove not just that a drug is effective but that it improves standard of care.
No. 3: China, total pharmaceutical sales in 2013: $86.8 billion
China accounts for 20% of the world's population. Assuming the country's goal of universal coverage for its 1.35 billion citizens by 2020 stays on track, China should make up 34% of the global growth in medication spending over the next five years. In fact, many believe China is destined to become the world's biggest pharmaceutical market.
Yet for all the excitement, cracking China has proven far more complicated than expected for drugmakers.
Bulldozing in with U.S.-approved drugs and expecting a red carpet has been a ticket to nowhere. China's regulatory environment is byzantine, its regions are highly diverse, and the country's poor intellectual property protection has wreaked havoc.
Adding to the pressure is the current recession. In fact, while sales in China for the eight largest drugmakers in the market, including Pfizer , Merck & Co. , and GlaxoSmithKline , climbed 40% in 2011, that growth dwindled to 20% in 2013, according to data compiled by Bloomberg.
China is still the biggest game in town, however. And with billions of dollars behind their efforts, Big Pharma is making unusual alliances. Pfizer produces and markets more than 40 innovative drugs in China, with manufacturing facilities in Dalian, Suzhou, and Wuxi. It also has a stake in one of China's top drug distributors, Shanghai Pharmaceuticals , as well as a joint venture to develop generic drugs with Zhejiang Hisun Pharmaceuticals.
One of the biggest opportunities in China is the diabetes market. According to IMS Health, China's diabetes market is expected to grow 20% to reach $3.2 billion by 2016. Johnson & Johnson is hoping its first diabetes drug, Invokana, will find success in China. As the diabetes market gets ever more crowded in the U.S., Merck's blockbuster Januvia is losing sales, but it may get a break in China, where Merck employs over 2,000 people. Other top U.S.-based drug companies with stakes in China include AbbVie Inc ., Abbott Laboratories , Amgen , and Eli Lilly & Co . Many have joint ventures in China, as well as manufacturing facilities.
No. 2: Japan, total pharmaceutical sales in 2013: $94 billion
Driven by the needs of a rapidly aging population, the world's third-largest economy is the world's second-largest drug market. Highly efficient drug reviews facilitate the rapid entry of new products into Japan, as seen by the country's rapid approval of Opdivo from Bristol-Myers Squibb , prior to its approval in the U.S.
Unfortunately, Japan's drug market has been declining rapidly as the economy struggles with stagnation, made worse by the triple disaster (earthquake, tsunami, nuclear leak) of 2011. The good news for Japan is that innovation in large-scale drug development is picking up.
Traditionally, Japanese drug companies keep research in-house, but that has been changing recently. Takeda Pharmaceutical , Japan's largest pharmaceutical company, is set to increase its global footprint with the announcement of incoming CEO Christopher Weber, a former GlaxoSmithKline executive. Weber will become Takeda's CEO in June, which will make him the company's first foreign CEO. Appointing a foreigner to Takeda's top job is an indication in itself that Takeda is looking to international markets.
No. 1: U.S., total pharmaceutical sales in 2013: $339.7 billion
The annual amount spent per-person on prescription drugs in the U.S. averages $1,000 -- more than twice as much as in countries like Canada, Germany, and Australia.
While the Affordable Care Act contains measures to control healthcare costs, it turns out that Americans not only spend more per drug, we also take more drugs. Disease rates are higher because of lifestyle risks such as obesity, physical inactivity, and excessive alcohol use, according to the Centers for Disease Control and Prevention. Accordingly, rates of heart disease, COPD, and diabetes are higher in the U.S. than in most developed countries.
Branded drugs take by far the biggest bite out of the healthcare drug budget, but a recent WSJ article pointed out that the price of a variety of generics -- whether from coincidence or collusion -- has also been sky-rocketing. It's estimated that half of all small-molecule generics sold through retailers have become more expensive in the past 12 months. In some cases, price hikes exceeded 1,000%, and some even topped 17,000%.
Investor takeaway
Knowing that China's pharmaceutical market is full of pitfalls as well as opportunities doesn't lead directly to finding a great stock pick. Nor does learning about Germany's pricing crackdown pave the way to big investment gains.
But smart investors do their homework. They lay a foundation of basic knowledge before they invest. That can be hard, slow, unglamorous work. But it leads to better investing, based on having realistic expectations for a company's growth in today's unique -- and uniquely challenging -- global marketplace.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... but you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article 5 Largest Markets for Pharmaceuticals originally appeared on Fool.com.
Cheryl Swanson has a position in Pfizer. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In general, the culture highly values treatment with expensive medications, as seen by the fact that more than 90% of doctor visits in France end with prescriptions, a much higher rate than other countries. In addition, some pharmaceutical companies are opting voluntarily not to provide their new products to Germany, in the face of needing to prove not just that a drug is effective but that it improves standard of care. Assuming the country's goal of universal coverage for its 1.35 billion citizens by 2020 stays on track, China should make up 34% of the global growth in medication spending over the next five years. | 4: Germany, total pharmaceutical sales in 2013: $45.8 billion Germany is the leading pharmaceutical market in Europe, but its growth has also slowed to a crawl. In fact, while sales in China for the eight largest drugmakers in the market, including Pfizer , Merck & Co. , and GlaxoSmithKline , climbed 40% in 2011, that growth dwindled to 20% in 2013, according to data compiled by Bloomberg. According to IMS Health, China's diabetes market is expected to grow 20% to reach $3.2 billion by 2016. | 4: Germany, total pharmaceutical sales in 2013: $45.8 billion Germany is the leading pharmaceutical market in Europe, but its growth has also slowed to a crawl. It also has a stake in one of China's top drug distributors, Shanghai Pharmaceuticals , as well as a joint venture to develop generic drugs with Zhejiang Hisun Pharmaceuticals. 2: Japan, total pharmaceutical sales in 2013: $94 billion Driven by the needs of a rapidly aging population, the world's third-largest economy is the world's second-largest drug market. | 4: Germany, total pharmaceutical sales in 2013: $45.8 billion Germany is the leading pharmaceutical market in Europe, but its growth has also slowed to a crawl. One of the biggest opportunities in China is the diabetes market. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34052.0 | 2015-05-04 00:00:00 UTC | Can Mylan (MYL) Specialty Segment Secure Earnings Beat? - Analyst Blog | ABT | https://www.nasdaq.com/articles/can-mylan-myl-specialty-segment-secure-earnings-beat-analyst-blog-2015-05-04 | nan | nan | MylanMYL is set to report first-quarter 2015 results on May 5 after market closes. Last quarter, the company posted a positive earnings surprise of 0.96%. The company has delivered positive earnings surprises in three of the last four quarters with an average beat of 1.51%. Let's see how things are shaping up for this announcement.
Specialty Segment Could Boost Sales
The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015.
The Specialty segment is expected to perform well in the quarter on the back of its flagship product - EpiPen Auto-Injector. Meanwhile, Mylan's Generics segment has been performing well over the last few quarters and is expected to continue its run in the first quarter as well. Mylan has seen quite a few generic launches over the past few quarters and this quarter was no exception. The newly launched products should perform well, driving segmental growth.
We remain positive on Mylan's deal with Abbott ABT . The deal is expected to be accretive to earnings by approximately 20 cents in 2015 and to increase thereafter through 2018. Mylan's agreement to acquire certain female health care businesses of Famy Care Limited, a privately held specialty women's health care company, is also encouraging.
Mylan expects 2015 earnings per share in the range of $4.00 to $4.30 and revenues in the range of $9.7 billion to $10.1 billion.
The company has been in the news lately for its efforts to acquire Perrigo Company PRGO . Meanwhile, Teva Pharmaceutical Industries, Ltd. (TEVA) has shown interest to acquire Mylan.
Earnings Whispers?
Our proven model does not conclusively show that Mylan is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below.
Zacks ESP: Earnings ESP for Mylan is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 70 cents per share.
Zacks Rank: Mylan carries a Zacks Rank #3 (Hold). Though a Zacks Rank #3 increases the predictive power, an ESP of 0.00% leaves the prediction inconclusive.
We caution against stocks with a Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stock to Consider
Here is a company you may want to consider as our model shows that it has the right combination of elements:
The Earnings ESP for Actavis ACT is +0.78% and it carries a Zacks Rank #2. The company is scheduled to release results on May 11.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remain positive on Mylan's deal with Abbott ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. The Specialty segment is expected to perform well in the quarter on the back of its flagship product - EpiPen Auto-Injector. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott ABT . Zacks Rank: Mylan carries a Zacks Rank #3 (Hold). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott ABT . Specialty Segment Could Boost Sales The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015. | We remain positive on Mylan's deal with Abbott ABT . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Specialty Segment Could Boost Sales The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015. |
34053.0 | 2015-04-23 00:00:00 UTC | Company News for April 23, 2015 - Corporate Summary | ABT | https://www.nasdaq.com/articles/company-news-for-april-23-2015-corporate-summary-2015-04-23 | nan | nan | • Shares of Yum! Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72
• Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01
• Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42
• Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
YUM! BRANDS INC (YUM): Free Stock Analysis Report
ANGIES LIST INC (ANGI): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
CHIPOTLE MEXICN (CMG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72 • Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01 • Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42 • Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion Want the latest recommendations from Zacks Investment Research? BRANDS INC (YUM): Free Stock Analysis Report ANGIES LIST INC (ANGI): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHIPOTLE MEXICN (CMG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72 • Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01 • Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42 • Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion Want the latest recommendations from Zacks Investment Research? BRANDS INC (YUM): Free Stock Analysis Report ANGIES LIST INC (ANGI): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHIPOTLE MEXICN (CMG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72 • Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01 • Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42 • Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion Want the latest recommendations from Zacks Investment Research? BRANDS INC (YUM): Free Stock Analysis Report ANGIES LIST INC (ANGI): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHIPOTLE MEXICN (CMG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Brands, Inc. ( YUM ) gained almost 4% after the company reported first quarter earnings per share of $0.80, beating the Zacks Consensus Estimate of $0.72 • Angie's List, Inc.'s ( ANGI ) shares advanced 5% after the company posted first quarter earnings per share of $0.07, in contrast to the Zacks Consensus Estimate of a loss of $0.01 • Shares of Abbott Laboratories ( ABT ) increased 2.6% after the company reported first quarter earnings per share of $0.47 that came ahead of the Zacks Consensus Estimate of $0.42 • Chipotle Mexican Grill, Inc.'s ( CMG ) shares plunged 7.4% after the company posted first quarter revenues of $1.09 billion that lagged the Zacks Consensus Estimate of $1.10 billion Want the latest recommendations from Zacks Investment Research? BRANDS INC (YUM): Free Stock Analysis Report ANGIES LIST INC (ANGI): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHIPOTLE MEXICN (CMG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34054.0 | 2015-04-23 00:00:00 UTC | ABT Dividend Yield Pushes Past 2% | ABT | https://www.nasdaq.com/articles/abt-dividend-yield-pushes-past-2-2015-04-23 | nan | nan | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Dividends are particularly important for investors to consider, because historically speaking dividends have provided a considerable share of the stock market's total return. To illustrate, suppose for example you purchased shares of the S&P 500 ETF ( SPY ) back on 12/31/1999 - you would have paid $146.88 per share. Fast forward to 12/31/2012 and each share was worth $142.41 on that date, a decrease of $4.67/share over all those years. But now consider that you collected a whopping $25.98 per share in dividends over the same period, for a positive total return of 23.36%. Even with dividends reinvested, that only amounts to an average annual total return of about 1.6%; so by comparison collecting a yield above 2% would appear considerably attractive if that yield is sustainable. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index.
In general, dividend amounts are not always predictable and tend to follow the ups and downs of profitability at each company. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield.
According to the ETF Finder at ETF Channel, ABT makes up 10.10% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading higher by about 0.6% on the day Thursday.
Click here to find out which 9 other dividend stocks just recently went on sale »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. | Looking at the universe of stocks we cover at Dividend Channel , in trading on Thursday, shares of Abbott Laboratories (Symbol: ABT) were yielding above the 2% mark based on its quarterly dividend (annualized to $0.96), with the stock changing hands as low as $47.83 on the day. Abbott Laboratories (Symbol: ABT) is an S&P 500 company, giving it special status as one of the large-cap companies making up the S&P 500 Index. In the case of Abbott Laboratories, looking at the history chart for ABT below can help in judging whether the most recent dividend is likely to continue, and in turn whether it is a reasonable expectation to expect a 2% annual yield. |
34055.0 | 2015-04-22 00:00:00 UTC | Abbott Labs (ABT) Beats On Earnings in Q1 - Tale of the Tape | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-earnings-in-q1-tale-of-the-tape-2015-04-22 | nan | nan | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. On Jan 1, 2013, Abbott Labs separated its pharmaceutical business.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. In Feb 2015, Abbott Labs completed the sale of its branded generics pharmaceuticals business in developed markets.
However, strengthening of the dollar against almost every currency and declining oil prices has significantly clouded the global economic outlook for 2015. Unfavorable movement in foreign currency rates is expected to impact 2015 results adversely, particularly in emerging markets where currencies have been devalued. Abbott Labs generates roughly 70% of its sales from outside the U.S.
Nevertheless, Abbott Labs' track record was impressive in 2014 with the company beating estimates comfortably in all the four quarters. The average earnings surprise over the last four quarters has been 7.7%.
Currently, Abbott Labs has a Zacks Rank #4 (Sell). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Abbott Labs reported earnings from continued operations of $0.47, up 38.2% y/y and beat our consensus estimate of $0.42.
Revenue: Abbott Labs posted revenues of $4.89 billion, up 3% y/y and roughly in line with the consensus estimate of $4.86 billion.
Key Stats: Strong performance in branded generics, international nutrition and global diagnostics businesses positively impacted first-quarter results. The company reiterated its earnings guidance for 2015.
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. In Feb 2015, Abbott Labs completed the sale of its branded generics pharmaceuticals business in developed markets. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In Feb 2015, Abbott Labs completed the sale of its branded generics pharmaceuticals business in developed markets. |
34056.0 | 2015-04-22 00:00:00 UTC | Abbott Labs (ABT) Beats on Q1 Earnings, View Reiterated - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-beats-on-q1-earnings-view-reiterated-analyst-blog-2015-04-22 | nan | nan | Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents.
Abbott Laboratories - Earnings Surprise | FindTheCompany
Abbott Labs generated sales of $4.9 billion in the first quarter of 2015, up 3% year over year (on a reported basis). Sales were impacted unfavorably by foreign exchange movements to the tune of 7% during the quarter. Quarterly sales were in line with the Zacks Consensus Estimate.
First Quarter in Detail
Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
EPD sales were up 31.8% to $897 million including the negative impact of 11.2% due to currency fluctuations. Sales in key emerging markets climbed 44.8% on an operational basis (excluding foreign currency fluctuations) driven by growth in India, China, Brazil and Russia.
We note that Abbott Labs completed the CFR Pharmaceuticals acquisition in 2014 thereby more than doubling its branded generics pharmaceuticals presence in Latin America. In Dec 2014, the company completed its acquisition of Russia-based Veropharm. In Feb 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan, Inc. MYL .
The Medical Devices business generated sales of $1.2 billion, down 6.6% year over year (up 1% on an operational basis). Diabetes Care sales were down 5.6%. The Vascular business was down 5.4%. The Medical Optics business was down 10.5% as sales growth in the quarter was impacted by competitive and market dynamics in the cataract and refractive businesses. Launch of new products through the rest of the year (Tecnis Multifocal Low Add and Tecnis Preloaded IOLs) should improve the company's growth trajectory.
The Nutrition business improved 2.3% year over year to $1.7 billion. Pediatric Nutrition sales were up 5.4% during the quarter driven by strong international performance, including double-digit growth in China and Latin America. However, Adult Nutrition sales were weak in the U.S. due to competitive and market dynamics. The company expects improvement in the adult nutrition business over the rest of the year with new product launches.
Diagnostics business sales decreased 2.1% year over year to $1.1 billion. Core Laboratory sales decreased 4.3%, while Point-of-Care Diagnostics grew 14.1%. Worldwide sales of Molecular Diagnostics inched up 0.4%.
2015 Outlook Reiterated
Abbott Labs expects earnings per share in the range of $2.10 to $2.20 in 2015. The Zacks Consensus Estimate currently stands at $2.15, well within the projected range.
Our Take
Abbott Labs currently carries a Zacks Rank #4 (Sell). Unfavorable currency exchange rate movements continue to dampen results. However, the first-quarter beat was impressive. We expect improved performance as the year progresses. The branded generics and international nutrition businesses should drive growth in the coming quarters.
We expect shareholders to react positively to the quarterly beat.
Some better-ranked stocks in the broader health care sector are Shire SHPG and Valeant Pharmaceuticals Inc. VRX . Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
MYLAN NV (MYL): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. First Quarter in Detail Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents. Abbott Laboratories - Earnings Surprise | FindTheCompany Abbott Labs generated sales of $4.9 billion in the first quarter of 2015, up 3% year over year (on a reported basis). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents. Abbott Laboratories - Earnings Surprise | FindTheCompany Abbott Labs generated sales of $4.9 billion in the first quarter of 2015, up 3% year over year (on a reported basis). | Abbott LaboratoriesABT reported first-quarter 2015 earnings of 47 cents per share, up 38.2% from the year-ago quarter and beat the Zacks Consensus Estimate of 42 cents. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories - Earnings Surprise | FindTheCompany Abbott Labs generated sales of $4.9 billion in the first quarter of 2015, up 3% year over year (on a reported basis). |
34057.0 | 2015-04-21 00:00:00 UTC | Pre-Market Earnings Report for April 22, 2015 : KO, BA, MCD, ABT, TMO, EMC, BK, TEL, TROW, STJ, APH, NLSN | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-april-22-2015-ko-ba-mcd-abt-tmo-emc-bk-tel-trow-stj-aph-nlsn | nan | nan | The following companies are expected to report earnings prior to market open on 04/22/2015. Visit our Earnings Calendar for a full list of expected earnings releases.
Coca-Cola Company ( KO ) is reporting for the quarter ending March 31, 2015. The beverages company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.43. This value represents a 2.27% decrease compared to the same quarter last year. In the past year KO has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for KO is 20.43 vs. an industry ratio of 10.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Boeing Company ( BA ) is reporting for the quarter ending March 31, 2015. The aerospace and defense company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.81. This value represents a 2.84% increase compared to the same quarter last year. In the past year BA has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 11.59%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BA is 18.02 vs. an industry ratio of 17.00, implying that they will have a higher earnings growth than their competitors in the same industry.
McDonald's Corporation ( MCD ) is reporting for the quarter ending March 31, 2015. The restaurant company's consensus earnings per share forecast from the 15 analysts that follow the stock is $1.05. This value represents a 13.22% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for MCD is 19.51 vs. an industry ratio of 367.30.
Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. The large cap pharmaceutical company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.42. This value represents a 2.44% increase compared to the same quarter last year. In the past year ABT has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 4.41%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending March 31, 2015. The medical instruments company's consensus earnings per share forecast from the 13 analysts that follow the stock is $1.61. This value represents a 5.23% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 2.58%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TMO is 18.34 vs. an industry ratio of -9.10, implying that they will have a higher earnings growth than their competitors in the same industry.
EMC Corporation ( EMC ) is reporting for the quarter ending March 31, 2015. The computer storage company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.25. This value represents a 7.41% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2015 Price to Earnings ratio for EMC is 17.28 vs. an industry ratio of 8.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Bank Of New York Mellon Corporation ( BK ) is reporting for the quarter ending March 31, 2015. The bank company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.59. This value represents a 1.67% decrease compared to the same quarter last year. BK missed the consensus earnings per share in the 4th calendar quarter of 2014 by -3.33%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BK is 15.62 vs. an industry ratio of 13.60, implying that they will have a higher earnings growth than their competitors in the same industry.
TE Connectivity Ltd. ( TEL ) is reporting for the quarter ending March 31, 2015. The electrical instrument company's consensus earnings per share forecast from the 5 analysts that follow the stock is $1.01. This value represents a 6.32% increase compared to the same quarter last year. In the past year TEL has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 8.89%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TEL is 16.78 vs. an industry ratio of 5.80, implying that they will have a higher earnings growth than their competitors in the same industry.
T. Rowe Price Group, Inc. ( TROW ) is reporting for the quarter ending March 31, 2015. The finance/investment management company's consensus earnings per share forecast from the 11 analysts that follow the stock is $1.13. This value represents a 7.62% increase compared to the same quarter last year. TROW missed the consensus earnings per share in the 3rd calendar quarter of 2014 by -2.61%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for TROW is 17.01 vs. an industry ratio of 15.50, implying that they will have a higher earnings growth than their competitors in the same industry.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending March 31, 2015. The medical products company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.91. This value represents a 5.21% decrease compared to the same quarter last year. In the past year STJ has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2015 Price to Earnings ratio for STJ is 17.27 vs. an industry ratio of 16.20, implying that they will have a higher earnings growth than their competitors in the same industry.
Amphenol Corporation ( APH ) is reporting for the quarter ending March 31, 2015. The electrical connectors company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.56. This value represents a 12.00% increase compared to the same quarter last year. In the past year APH has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 6.78%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for APH is 23.66 vs. an industry ratio of 20.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Nielsen N.V. ( NLSN ) is reporting for the quarter ending March 31, 2015. The business info service company's consensus earnings per share forecast from the 4 analysts that follow the stock is $0.44. This value represents a 7.32% increase compared to the same quarter last year. In the past year NLSN has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 5.33%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for NLSN is 17.60 vs. an industry ratio of 20.10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. In the past year ABT has beat the expectations every quarter. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. In the past year ABT has beat the expectations every quarter. | Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. In the past year ABT has beat the expectations every quarter. | In the past year ABT has beat the expectations every quarter. Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2015. Zacks Investment Research reports that the 2015 Price to Earnings ratio for ABT is 21.69 vs. an industry ratio of 21.10, implying that they will have a higher earnings growth than their competitors in the same industry. |
34058.0 | 2015-04-16 00:00:00 UTC | Notable ETF Outflow Detected - SSO, ABT, ABBV, ACN | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-sso-abt-abbv-acn-2015-04-16 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $60.4 million dollar outflow -- that's a 2.9% decrease week over week (from 15,775,000 to 15,325,000). Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $99.04 per share, with $136.10 as the 52 week high point - that compares with a last trade of $133.61. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $60.4 million dollar outflow -- that's a 2.9% decrease week over week (from 15,775,000 to 15,325,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $99.04 per share, with $136.10 as the 52 week high point - that compares with a last trade of $133.61. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $60.4 million dollar outflow -- that's a 2.9% decrease week over week (from 15,775,000 to 15,325,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $99.04 per share, with $136.10 as the 52 week high point - that compares with a last trade of $133.61. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.4%, AbbVie Inc. (Symbol: ABBV) is up about 1.1%, and Accenture plc (Symbol: ACN) is lower by about 0.4%. For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $99.04 per share, with $136.10 as the 52 week high point - that compares with a last trade of $133.61. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). |
34059.0 | 2015-04-15 00:00:00 UTC | Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-sekisui-medical-to-offer-coagulation-tests-analyst-blog-2015-04-15 | nan | nan | Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis.
As per the terms of the agreement, Abbott Labs will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the U.S., Europe and other regions that recognize CE Mark.
Abbott Labs expects that sales of the CP3000 will begin later in Europe, countries that recognize CE Mark and non-regulated countries in 2015, and in the U.S. in 2016. The company will also have non-exclusive distribution rights with Sekisui in China, Hong Kong, Japan and Macau.
Coagulation tests enable measurement of a person's blood clotting ability, which can enable doctors assess risks of excessive bleeding or developing clots.
The testing will help clinicians to assess patients prior to medical treatments and monitor those who take medications that may affect clotting. The tests are also useful for the diagnosis of blood-related disorders, such as hemophilia and thrombosis.
Abbott Labs is a diversified company with presence in diagnostics, nutrition, branded generics and medical devices, after having separated its pharmaceutical business into a new company called AbbVie ABBV in Jan 2013.
However, lackluster performance in the established pharmaceuticals division propelled the company to realign the segment and divest its branded generic business in developed markets. Growth has dampened in medical devices and diagnostics segment. Hence, Abbott Labs has been putting efforts on boosting its diagnostics segment.
Abbott Labs currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Mallinckrodt plc MNK and Valeant Pharmaceuticals VRX . Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the agreement, Abbott Labs will be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the U.S., Europe and other regions that recognize CE Mark. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis. Abbott Labs expects that sales of the CP3000 will begin later in Europe, countries that recognize CE Mark and non-regulated countries in 2015, and in the U.S. in 2016. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis. Abbott Labs is a diversified company with presence in diagnostics, nutrition, branded generics and medical devices, after having separated its pharmaceutical business into a new company called AbbVie ABBV in Jan 2013. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott LaboratoriesABT announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis. The testing will help clinicians to assess patients prior to medical treatments and monitor those who take medications that may affect clotting. |
34060.0 | 2015-04-10 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 13, 2015 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-13-2015-2015-04-10 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 13, 2015. A cash dividend payment of $0.24 per share is scheduled to be paid on May 15, 2015. Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over the same period a year ago. At the current stock price of $47, the dividend yield is 2.04%.
The previous trading day's last sale of ABT was $47, representing a -1.84% decrease from the 52 week high of $47.88 and a 28.24% increase over the 52 week low of $36.65.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). ABT's current earnings per share, an indicator of a company's profitability, is $1.49. Zacks Investment Research reports ABT's forecasted earnings growth in 2015 as -5.55%, compared to an industry average of -3.9%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
SPDR S&P Health Care Equipment ( XHE )
Direxion S&P 500 Volatility Response Shares ( VSPY ).
The top-performing ETF of this group is XHE with an increase of 13.43% over the last 100 days. IHI has the highest percent weighting of ABT at 10.66%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2015 as -5.55%, compared to an industry average of -3.9%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | ABT's current earnings per share, an indicator of a company's profitability, is $1.49. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 13, 2015. | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $47, representing a -1.84% decrease from the 52 week high of $47.88 and a 28.24% increase over the 52 week low of $36.65. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) SPDR S&P Health Care Equipment ( XHE ) Direxion S&P 500 Volatility Response Shares ( VSPY ). | Shareholders who purchased ABT prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $1.49. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 13, 2015. |
34061.0 | 2015-04-09 00:00:00 UTC | Bulls coming back to Abbott Labs | ABT | https://www.nasdaq.com/articles/bulls-coming-back-abbott-labs-2015-04-09 | nan | nan | (The following is an example of notable trading cited on optionMONSTER's InsideOptions Pro service yesterday.)
Traders are looking for another quick buck in Abbott Laboratories.
optionMONSTER's Heat Seeker system detected heavy activity in the April 46 calls yesterday, with large blocks mostly purchased for $0.55 to $0.75. More than 9,300 changed hands by the closing bell, eclipsing previous open interest of 1,238 contracts.
Long calls lock in the price where investors can buy a stock, allowing them to position for a rally with limited risk. The low cost of the options can also generate significant leverage on a percentage basis. (See our Education section)
The March 47 calls, for instance, were bought for $0.38 on March 11 . They almost doubled to $0.63 the next day as shares inched higher and nearly tripled the following week.
ABT pulled back later that month, only to find support at $45.50 by last week. The drug company ended yesterday's session up 0.91 percent to $46.61. Earnings are due on April 22, after the most recent contracts expire, so the call buyers are looking for a quick move higher before the news.
Overall option volume in the name was 9 times greater than average yesterday, with calls accounting for a bullish 77 percent of the total.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABT pulled back later that month, only to find support at $45.50 by last week. optionMONSTER's Heat Seeker system detected heavy activity in the April 46 calls yesterday, with large blocks mostly purchased for $0.55 to $0.75. Long calls lock in the price where investors can buy a stock, allowing them to position for a rally with limited risk. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ABT pulled back later that month, only to find support at $45.50 by last week. optionMONSTER's Heat Seeker system detected heavy activity in the April 46 calls yesterday, with large blocks mostly purchased for $0.55 to $0.75. | ABT pulled back later that month, only to find support at $45.50 by last week. optionMONSTER's Heat Seeker system detected heavy activity in the April 46 calls yesterday, with large blocks mostly purchased for $0.55 to $0.75. Earnings are due on April 22, after the most recent contracts expire, so the call buyers are looking for a quick move higher before the news. | ABT pulled back later that month, only to find support at $45.50 by last week. (The following is an example of notable trading cited on optionMONSTER's InsideOptions Pro service yesterday.) Traders are looking for another quick buck in Abbott Laboratories. |
34062.0 | 2015-04-08 00:00:00 UTC | SSO, ABT, ABBV, ACN: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/sso-abt-abbv-acn-etf-outflow-alert-2015-04-08 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $45.6 million dollar outflow -- that's a 2.2% decrease week over week (from 16,125,000 to 15,775,000). Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $98.84 per share, with $136.10 as the 52 week high point - that compares with a last trade of $131.47. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $45.6 million dollar outflow -- that's a 2.2% decrease week over week (from 16,125,000 to 15,775,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $98.84 per share, with $136.10 as the 52 week high point - that compares with a last trade of $131.47. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $45.6 million dollar outflow -- that's a 2.2% decrease week over week (from 16,125,000 to 15,775,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $98.84 per share, with $136.10 as the 52 week high point - that compares with a last trade of $131.47. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.1%, AbbVie Inc. (Symbol: ABBV) is trading flat, and Accenture plc (Symbol: ACN) is higher by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $45.6 million dollar outflow -- that's a 2.2% decrease week over week (from 16,125,000 to 15,775,000). For a complete list of holdings, visit the SSO Holdings page » The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $98.84 per share, with $136.10 as the 52 week high point - that compares with a last trade of $131.47. |
34063.0 | 2015-04-02 00:00:00 UTC | Is AbbVie Inc. Stock About to Crash? | ABT | https://www.nasdaq.com/articles/abbvie-inc-stock-about-crash-2015-04-02 | nan | nan | AbbVie has undoubtedly been one of the best performing healthcare stocks since it was spun-off from Abbott Laboratories in 2013:
However, many onlookers believe Abbott decided to jettison AbbVie as a way to isolate itself from the patent expiration of the anti-inflammatory drug Humira. Indeed, AbbVie is pretty much the "Humira stock" given that the drug composes over 60% of its total sales, making its patent expiration in late 2016 a major concern for investors.
Source: Johnson & Johnson
In a surprisingly rich deal, AbbVie's management recently decided to buyout Pharmacyclics for $21 billion, mainly for its top-notch cancer drug Imbruvica, as a means to smooth out the company's transition following Humira's patent expiration. In spite of this buyout, though, AbbVie's stock could still be in deep trouble. Here's why.
Source: AbbVie
Humira's revenues are under threat
With Humira's aforementioned patent expiration in the U.S. set for 2016, U.S. sales revenue are expected to drop by 20 to 30 percent in the 2017 to 2018 time frame. That would translate into about $1.5 to $2 billion in sales lost to copycat biosimilars, if they can get past the onerous regulatory process for biosimilars put in place by the Affordable Care Act.
On the bright side, Humira won't go off-patent in most of Europe until 2018, but the company does face a less rigorous pathway for biosimilar entry in the EU once the drug loses exclusivity. As such, AbbVie could see Humira revenues drop by $3 to $4 billion come 2019, relative to today's figures.
The Pharmacyclics buyout isn't ideal
Once you get past the impressive potential of Imbruvica, the Pharmacyclics buyout ends up looking like an accounting maneuver -- i.e., actual net profits probably won't even cover the cost of the acquisition before Pharmacyclics' orally administered BTK-inhibitor Imbruvica loses patent protection in 2026, especially when taking the interest on AbbVie's new debt into account.
Digging into this assertion a bit deeper, AbbVie is forecasting peak sales of the drug to hit $7 billion by 2020 . Given that AbbVie believes Imbruvica's profit margin could be improved to a stately 50% at some point, the company would thus have $3.5 billion left over, after accounting for marketing and manufacturing expenses. Then, Johnson & Johnson is owed about half of the net profits, meaning that AbbVie would book around $1.75 billion in profit -- and this is AbbVie's rather optimistic scenario.
The Street believes this final number will be closer to $1.5 billion in net profits at peak . Once you add interest on the new debt back into the mix, it would take AbbVie 15 to 16 years to recoup its initial investment in Pharmacyclics and Imbruvica at this rate. Unfortunately, the drug will lose patent protection well before AbbVie has even made its money back.
So, what AbbVie really did was pay $21 billion upfront in order to bolster its EPS once Humira loses patent protection. In short, the EPS should look acceptable going forward because of Imbruvica's sales revenue, but this is akin to running as fast as you can just to stay in the same place.
Imbruvica's peak sales projections are questionable
Cancer drugs are drawing the ire of payers right now. After successfully forcing Gilead Sciences to slash the price of its hep C drugs, top pharmacy benefits managers like Express Scripts are hoping to do the same thing with costly cancer treatments.
Breakthrough treatments such as Imbruvica may be able to maintain premium pricing levels. But the drug is set to face serious competition in the not-so-distant future, and payers almost certainly will use alternative therapies as leverage to lower costs.
Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. And Gilead Sciences' Idelalisib, its BTK inhibitor GS-4059, and its PI3K delta inhibitor GS-9901 are all serious threats to Imbruvica's ultimate commercial potential.
Making matters worse, there are several BTK inhibitors in development across the biopharma landscape that are targeting nearly identical indications (i.e., B-cell malignancies) as Imbruvica. Some of these experimental drugs should eventually reach the market, especially since they are targeting the same basic mechanism as Imbruvica.
What's key to understand is that the current revenue models for Imbruvica -- at least those that I've seen -- do not account for the potential of huge price decreases or the impact of early to midstage rival therapies. Rather, they assume that Imbruvica's stellar clinical profile will allow it to command a premium pricing structure going forward and give it an economic moat against would-be competitors.
As the hep C drug wars have clearly shown, this is probably a highly unlikely scenario, as big pharma enters a new reality where payers have the power to leverage their formularies. As a further example, GlaxoSmithKline relied on similar faulty assumptions for its new respiratory medicines Anoro and Breo Ellipta, only to get stung by U.S. payers in a big way. The net result has been a huge price decrease, massive layoffs, and a revised outlook.
Foolish takeaways
There is a real possibility that AbbVie ends up booking less than a billion in profits from this newly acquired drug at peak -- all for the sake of dressing up its EPS post-Humira patent expiration. So, to make its money back, the drugmaker must be putting an awful lot of faith in Pharmacyclics' clinical pipeline.
In the near term, though, AbbVie's EPS is likely going to tank because of the negative impacts of a $21 billion acquisition, and no meaningful revenue upswing to offset it. After the second quarter of this year when this deal wraps up, AbbVie should thus start posting net losses for multiple consecutive quarters. And that's the underlying reason why AbbVie's shares could tank in 2015.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article Is AbbVie Inc. Stock About to Crash? originally appeared on Fool.com.
George Budwell owns shares of AbbVie Inc. The Motley Fool recommends Johnson & Johnson and Gilead Sciences. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. On the bright side, Humira won't go off-patent in most of Europe until 2018, but the company does face a less rigorous pathway for biosimilar entry in the EU once the drug loses exclusivity. After successfully forcing Gilead Sciences to slash the price of its hep C drugs, top pharmacy benefits managers like Express Scripts are hoping to do the same thing with costly cancer treatments. | Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. Source: Johnson & Johnson In a surprisingly rich deal, AbbVie's management recently decided to buyout Pharmacyclics for $21 billion, mainly for its top-notch cancer drug Imbruvica, as a means to smooth out the company's transition following Humira's patent expiration. Source: AbbVie Humira's revenues are under threat With Humira's aforementioned patent expiration in the U.S. set for 2016, U.S. sales revenue are expected to drop by 20 to 30 percent in the 2017 to 2018 time frame. | Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. Source: Johnson & Johnson In a surprisingly rich deal, AbbVie's management recently decided to buyout Pharmacyclics for $21 billion, mainly for its top-notch cancer drug Imbruvica, as a means to smooth out the company's transition following Humira's patent expiration. The Pharmacyclics buyout isn't ideal Once you get past the impressive potential of Imbruvica, the Pharmacyclics buyout ends up looking like an accounting maneuver -- i.e., actual net profits probably won't even cover the cost of the acquisition before Pharmacyclics' orally administered BTK-inhibitor Imbruvica loses patent protection in 2026, especially when taking the interest on AbbVie's new debt into account. | Oddly enough, AbbVie's own experimental drug ABT-199 might hurt Imbruvica's pricing structure, if approved. Source: Johnson & Johnson In a surprisingly rich deal, AbbVie's management recently decided to buyout Pharmacyclics for $21 billion, mainly for its top-notch cancer drug Imbruvica, as a means to smooth out the company's transition following Humira's patent expiration. The Pharmacyclics buyout isn't ideal Once you get past the impressive potential of Imbruvica, the Pharmacyclics buyout ends up looking like an accounting maneuver -- i.e., actual net profits probably won't even cover the cost of the acquisition before Pharmacyclics' orally administered BTK-inhibitor Imbruvica loses patent protection in 2026, especially when taking the interest on AbbVie's new debt into account. |
34064.0 | 2015-03-31 00:00:00 UTC | The Single Worst Practice of the Drug Industry | ABT | https://www.nasdaq.com/articles/single-worst-practice-drug-industry-2015-03-31 | nan | nan | For millions of ordinary folks like you and me, generic drugs make needed prescription medicines affordable. Generics also reduce the dent in our collective pocketbooks come tax time by cutting billions of dollars annually from the costs of taxpayer-funded healthcare programs such as Medicare and Medicaid.
But if you're a Big Pharma with blockbuster-branded drugs, generic drugs are the enemy. Last year, about 84% of the 4 billion prescriptions written were for generic medicines. The huge discount for a generic med -- up to 90% less than the cost of a branded counterpart -- makes it very rare for patients to switch back to the branded drug once a generic becomes available.
With generic equivalents threatening to obliterate the sales of prized drugs, it comes as no surprise that the Big Pharma giants have developed some pretty questionable legal maneuvers to head off this competition.
While some of these tactics might be defensible, one really raises the hackles on consumers' and taxpayers' necks. Called "pay for delay," it allows many pharmaceutical and biotech companies to make deals that enable them to continue to enjoy monopoly pricing much longer than they otherwise would be able to. The Federal Trade Commission claims this tactic adds up to $3.5 billion in higher drug costs every year for taxpayers and consumers.
Let's make a deal
On a company-to-company basis, the specifics of these deals -- which are also called reverse payment, or exclusion payment -- vary widely. But they all boil down to this: As part of a patent litigation settlement, the branded-drug manufacturer pays a competitor an agreed-upon sum to delay the release of the latter's generic alternative.
Hence, "pay for delay." Or, as we might call it today, "go slow or go home."
It's obvious what Big Pharma gets out of these deals. By keeping the generic drug off the market, companies can continue to control the market for their branded drug. But why do generic companies go along with this? It turns out the loss of revenue loss from keeping a generic off the market is vastly less than the loss of sales at the branded-drug company. So Big Pharma can pay a sum big enough for each company to profit.
Who are the losers in these deals? Patients. In the case of uninsured individuals, the consequences can be devastating. To see the impact, let's look at one pay-for-delay case the FTC is pursuing.
The case involves the drug Provigil, which is often prescribed for multiple sclerosis-related fatigue. A generic version should have gone on market in 2005, but the FTC said brand-name drug manufacturer Cephalon paid more than $200 million to four different generic-drug manufacturers, which therefore agreed to kept their generic versions off the market until 2012. In the meantime, MS patients without insurance had to pay up to $1,200 each month for the drug, or manage without it.
What about patients with insurance? They aren't off the hook, either. Karen Winkler was a 46-year old mother in need of treatment for multiple sclerosis-related fatigue. In an interview with PBS NewsHour , she explained that at the time that Provigil's generics were blocked, she had three young children, and the cost burden was a severe hardship for her family. Her doctor had told her to expect a generic version, but instead Cephalon's pay-for-delay deal kept her paying "$700 for a three-month supply of Provigil, out-of-pocket, even with insurance." Despite overwhelming fatigue, Winkler said, "for years, I'd skip pills or split doses just to get by." Eventually, she stopped taking the medicine "because I could no longer afford its high price."
Overall costs and the latest deals
Prescription drugs vary widely in price. Looking at an overall average, the Federal Trade Commission estimates pay-for-delay deals add $4,590 to a single drug over 17 months. When you project that over the typical five-year length of a pay-for-delay scheme, we're talking about $16,200 in extra spending per patient, per drug, assuming treatment continues over that length of time.
Provigil's generics are on the market now, dropping the cost for the drug to about $16 for a three-month supply. But many other pay-for-delay deals are still in effect. In September, the The Wall Street Journalreported that the FTC had sued several drug makers -- including AbbVie Inc . , Abbott Laboratories , and Teva Pharmaceutical -- for striking deals that delayed the availability of the blockbuster AndroGel testosterone replacement therapy.
And that's just the tip of the iceberg.
A 2012 FTC report cited 40 potential pay-to-delay deals, up from 28 the year before. Looking back to 2005, annual reports by the FTC show as many as 142 generics have been delayed by pay-for-delay tactics, with drug companies raking in an estimated $98 billion in additional branded-drug sales when generic versions were delayed.
Pay-for-delay deals are currently blocking generic versions of popular drugs Nexium (heartburn and GERD), Nuvigil (narcolepsy), Niaspan (high cholesterol), and Aggrenox (stroke prevention), according to a report from consumer group U.S. PIRG.
A good idea gone wrong
The genesis of pay-for-delay goes back to the Hatch-Waxman Act of 1984. The act was supposed to spur competition by encouraging generic-drug makers to challenge brand-name patents. The first successful generic challenger was therefore granted incentives, including a period of marketing exclusivity for its generic drug.
At first, the scheme worked beautifully. But soon, a problem arose.
Rather than compete with the generics, branded-drug companies started creating legal mechanisms in which the brand manufacturer would sue the generic for infringement, then pay a sum of money for an noncompetition agreement. In 2005, when a few appellate courts upheld these agreements, pay-for-delay deals began snowballing.
Thus far, the FTC has had limited success in overturning these deals, but the legal landscape could be changing. Recently, a Supreme Court decision in a reverse payment case discarded lower-court rulings that deemed these agreements automatically legal, and instead declared that reverse payments could violate antitrust laws.
Summing up
The market for drugs is not like the market for a new appliance or an iPhone. When patients don't have reasonably priced access to needed drugs, drug companies risk angering patients and significantly damaging their reputations. Critical questions can then be raised about corporate ethics. Karen Winkler spoke for many patients who have suffered from pay-for-delay deals when she said "It's definitely not moral. It's not humane. It's not fair."
While profits are an important piece of the puzzle for drug companies, at the risk of being branded a hopeless idealist, I don't believe achieving sustainable profit targets and meeting the needs of patients are inherently incompatible. Many great American CEOs in the past didn't believe so, either. For instance, in 1950, George W. Merck, the founder of Merck , said, "We try never to forget that medicine is for the people. It is not for profits. The profits follow, and if we have remembered that, they will never fail to appear."
George Merck was in part responsible for the development of synthetic vitamins, sulfas, antibiotics, and hormones. Under his guidance, Merck generated profits to satisfy shareholders while also greatly improving the lives of patients. Profits before patients is a terrific performance metric, or best practice, for this industry. Here's hoping more multinational pharmaceutical companies aspire to pursue both profit and making a meaningful difference in the quality of life of the patients their drugs treat.
This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act right away, it could make you wildly rich. Experts are calling it the single largest business opportunity in the history of capitalism... The Economist is calling it "transformative"... But you'll probably just call it "how I made my millions." Don't be too late to the party -- click here for one stock to own when the Web goes dark.
The article The Single Worst Practice of the Drug Industry originally appeared on Fool.com.
Cheryl Swanson has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Generics also reduce the dent in our collective pocketbooks come tax time by cutting billions of dollars annually from the costs of taxpayer-funded healthcare programs such as Medicare and Medicaid. With generic equivalents threatening to obliterate the sales of prized drugs, it comes as no surprise that the Big Pharma giants have developed some pretty questionable legal maneuvers to head off this competition. Pay-for-delay deals are currently blocking generic versions of popular drugs Nexium (heartburn and GERD), Nuvigil (narcolepsy), Niaspan (high cholesterol), and Aggrenox (stroke prevention), according to a report from consumer group U.S. PIRG. | For millions of ordinary folks like you and me, generic drugs make needed prescription medicines affordable. Looking at an overall average, the Federal Trade Commission estimates pay-for-delay deals add $4,590 to a single drug over 17 months. Looking back to 2005, annual reports by the FTC show as many as 142 generics have been delayed by pay-for-delay tactics, with drug companies raking in an estimated $98 billion in additional branded-drug sales when generic versions were delayed. | By keeping the generic drug off the market, companies can continue to control the market for their branded drug. A generic version should have gone on market in 2005, but the FTC said brand-name drug manufacturer Cephalon paid more than $200 million to four different generic-drug manufacturers, which therefore agreed to kept their generic versions off the market until 2012. Looking back to 2005, annual reports by the FTC show as many as 142 generics have been delayed by pay-for-delay tactics, with drug companies raking in an estimated $98 billion in additional branded-drug sales when generic versions were delayed. | Last year, about 84% of the 4 billion prescriptions written were for generic medicines. A generic version should have gone on market in 2005, but the FTC said brand-name drug manufacturer Cephalon paid more than $200 million to four different generic-drug manufacturers, which therefore agreed to kept their generic versions off the market until 2012. Looking back to 2005, annual reports by the FTC show as many as 142 generics have been delayed by pay-for-delay tactics, with drug companies raking in an estimated $98 billion in additional branded-drug sales when generic versions were delayed. |
34065.0 | 2015-03-13 00:00:00 UTC | Noteworthy ETF Inflows: VIG, XOM, MMM, ABT | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vig-xom-mmm-abt-2015-03-13 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $1.6 billion dollar inflow -- that's a 7.5% increase week over week in outstanding units (from 255,720,767 to 275,020,766). Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $1.6 billion dollar inflow -- that's a 7.5% increase week over week in outstanding units (from 255,720,767 to 275,020,766). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74. | Among the largest underlying components of VIG, in trading today Exxon Mobil Corp. (Symbol: XOM) is down about 1.7%, 3M Co (Symbol: MMM) is off about 0.5%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $1.6 billion dollar inflow -- that's a 7.5% increase week over week in outstanding units (from 255,720,767 to 275,020,766). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $80.74. |
34066.0 | 2015-03-09 00:00:00 UTC | Why AbbVie Inc.'s $21 Billion Deal Had To Happen | ABT | https://www.nasdaq.com/articles/why-abbvie-incs-21-billion-deal-had-happen-2015-03-09 | nan | nan | Looking ahead
Whether or not Imbruvica can deliver on the industry's lofty expectations remains to be seen, but it's certainly positioned for success. A fast launch and the fact that there are more than 50 ongoing trials that could expand its market significantly could mean that this is just the kind of product that AbbVie needs to offset its risk to Humira. Pharmacyclics thinks that Imbruvica's addressable patient population in blood cancer alone could expand from 40,000 today to 374,000 over time. If so, then it seems that Pharmacylics guidance for more than $1 billion in Imbruvica sales this year isn't misplaced. Where the peak for Imbruvica could be remains to be seen, but with a motivated AbbVie at the helm and J&J as a partner, it's probably not wise to bet against its success.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Why AbbVie Inc.'s $21 Billion Deal Had To Happen originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A fast launch and the fact that there are more than 50 ongoing trials that could expand its market significantly could mean that this is just the kind of product that AbbVie needs to offset its risk to Humira. Pharmacyclics thinks that Imbruvica's addressable patient population in blood cancer alone could expand from 40,000 today to 374,000 over time. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Motley Fool owns shares of Johnson & Johnson. | If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. | If so, then it seems that Pharmacylics guidance for more than $1 billion in Imbruvica sales this year isn't misplaced. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34067.0 | 2015-03-07 00:00:00 UTC | 3 Little-Known Biotech Stocks I'm Keeping an Eye On | ABT | https://www.nasdaq.com/articles/3-little-known-biotech-stocks-im-keeping-eye-2015-03-07 | nan | nan | Source: Neuralstem.
I haven't bought these three little-known biotech stocks (yet), but I am watching them closely because I think each of them could have catalysts soon that could move their shares this year. All three are small-market-cap companies that come with risks that are common in this highly speculative pop-and-drop industry, but for investors willing to take a risk, these three may soon offer up news that could make them worthy of portfolios.
No. 1:Neuralstem, Inc.
Neuralstem's shares have been on a bit of a roll. Since bottoming at less than $2.50 per share in December, the company's shares have jumped 55%. That rally has come as analysts have become increasingly intrigued by the treatments it's developing for central nervous system diseases.
One of those treatments is NSI-566 for ALS, an important indication with a big need for new treatment options.
The company's phase 2 trials for NSI-566 dosed its last patient last July, and results from that trial should be announced soon. If results show that NSI-566 is effective, then it could mark a significant advance, given that the 5,000 ALS patients diagnosed with the disease every year have few treatment options.
Source: Neuralstem.
No. 2: Depomed
While Neuralstem is pinning its hopes on its clinical pipeline, Depomed has been breathing new life into previously approved drugs that have been under-marketed.
Its best-seller is Gralise, a drug that had originally been licensed to Solvay, which Abbott Labs later bought. Abbott chose not to commercialize the shingles pain drug after it was approved in 2010 and instead returned the rights to it back to Depomed in 2011. In the fourth quarter, Gralise sales jumped 55% to $18.1 million.
In addition to Gralise, the company markets the migraine drug Cambia, which it acquired U.S. rights to in December 2013. Sales of Cambria totaled $6.3 million last quarter, giving the drug a $24 million annualized sales run rate that's nicely higher than the $18 million annualized run rate it had when it was acquired.
Thanks in large part to Gralise and Cambria, Depomed reported fourth-quarter net product sales that jumped by 80% year over year to $33.9 million and full-year net product sales of $114.2 million, up from $58.3 million in 2013.
Although Gralise and Cambria are intriguing, I'm even more interested in whether Depomed can kick-start sales for its newly acquired opioid drug Nucynta. In January, Depomed announced the acquisition of Nucynta from Johnson & Johnson for $1.05 billion. Nucynta already has annualized sales of $176 million, and Depomed believes that Nucynta will be immediately accretive to earnings, but the big question on my mind is howaccretive the drug will prove to be. Depomed expects to provide investors with a bit more insight into its Nucynta game plan soon, so I'll be listening carefully to what the company says.
No. 3:Xoma Corp.
Xoma is teamed up with the French drugmaker Servier on gevokizumab, a monoclonal antibody drug that the two companies are studying across a variety of eye-related diseases.
The trial results that I'm waiting eagerly to see are for the use of gevokizumab in Behcet's disease, a rare immune disease of the eye that can damage the optic nerve and cause permanent vision loss.
Servier's trial enrolled its targeted number of patients last year; however, delays in achieving the appropriate number of exacerbations have pushed back the release of data.
Hopefully, those results will come soon, and if they're positive, it could mean that gevokizumab will also post solid results in its trials as a treatment for non-infectious uveitis. The company has two ongoing phase 3 studies for that indication that could have data readouts in the coming year.
Source: Xoma Corporation.
Looking ahead
Biotech stocks aren't for the faint of heart, and these biotechs are no exception; however, investors who are willing to accept the risk of failure may want to join me in keeping tabs on these three tiny biotech stocks because each could end up delivering some profit-friendly news this year.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article 3 Little-Known Biotech Stocks I'm Keeping an Eye On originally appeared on Fool.com.
Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If results show that NSI-566 is effective, then it could mark a significant advance, given that the 5,000 ALS patients diagnosed with the disease every year have few treatment options. Depomed expects to provide investors with a bit more insight into its Nucynta game plan soon, so I'll be listening carefully to what the company says. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. | Sales of Cambria totaled $6.3 million last quarter, giving the drug a $24 million annualized sales run rate that's nicely higher than the $18 million annualized run rate it had when it was acquired. Thanks in large part to Gralise and Cambria, Depomed reported fourth-quarter net product sales that jumped by 80% year over year to $33.9 million and full-year net product sales of $114.2 million, up from $58.3 million in 2013. The Motley Fool owns shares of Johnson & Johnson. | Sales of Cambria totaled $6.3 million last quarter, giving the drug a $24 million annualized sales run rate that's nicely higher than the $18 million annualized run rate it had when it was acquired. Thanks in large part to Gralise and Cambria, Depomed reported fourth-quarter net product sales that jumped by 80% year over year to $33.9 million and full-year net product sales of $114.2 million, up from $58.3 million in 2013. Looking ahead Biotech stocks aren't for the faint of heart, and these biotechs are no exception; however, investors who are willing to accept the risk of failure may want to join me in keeping tabs on these three tiny biotech stocks because each could end up delivering some profit-friendly news this year. | In addition to Gralise, the company markets the migraine drug Cambia, which it acquired U.S. rights to in December 2013. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34068.0 | 2015-03-05 00:00:00 UTC | VIG, ABT, OXY, CAT: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/vig-abt-oxy-cat-etf-outflow-alert-2015-03-05 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $41.0 million dollar outflow -- that's a 0.2% decrease week over week (from 256,219,629 to 255,720,767). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $41.0 million dollar outflow -- that's a 0.2% decrease week over week (from 256,219,629 to 255,720,767). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is up about 0.8%, Occidental Petroleum Corp (Symbol: OXY) is down about 1.3%, and Caterpillar Inc. (Symbol: CAT) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $41.0 million dollar outflow -- that's a 0.2% decrease week over week (from 256,219,629 to 255,720,767). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $72.32 per share, with $83.28 as the 52 week high point - that compares with a last trade of $82.44. |
34069.0 | 2015-03-03 00:00:00 UTC | Mylan Beats on Q4 Earnings, 2015 Guidance Encouraging - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-beats-on-q4-earnings-2015-guidance-encouraging-analyst-blog-2015-03-03 | nan | nan | Mylan 's MYL fourth-quarter 2014 earnings (excluding special items) of $1.05 per share beat the Zacks Consensus Estimate by a penny. Earnings in the fourth quarter of 2014 increased 35% from the year-ago quarter. Earnings benefited from higher revenues and higher gross margins.
Mylan Inc. - Quarterly EPS | FindTheCompany
On a reported basis (including special items), fourth-quarter 2014 earnings increased 4% to 47 cents per share. Revenues climbed 15% to $2.08 billion, broadly in line with the Zacks Consensus Estimate. Mylan recorded year-over-year growth on the back of double-digit revenue growth in both the Specialty and Generics segments.
The company's full-year earnings were up 23% from the prior year to $3.56 per share, a penny above the Zacks Consensus Estimate. Revenues came in at $7.7 billion, increasing 12% and broadly in line with the Zacks Consensus Estimate.
Fourth Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 12% to $1.82 billion. Segmental third-party net sales grew 17% to $1 billion in North America. New product launches aided revenues.
Third-party net sales from the European market decreased 1% to $373.4 million due to unfavorable currency translations. Third party net sales from rest of the world rose 13% to $441 million. Segmental performance improved on the back of increased sales of its antiretroviral products in India. Performance in emerging markets and Brazil was also strong during the quarter.
Third-party net sales in the Specialty segment jumped 38% to $242.7 million. Specialty segment sales were boosted by the strong performance of its flagship product - EpiPen Auto-Injector - for severe allergic reactions. Sales of the product improved due to increased volume and favorable pricing.
Adjusted gross margin during the fourth quarter of 2014 expanded to 54% from 51% in the year-ago quarter on the back of strong sales of EpiPen Auto-Injector and new products.
2015 Outlook
Mylan expects adjusted earnings per share in the range of $4.00 to $4.30, representing an increase of 17%. The company expects revenues in the range of $9.7 billion to $10.1 billion, up 28% from 2014. The Generics segment is expected to see revenue growth of approximately 40% in 2015. The guidance assumes the launch of AB-rated generic Copaxone in the second half of 2015.
Specialty revenues are expected to be flat in 2015. The company expects to face generic competition for EpiPen Auto-Injector in the second half of 2015.
The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. The products acquired from Abbott are expected to generate revenues of approximately $1.5 billion to $1.8 billion in 2015. Foreign exchange translations are expected to impact revenues by approximately $300 million to $400 million.
The Zacks Consensus Estimate for 2015 earnings is at $4.15 per share on revenues of approximately $9.2 billion.
The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015. Third-quarter earnings are expected to be the strongest.
Our Take
Mylan's fourth-quarter results were better than expected with the company beating on earnings. Revenues were driven by strong sales in the Specialty segment. We are looking forward to the potential launch of generic versions of Copaxone, which should boost revenues further. We are pleased with the company's 2015 guidance.
We remain positive on Mylan's deal with Abbott. The deal is expected to be accretive to earnings by approximately 20 cents in 2015 and to increase thereafter through 2018. Mylan's agreement to acquire certain female health care businesses of Famy Care Limited, a privately held specialty women's health care company, is also encouraging. The deal is expected to complete in the second half of 2015. The Famy Care acquisition will also complement Mylan's acquisition of Abbott's ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Mylan is expected to remain active on the acquisition front in 2015 in order to drive long-term growth.
Mylan carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Cytokinetics, Inc CYTK and Alnylam Pharmaceuticals, Inc. ALNY . While Cytokinetics sports a Zacks Rank #1 (Strong Buy), Alnylam is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
CYTOKINETCS INC (CYTK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan 's MYL fourth-quarter 2014 earnings (excluding special items) of $1.05 per share beat the Zacks Consensus Estimate by a penny. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. Mylan 's MYL fourth-quarter 2014 earnings (excluding special items) of $1.05 per share beat the Zacks Consensus Estimate by a penny. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. The company expects adjusted earnings per share to be flat in the first quarter with growth expected in the following three quarters of 2015. | The guidance includes contributions from the business acquired from Abbott Laboratories ABT and the pending Famy Care acquisition. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The Generics segment is expected to see revenue growth of approximately 40% in 2015. |
34070.0 | 2015-03-02 00:00:00 UTC | These Stocks Just Raised Their Dividends | ABT | https://www.nasdaq.com/articles/these-stocks-just-raised-their-dividends-2015-03-02 | nan | nan | With all the dividend raises occurring in this early part of the year, several likely suspects have decided to get in on the action.
These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a minimum of 25 years in a row.
Last week, several of these blue bloods maintained this rarefied status by hiking their payouts. Here are three making their stockholders incrementally richer:
Coca-Cola( KO )
This top beverage company, which needs no introduction, is the most durable of our chosen Aristocrats based on longevity. With its latest quarterly dividend raise -- by 8% to $0.33 per share -- it's now lifted its payout for a hard-to-believe 53 consecutive years.
That should improve morale among Coca-Cola's many investors following a 55% drop in net profit in the firm's just-reported Q4 (to $770 million, its lowest quarterly figure in years).
KO Net Income (Quarterly) data by YCharts
That pain might not melt away soon; this most global of American firms is projecting a negative impact of 7 to 8 percentage points to pre-tax profit this year due to the strengthened dollar.
But there's substantial reason for optimism. Although sales of its carbonated products aren't advancing much, the company has done an admirable job selling the heck out of its non-fizzy beverages. Recently three products -- Gold Peak and FUZE teas, and I Lohas mineral water -- became billion dollar brands (i.e., annual sales totaling at least that amount).
That's why I believe Coca-Cola has good potential for the future. Also worth keeping in mind is that the firm is still in the black and, more importantly for dividend purposes, continuing to generate plenty of cash. At the end of Q4 its cash and equivalents stood at just under $9 billion, which is well above the approximately $5.8 billion it would hand out in its new, higher dividend should it be maintained for the rest of this year.
That payout is to be dispensed on April 1 to shareholders of record as of March 16.
Colgate-Palmolive( CL )
On the subject of durable companies that reliably spit out a dividend, this consumer goods giant is keeping its own streak alive. Last week it hiked its quarterly distribution by 6% to $0.38 per share.
This comes on the heels of a modest yet satisfying quarter for the firm. It edged past the market's expectations for its Q4 profitability, driven by strong organic growth contributed by all of its operating divisions.
This was good enough to boost the company's share price, which inched upwards by 2% the day after the results were announced.
CL data by YCharts
Going forward, this multinational conglomerate anticipates facing strong headwinds because of the recent, and likely sustained, rise of the US dollar (over 80% of its sales come from outside North America). But even in the face of that, the company's anticipating per-share earnings growth.
Meanwhile, Colgate-Palmolive has managed to keep its free cash flow remarkably steady over the past few years at around $2.5 billion. This is more than enough for the approximately $1.4 billion it'll need to pay a year's worth of the enhanced distribution.
Colgate-Palmolive will hand out that raised dividend on May 15 to stockholders of record as of April 23.
AbbVie( ABBV )
Technically, this pharmaceutical major shouldn't be a dividend aristocrat, because it's only existed since 2013. But AbbVie makes the team because it's a spinoff of Abbott Laboratories , a steady longtime dividend raiser. The former declared a fresh quarterly distribution last week of $0.51 per share, 4% higher than its predecessor.
Certain alarm bells might ring over that, since the company posted a net loss in its most recently reported quarter. This was due in no small part to a fat $1.6 billion-plus break-up fee it paid fellow pharmaceutical Shire PLC following an abandoned buyout attempt.
Yet in terms of core earnings drivers, AbbVie's doing well. Sales of its star drug Humira advanced by 14% on a currency-adjusted basis in Q4. Humira accounted for 63% of the company's revenue last year , but that doesn't mean it's the only good performer -- lung infection treatment Synagis and Parkinson's disease drug Synagis grew by a respective 5% and 9% in Q4.
ABBV Cash from Operations (Annual) data by YCharts
The current portfolio should continue to be popular and profitable, meanwhile the company's pipeline features treatments with a lot of potential. Considering that, I believe the firm will find a way to stay Aristocratic.
AbbVie's next distribution is to be paid on May 15 to shareholders of record as of April 15.
Bank of America + Apple? This device makes it possible.
Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out , and some early viewers are claiming it's destined to change everything from banking to health care. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here !
The article These Stocks Just Raised Their Dividends originally appeared on Fool.com.
Eric Volkman has no position in any stocks mentioned. The Motley Fool recommends Coca-Cola, owns and recommends shares of Apple and Bank of America, and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | KO Net Income (Quarterly) data by YCharts That pain might not melt away soon; this most global of American firms is projecting a negative impact of 7 to 8 percentage points to pre-tax profit this year due to the strengthened dollar. CL data by YCharts Going forward, this multinational conglomerate anticipates facing strong headwinds because of the recent, and likely sustained, rise of the US dollar (over 80% of its sales come from outside North America). ABBV Cash from Operations (Annual) data by YCharts The current portfolio should continue to be popular and profitable, meanwhile the company's pipeline features treatments with a lot of potential. | ABBV Cash from Operations (Annual) data by YCharts The current portfolio should continue to be popular and profitable, meanwhile the company's pipeline features treatments with a lot of potential. But one small company makes Apple's gadget possible. The Motley Fool recommends Coca-Cola, owns and recommends shares of Apple and Bank of America, and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. | These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a minimum of 25 years in a row. With its latest quarterly dividend raise -- by 8% to $0.33 per share -- it's now lifted its payout for a hard-to-believe 53 consecutive years. The Motley Fool recommends Coca-Cola, owns and recommends shares of Apple and Bank of America, and has the following options: long January 2016 $37 calls on Coca-Cola and short January 2016 $37 puts on Coca-Cola. | These are the Dividend Aristocrats, the companies that have raised their distributions at least once annually for a minimum of 25 years in a row. Colgate-Palmolive will hand out that raised dividend on May 15 to stockholders of record as of April 23. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34071.0 | 2015-02-27 00:00:00 UTC | Will Mylan (MYL) Beat Earnings on New Product Launches? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-mylan-myl-beat-earnings-on-new-product-launches-analyst-blog-2015-02-27 | nan | nan | Mylan ( MYL ) is set to report fourth quarter 2014 results on Mar 2 before the market opens. Last quarter, the company posted a positive earnings surprise of 1.75%. The company has delivered positive earnings surprises in three of the last four quarters with an average beat of 2.27%. We expect the company to beat expectations in the fourth quarter as well.
Why a Likely Positive Surprise?
Our proven model shows that Mylan is likely to beat earnings because it has the right combination of two key ingredients.
Positive Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +2.89%. This is a meaningful and leading indicator of a likely positive earnings surprise.
Zacks Rank #3 (Hold): Note that stocks with Zacks Ranks #1 (Strong Buy), 2 (Buy) and 3 have a significantly higher chance of beating earnings estimates. We caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
The combination of Mylan's Zacks Rank #3 and an earnings ESP of +2.89% makes us confident of an earnings beat this season.
Specialty Segment and Product Launches to Boost Sales
Mylan expects its fourth quarter adjusted earnings to be in the band of $1.03 to $1.09 per share, much above the year-ago earnings of 78 cents. Earnings in the fourth quarter are expected to be boosted by new product launches in North America along with the strong performance of the Specialty segment.
The Specialty segment is expected to perform well in the quarter on the back of its flagship product - EpiPen Auto-Injector. The company said on its third quarter conference call that the Specialty segment will continue to grow.
Meanwhile, Mylan's Generics segment has been performing well over the last few quarters and is expected to continue its run in the fourth quarter as well. Mylan has seen quite a few generic launches over the past few quarters and this quarter was no exception. The newly launched products should perform well, driving segmental growth.
Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. We expect some updates on the impending deal at the release.
Mylan expects 2014 earnings per share in the range of $3.54 to $3.60 and revenues in the range of $7.7 billion to $7.8 billion. Mylan is expected to provide its guidance for 2015 on its fourth quarter call. We expect investor focus to be on the company's guidance.
Other Stocks to Consider
Here are some other companies you may consider as our model shows that they also have the right combination of elements.
Amarin Corporation plc ( AMRN ) has an earnings ESP of +14.29% and carries a Zacks Rank #2. It is set to report fourth quarter results on Mar 3.
Aratana Therapeutics, Inc. ( PETX ) has an earnings ESP of +10.00% and carries a Zacks Rank #3. It is expected to report fourth quarter results on Mar 12.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
AMARIN CORP PLC (AMRN): Free Stock Analysis Report
ARATANA THERAP (PETX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan ( MYL ) is set to report fourth quarter 2014 results on Mar 2 before the market opens. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. Mylan ( MYL ) is set to report fourth quarter 2014 results on Mar 2 before the market opens. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. Specialty Segment and Product Launches to Boost Sales Mylan expects its fourth quarter adjusted earnings to be in the band of $1.03 to $1.09 per share, much above the year-ago earnings of 78 cents. | Mylan is set to strengthen its Generics segment further with the impending acquisition of Abbott Laboratories' ( ABT ) branded specialty and generics business that the company had announced last year. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report ARATANA THERAP (PETX): Free Stock Analysis Report To read this article on Zacks.com click here. We expect the company to beat expectations in the fourth quarter as well. |
34072.0 | 2015-02-20 00:00:00 UTC | Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO | ABT | https://www.nasdaq.com/articles/daily-dividend-report-abt-stt-apa-irm-abbv-cl-cp-lo-2015-02-20 | nan | nan | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. This marks the 365th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2015, to shareholders of record at the close of business on April 15, 2015.
State Street ( STT ) declared a quarterly cash dividend of $0.30 per share of common stock, payable April 16, 2015 to common shareholders of record as of April 1, 2015.
Apache Corporation ( APA ) has declared regular cash dividends on the company's common shares. The dividend on common shares of 25 cents per share is payable on May 22, 2015, to stockholders of record on April 22, 2015.
Iron Mountain ( IRM ) declared a cash dividend of $0.475 per share on the common stock of the company, payable on March 20, 2015 to shareholders of record at the close of business on March 6, 2015.
AbbVie ( ABBV ) increased the company's quarterly cash dividend by 4 percent from $0.49 per share to $0.51 per share. The cash dividend is payable May 15, 2015 to stockholders of record at the close of business on April 15, 2015.
Colgate-Palmolive Company increased the ongoing quarterly common stock cash dividend by 6%. The increase will be effective in the second quarter, 2015. The new rate of $.38 per share is up from $.36 per share. The Board declared that the second quarter dividend is to be paid on May 15, 2015 to shareholders of record as of April 23, 2015. On an annualized basis, the new dividend rate is $1.52 versus $1.44 per share previously. The Company has paid uninterrupted dividends on its common stock since 1895.
Canadian Pacific Railway (CP) declared a quarterly dividend of thirty-five cents ($0.35) Canadian per share on the outstanding Common Shares. The dividend is payable on April 27, 2015 to holders of record at the close of business on March 27, 2015.
And, Lorillard (LO) approved a 7% increase in the quarterly dividend on its common stock from $0.615 per share to $0.66 per share. The dividend is payable on March 10, 2015 to stockholders of record as of March 2, 2015.
VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. Apache Corporation ( APA ) has declared regular cash dividends on the company's common shares. | VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. State Street ( STT ) declared a quarterly cash dividend of $0.30 per share of common stock, payable April 16, 2015 to common shareholders of record as of April 1, 2015. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. State Street ( STT ) declared a quarterly cash dividend of $0.30 per share of common stock, payable April 16, 2015 to common shareholders of record as of April 1, 2015. | Abbott ( ABT ) declared a quarterly common dividend of 24 cents per share. VIDEO: Daily Dividend Report: ABT, STT, APA, IRM, ABBV, CL, CP, LO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The dividend on common shares of 25 cents per share is payable on May 22, 2015, to stockholders of record on April 22, 2015. |
34073.0 | 2015-02-11 00:00:00 UTC | Zoetis Beats on Q4 Earnings, Provides In-Line 2015 Outlook - Analyst Blog | ABT | https://www.nasdaq.com/articles/zoetis-beats-on-q4-earnings-provides-in-line-2015-outlook-analyst-blog-2015-02-11 | nan | nan | Zoetis ' ( ZTS ) fourth-quarter 2014 adjusted earnings of 40 cents per share were ahead of the Zacks Consensus Estimate of 36 cents. Fourth-quarter 2014 earnings were above the year-ago figure by 4 cents. The year-over-year increase was primarily due to higher revenues.
Zoetis Inc. - Earnings Surprise | FindTheBest
Including one-time items, Zoetis reported earnings of 25 cents per share, up 19%. We expect investors to react positively to the news.
Revenues at Zoetis climbed 5% to $1.32 billion in the fourth quarter of 2014. Foreign currency movements impacted revenues negatively. Revenues were slightly above the Zacks Consensus Estimate of $1.26 billion.
The company's full-year adjusted earnings were up 11% from the year-ago period to $1.57 per share, above the Zacks Consensus Estimate of $1.53. Revenues came in at $4.8 billion, increasing 5% and exceeding the Zacks Consensus Estimate of $4.7 billion.
Quarterly Details
Zoetis boasts a robust and diversified product portfolio. The product portfolio is divided into five categories - anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals for veterinarians and livestock producers.
Zoetis markets its offerings primarily across the following species: cattle, swine, poultry, others (livestock) and dogs, cats and horses (companion animals). In the fourth quarter of 2014, sales of livestock products accounted for 68.5% of total revenues. Approximately 30.7% of revenues in the quarter came from the sale of companion animal products. The balance came from contract manufacturing.
Geographically, the company operates in four segments - the U.S, Europe/Africa/Middle East (EuAfME), Canada/Latin America (CLAR), and Asia/Pacific (APAC). Sales improved in the U.S. by 14% driven by strong sales of livestock products and improvement in companion animal products sales. Sales in the EuAfME market fell 6%. Sales in the CLAR and APAC markets however increased by 7% and 1% respectively. The growth rates are inclusive of foreign exchange impact.
2015 Outlook Updated
The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions.
For 2015, excluding one-time items, earnings are expected to be in the range of $1.61 to $1.68 per share. The Zacks Consensus Estimate of $1.66 is within the guidance range. The company expects revenues to be between $4.8 billion and $4.9 billion; the Zacks Consensus Estimate of $4.9 billion is in line with the guided range.
Our Take
We are impressed with the company's performance in the fourth quarter driven primarily by total livestock revenue growth and improvement in companion animal products.
We are also positive on the company's deal with Abbott. Zoetis has purchased Abbott's animal health assets for $255 million. The transaction will boost Zoetis' companion animal product portfolio and expand its diagnostics business. We expect to see more such acquisitions/deals at the company in the near future as it continues to focus on its strategy of acquiring complementary businesses and products.
Zoetis carries a Zack Rank #3 (Hold). Some better-ranked stocks in the health care space include Alnylam Pharmaceuticals, Inc. ( ALNY ) and Achillion Pharmaceuticals, Inc. ( ACHN ). Both stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ZOETIS INC (ZTS): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALNYLAM PHARMA (ALNY): Free Stock Analysis Report
ACHILLION PHARM (ACHN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | 2015 Outlook Updated The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions. Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. The product portfolio is divided into five categories - anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals for veterinarians and livestock producers. | Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. 2015 Outlook Updated The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions. Zoetis Inc. - Earnings Surprise | FindTheBest Including one-time items, Zoetis reported earnings of 25 cents per share, up 19%. | Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. 2015 Outlook Updated The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions. Sales improved in the U.S. by 14% driven by strong sales of livestock products and improvement in companion animal products sales. | 2015 Outlook Updated The company updated its 2015 guidance to incorporate the expected impact of foreign currency, acquisition of certain assets from Abbott Laboratories ( ABT ) and other changes in its operating assumptions. Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Sales in the CLAR and APAC markets however increased by 7% and 1% respectively. |
34074.0 | 2015-02-10 00:00:00 UTC | Mylan Faces Patent Infringement Lawsuit for Nexavar - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-faces-patent-infringement-lawsuit-for-nexavar-analyst-blog-2015-02-10 | nan | nan | Mylan Inc. ( MYL ) announced that it is looking to bring its generic version of Bayer's ( BAYRY ) cancer drug, Nexavar (sorafenib) to market. Mylan confirmed that Bayer Healthcare, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc. have filed a patent infringement lawsuit against Mylan in the United States District Court in the District of Delaware.
Nexavar is approved for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Mylan believes it was first to file, which means it would be entitled to 180 days of marketing exclusivity, once it gains final approval.
According to IMS Health, annual U.S. sales of Nexavar were about $48 million in 2014.
Currently, Mylan has 283 abbreviated new drug applications (ANDAs) pending with the FDA representing branded annual sales of $107.1 billion, according to IMS Health. Mylan believes that 43 of these pending ANDAs are potential first-to-file opportunities representing annual branded sales of $27.2 billion (according to IMS Health) for the 12 months ending Jun 30, 2014.
Mylan is one of the leading players in the global generics market and boasts of a deep generic pipeline. The company was among the first to launch a generic version of Celebrex in Dec 2014.
Earlier this year, Mylan launched its generic versions of Epivir-HBV and Diovan. Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets.
Mylan currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Impax Laboratories ( IPXL ), sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Mylan has 283 abbreviated new drug applications (ANDAs) pending with the FDA representing branded annual sales of $107.1 billion, according to IMS Health. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets. Mylan Inc. ( MYL ) announced that it is looking to bring its generic version of Bayer's ( BAYRY ) cancer drug, Nexavar (sorafenib) to market. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets. Mylan Inc. ( MYL ) announced that it is looking to bring its generic version of Bayer's ( BAYRY ) cancer drug, Nexavar (sorafenib) to market. | Meanwhile, we remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan Inc. ( MYL ) announced that it is looking to bring its generic version of Bayer's ( BAYRY ) cancer drug, Nexavar (sorafenib) to market. |
34075.0 | 2015-02-09 00:00:00 UTC | Will Zoetis (ZTS) Earnings Disappoint Expectation in Q4? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-zoetis-zts-earnings-disappoint-expectation-in-q4-analyst-blog-2015-02-09 | nan | nan | Zoetis Inc . ( ZTS ) is scheduled to report fourth-quarter 2014 results before the opening bell on Feb 11. Last quarter, the company posted a positive earnings surprise of 10.81%. The company has recorded positive earnings surprises in three of the four trailing quarters with an average beat of 3.45%. Let's see how things are shaping up for this announcement.
Factors at Play this Quarter
Zoetis' robust and diversified product portfolio should help support revenues. The company's livestock segment should continue to do well. We note that Zoetis is the former Animal Health business of Pfizer Inc. ( PFE ). The company is working on building global manufacturing and supply functions, which may lead to higher costs.
For 2014, the company expects adjusted earnings per share in the range of $1.50 to $1.54 on revenues of $4.7 billion to $4.75 billion. Although, foreign currency movements did not have any significant impact on revenues in the third quarter, it can prove to be a threat this quarter.
For 2015, excluding one-time items, earnings are expected to be in the range of $1.61 to $1.68 per share. The company expects revenues to be between $4.85 billion and $4.95 billion. We could see an update on the same along with the fourth quarter results. An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. Zoetis has entered into an agreement with Abbott Labs to buy the latter's animal health assets for $255 million.
Earnings Whispers?
Our proven model does not conclusively show that Zoetis is likely to beat earnings estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below.
Zacks ESP: Earnings ESP for Zoetis is 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 36 cents per share.
Zacks Rank: Zoetis carries a Zacks Rank #4 (Sell). Zoetis' Zacks Rank #4 when combined with an ESP of 0.00% makes an earnings beat unlikely.
As it is, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks that Warrant a Look
Here are some companies you may want to consider as our model shows that these have the right combination of elements:
Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). The company is expected to release results on Feb 12.
Actavis ( ACT ) has an earnings ESP of +4.38% and carries a Zacks Rank #2 (Buy). The company is expected to release fourth-quarter 2014 results on Feb 18.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
ACORDA THERAPT (ACOR): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. Zoetis has entered into an agreement with Abbott Labs to buy the latter's animal health assets for $255 million. Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). | An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. Zacks Rank: Zoetis carries a Zacks Rank #4 (Sell). Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. | An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. As it is, we caution against stocks with Zacks Ranks #4 and 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions. Stocks that Warrant a Look Here are some companies you may want to consider as our model shows that these have the right combination of elements: Acorda Therapeutics, Inc. ( ACOR ) has an Earnings ESP of +106.67% and a Zacks Rank #3 (Hold). | An update on the company's $500 million share repurchase program as well as Abbott Laboratories' (ABT) deal is also expected on the call. Zoetis Inc . This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. |
34076.0 | 2015-02-04 00:00:00 UTC | 5 Things AbbVie Inc.'s Management Wants You to Know | ABT | https://www.nasdaq.com/articles/5-things-abbvie-incs-management-wants-you-know-2015-02-04 | nan | nan | Source: AbbVie
By most measures, AbbVie performed well in the fourth quarter of 2014. Earnings handily beat expectations. Revenue increased in line with consensus forecasts. And yet shares dropped over 4% on Friday after the company released its financial results.
What happened? During AbbVie'searnings call the company provided projections for hepatitis C drug Viekira Pak that disappointed analysts. This underscores how the message from a company's management team about the future usually outweighs numbers from the prior quarter. In case you missed it, here are the key things from AbbVie's call that management wants investors to know. (Quotes courtesy of Thomson Reuters StreetEvents .)
1. Under-promised and over-delivered
Chairman and CEO Rick Gonzalez spoke only a few seconds before noting that sales and earnings topped the company's projections for the year. Gonzalez pointed out that when AbbVie was first spun off from Abbott Labs two years ago a key priority was to "return to strong growth in 2015". He added that the company was "able to achieve that goal a year ahead of schedule".
You can't blame AbbVie's management for bragging just a little bit about 2014. They hewed closely to the old mantra that you should under-promise and over-deliver. Despite a pullback in share prices over the last couple of months, investors have still benefited from the company's beating expectations. AbbVie's stock is up 22% over the last 12 months.
2. Humira still has plenty of juice
The solid results from 2014 came largely on the back of AbbVie's star performer, Humira. The drug saw operational growth of nearly 19% year-over-year. Rick Gonzalez highlighted just how successful Humira has been by noting that it "has averaged well over $1 billion of growth per year for the past eight years".
Management doesn't see any signs that Humira is losing much steam. Gonzalez stated that they expect Humira will experience operational growth in the mid-teens for 2015. AbbVie anticipates decisions in the U.S. and Europe for use of Humira in treating chronic skin disease hidradenitis suppurativa. Management thinks the market for this indication could approach $1 billion annually.However, it's worth keeping in mind that the drug is set to lose patent protection in the U.S. by December 2016.
3. Viekira Pak is on track
Gonzalez said that the company is "pleased with our progress" when it comes to hepatitis C drug Viekira Pak. AbbVie estimates that over 40% of Americans will have access to Viekira Pak. More than 20% of those stem from exclusive contracts, most importantly from the deal that AbbVie struck with Express Scripts , the nation's largest pharmacy benefits manager.
AbbVie CEO Rick Gonzalez. Source: AbbVie
AbbVie projects global annual sales for Viekira Pak will top $3 billion in 2015. The company's vagueness disconcerted some analysts, who were expecting sales of $3.11 billion. To be fair, though, Rick Gonzalez stated that the company would provide "more specific guidance... as the year unfolds". His reminder that AbbVie is "early in our launch" for Viekira and that "there are numerous factors at play" should be kept in mind when assessing the $3 billion figure.
4. The pipeline is percolating
Management didn't spend a lot of time talking about AbbVie's pipeline but did emphasize several key products in development. Cancer drug ABT-199 was one mentioned. AbbVie expects to submit the drug for regulatory approval as a treatment for chronic lymphocytic leukemia later this year.
Daclizumab, also known as Zinbryta, stands out as perhaps the most exciting prospect in AbbVie's pipeline right now. The drug, which is being developed by AbbVie and Biogen Idec , targets treatment of patients with relapsing remitting multiple sclerosis. AbbVie and Biogen should submit for regulatory approval of daclizumab in the first half of 2015.
5. 2015 looks solid
AbbVie confirmed its previous 2015 earnings guidance of $4.25 to $4.45 per share. Analysts expect at or above the top end of that range.
One question mark for AbbVie relates to currency fluctuations. CFO Bill Chase acknowledged that currency rates could impact sales. However, he also stated that AbbVie is comfortable with its earnings guidance despite the risk of foreign exchange rate fluctuation.
Shareholders can take heart especially from one comment from CEO Rick Gonzalez. He noted that AbbVie "generates significant cash flow which we expect will grow in 2015". Gonzalez said that the company plans to return much of that cash to shareholders primarily through increasing dividends. AbbVie bumped its quarterly dividend payment up by 17% beginning in February 2015.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article 5 Things AbbVie Inc.'s Management Wants You to Know originally appeared on Fool.com.
Keith Speights owns shares of Express Scripts but doesn't own AbbVie despite a bullish view on the stock. As luck would have it, AbbVie has outperformed Express Scripts over the last year.C'est la vie -- and ce'st l'AbbVie, too. The Motley Fool recommends and owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Cancer drug ABT-199 was one mentioned. Under-promised and over-delivered Chairman and CEO Rick Gonzalez spoke only a few seconds before noting that sales and earnings topped the company's projections for the year. Management thinks the market for this indication could approach $1 billion annually.However, it's worth keeping in mind that the drug is set to lose patent protection in the U.S. by December 2016. | Cancer drug ABT-199 was one mentioned. During AbbVie'searnings call the company provided projections for hepatitis C drug Viekira Pak that disappointed analysts. Source: AbbVie AbbVie projects global annual sales for Viekira Pak will top $3 billion in 2015. | Cancer drug ABT-199 was one mentioned. Source: AbbVie By most measures, AbbVie performed well in the fourth quarter of 2014. Under-promised and over-delivered Chairman and CEO Rick Gonzalez spoke only a few seconds before noting that sales and earnings topped the company's projections for the year. | Cancer drug ABT-199 was one mentioned. Rick Gonzalez highlighted just how successful Humira has been by noting that it "has averaged well over $1 billion of growth per year for the past eight years". Gonzalez said that the company plans to return much of that cash to shareholders primarily through increasing dividends. |
34077.0 | 2015-02-03 00:00:00 UTC | Should You Buy AbbVie Inc. Stock on This Dip? | ABT | https://www.nasdaq.com/articles/should-you-buy-abbvie-inc-stock-dip-2015-02-03 | nan | nan | Shares of the Illinois-based drugmaker AbbVie have slumped in a big way of late, perhaps reflecting the dampened expectations for the company's new hepatitis C therapy Viekira Pak. In fact, shares have now fallen by over 13% from their 52-week high following the high-volume sell-off that accompanied the company's fourth-quarter earnings release, as shown by this chart:
Weaker than expected projections for Viekira Pak going forward appear to have accelerated the stock's decline. Prior to management's recent update, the Street expected sales to top $3 billion in 2015. But the drug's relatively slow uptake compared to other next-generation hep C drugs puts it on track for something closer to $2.5 billion. And the potential launch of Merck 's rival therapy in 2016 could cut deeply into sales next year.
Putting all this doom and gloom aside for the moment, it's important to remember AbbVie has richly rewarded its shareholders, through the market-trouncing performance of its stock, billions in share buybacks, and multiple increases to the dividend, since the company was spun off from Abbott Laboratories in January 2013.
With this in mind, let's consider if this dip represents a compelling buying opportunity, or if it truly is time to hit the exits on this top healthcare stock.
.
AbbVie offers far more than hep C drugs
I think the negative sentiment surrounding AbbVie on account of Viekira Pak not being a true rival to Gilead Sciences ' Harvoni is shortsighted in many ways.
For example, based on the promising outlook for key products like Humira for a host of inflammatory diseases and Duodopa for symptoms associated with Parkinson's disease, AbbVie management is forecasting an astonishing 28% to 34% increase in earnings per share this year. Outside of Gilead and Celgene , you would be hard-pressed to find another large-cap biopharma growing as quickly.
Also, unlike its rapidly growing peers, AbbVie offers a dividend. The drugmaker has one of the highest yields in the healthcare sector (now topping 3.2%), and its rising cash flow suggests this high yield should be stable for the long term. The same can't be said for many other high yielders in healthcare that are facing steep declines in revenue from the ravages of the patent cliff.
What truly sets AbbVie apart from many of its biopharma brethren, though, is its often-overlooked pipeline of more than 40 ongoing clinical trials and multiple potential blockbusters.
AbbVie and partner Biogen Idec , for instance, last year successfully completed late-stage trials for the monoclonal antibody daclizumab as a potential treatment for the relapsing remitting form of multiple sclerosis, meaning a regulatory filing should be close at hand. This single drug is expected to generate upward of $700 million in revenue by 2020 , before eventually reaching blockbuster status.
Then there's the company's host of high-value experimental oncology compounds in late-stage development, as shown below. If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs.
.
AbbVie's pipeline also holds several additional gems that simply haven't garnered the attention they deserve in light of Viekira's commercial launch and the upcoming patent expiration for Humira.
Is AbbVie a good long-term buy?
After this recent sell-off, AbbVie's shares are now trading at a forward price-to-earnings ratio of 13. That dropoff is way overdone in my book, especially for a Dividend Aristocrat like AbbVie.
With multiple business and clinical catalysts expected over the year, I have a hard time believing this stock will remain at this level much longer. So I'd say this is indeed a good time to pick up some shares.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Should You Buy AbbVie Inc. Stock on This Dip? originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool recommends Celgene and Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs. In fact, shares have now fallen by over 13% from their 52-week high following the high-volume sell-off that accompanied the company's fourth-quarter earnings release, as shown by this chart: Weaker than expected projections for Viekira Pak going forward appear to have accelerated the stock's decline. Putting all this doom and gloom aside for the moment, it's important to remember AbbVie has richly rewarded its shareholders, through the market-trouncing performance of its stock, billions in share buybacks, and multiple increases to the dividend, since the company was spun off from Abbott Laboratories in January 2013. | If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs. Prior to management's recent update, the Street expected sales to top $3 billion in 2015. What truly sets AbbVie apart from many of its biopharma brethren, though, is its often-overlooked pipeline of more than 40 ongoing clinical trials and multiple potential blockbusters. | If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs. Shares of the Illinois-based drugmaker AbbVie have slumped in a big way of late, perhaps reflecting the dampened expectations for the company's new hepatitis C therapy Viekira Pak. Putting all this doom and gloom aside for the moment, it's important to remember AbbVie has richly rewarded its shareholders, through the market-trouncing performance of its stock, billions in share buybacks, and multiple increases to the dividend, since the company was spun off from Abbott Laboratories in January 2013. | If ABT-199 can gain a regulatory approval as a treatment for relapsed chronic lymphocytic leukemia, its sales should exceed $2 billion in short order, according to Goldman Sachs. In fact, shares have now fallen by over 13% from their 52-week high following the high-volume sell-off that accompanied the company's fourth-quarter earnings release, as shown by this chart: Weaker than expected projections for Viekira Pak going forward appear to have accelerated the stock's decline. AbbVie offers far more than hep C drugs I think the negative sentiment surrounding AbbVie on account of Viekira Pak not being a true rival to Gilead Sciences ' Harvoni is shortsighted in many ways. |
34078.0 | 2015-02-03 00:00:00 UTC | Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-to-buy-famy-care-businesses-boost-womens-health-analyst-blog-2015-02-03 | nan | nan | Mylan, Inc. ( MYL ) announced its intention to acquire certain female health care businesses of Famy Care Limited, a privately held specialty women's health care company focused on generic oral and injectable contraceptives, intra-uterine devices, tubal rings and hormone-replacement therapies. Mylan will acquire certain female reproductive health care businesses from Famy Care.
Terms of the Deal
Mylan has agreed to pay $750 million in cash at the closing of the transaction subject to certain adjustments. In addition to this, the company could pay up to $50 million depending on the achievement of certain development and regulatory milestones.
Under the deal, Famy Care will spin off its female health care businesses in accordance with a court-approved scheme of demerger, following which Mylan will acquire the shares of the new resulting company.
The deal is expected to complete in the second half of 2015.
How Will Mylan Benefit?
We note that Mylan and Famy Care's partnership goes back to 2008, when the companies had entered into an agreement under which Famy Care handled development and supply of oral contraceptive products to Mylan for distribution to customers in the U.S. and a few other markets. Mylan and Famy Care together have a portfolio of 12 approved products with abbreviated new drug applications pending FDA approval for 30 products in the U.S.
The proposed acquisition will make Mylan a hormonal contraceptives leader in the high-growth emerging markets. Moreover, Mylan expects the deal to be immediately accretive to earnings and growth profile upon closing.
The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities.
Our Take
We believe the Famy Care acquisition is in line with Mylan's strategy of strengthening its women's health care portfolio as well as focusing on the lucrative emerging markets. Meanwhile, with the Abbott deal on track to close in the first quarter of 2015, we expect Mylan to remain active on the business development front in 2015 in order to drive long-term growth.
Mylan currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Impax Laboratories Inc. ( IPXL ) and Mallinckrodt plc ( MNK ). While Impax carries a Zacks Rank #1 (Strong Buy), Mallinckrodt is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYLAN INC (MYL): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Terms of the Deal Mylan has agreed to pay $750 million in cash at the closing of the transaction subject to certain adjustments. | The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. While Impax carries a Zacks Rank #1 (Strong Buy), Mallinckrodt is a Zacks Rank #2 (Buy) stock. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Mylan, Inc. ( MYL ) announced its intention to acquire certain female health care businesses of Famy Care Limited, a privately held specialty women's health care company focused on generic oral and injectable contraceptives, intra-uterine devices, tubal rings and hormone-replacement therapies. | The Famy Care acquisition will also complement Mylan's pending acquisition of Abbott's ( ABT ) ex-U.S. developed markets specialty and branded generics business including the women's health care portfolio and sales and marketing capabilities. Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Mylan and Famy Care's partnership goes back to 2008, when the companies had entered into an agreement under which Famy Care handled development and supply of oral contraceptive products to Mylan for distribution to customers in the U.S. and a few other markets. |
34079.0 | 2015-01-30 00:00:00 UTC | Best Dividend Stocks for Bear Markets | ABT | https://www.nasdaq.com/articles/best-dividend-stocks-bear-markets-2015-01-30 | nan | nan | It's no secret that dividend-paying stocks often come out ahead during a market sell-off. In 2008, when Standard & Poor's 500-stock index nosedived 37%, the S&P 500 Dividend Aristocrats, an index of large companies that have raised their dividends every year for the past 25 years, surrendered a more tolerable 22%.
But dividends don't always protect you against the worst of a market drop. Consider Bank of America ( BAC ), which had been a steady dividend payer up until the financial crisis. Then, in 2008, the stock gave up a whopping 63%. How dividend-paying stocks perform "depends on the type of bear market you have," says Chris Philips, a senior investment analyst at Vanguard.
That being said, some dividend stocks have a better record than others. Here, we've identified nine such firms based on their performance during three hostile periods: the bursting-of-the-tech-bubble bear market, from 2000 to 2002, when the S&P 500 plunged 47.4%; the financial-crisis-related 2007-09 disaster, during which the index plummeted 55.3%; and the 2011 correction, a five-month period during which the S&P stumbled 18.6%, just shy of the 20% drop that typically defines a bear market.
These companies have products or services that consumers will pay for, even in a tough economy. Seven out of the nine stocks boast yields higher than the S&P 500's 1.9% payout. And eight of the nine companies derive the bulk of their sales in the U.S., leaving them relatively insulated from the negative effects of a powerful dollar (when the greenback strengthens, overseas profits translate into fewer dollars).
Share price: $43.41
Market capitalization: $65.4 billion
Yield: 2.2%
Headquarters: Abbott Park, Ill.
Down market total returns:
2000-02 bear market: 26.0%
2007-09 bear market: -11.6%
2011 correction: -2.8%
Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. In 2013, the firm spun off its brand-name-drug business, AbbVie ( ABBV ). Last year, Abbott announced that it would sell its generic-drug operations in foreign developed markets but hang on to the business in developing nations. The moves should allow Abbott to focus on faster-growing regions. An aging population and broader insurance coverage in the U.S., for example, will help drive sales of medical devices in 2015, according to investment bank Barclays. Abbot has the most global exposure of the companies on our list, with 69% of sales coming from foreign markets in the third quarter of 2014. And although a strong dollar could hurt overseas profits in the near term, company execs believe the market in China alone for in-vitro diagnostics (tests to detect health conditions and diseases) could grow by an average of more than 15% annually through 2018.
Share price: $107.10
Market capitalization: $13.9 billion
Yield: 2.8%
Headquarters: Oakland, Calif.
Down market total returns:
2000-02 bear market: 28.6%
2007-09 bear market: -22.9%
2011 correction: -6.6%
During a market downturn, stocks of companies that make essential consumer goods tend to do better than most. Clorox ( CLX ), which makes household cleaning and other supplies, is one of the best examples. The company owns category-leading brands, including its namesake bleach and Glad trash bags. As such, from 2008 to 2010, Clorox was able to increase sales by an average of 4.5% annually. The company also continued to raise its dividend, which it has upped every year since 1977.
Lately, competition has put pressure on core segments of the business, such as bleach, disinfecting wipes and cat litter. But Clorox has taken steps to roll out new products. Sales edged down by 0.3% in the fiscal year that ended in June 2014, but analysts expect revenues to climb for the fiscal year that ends this June. Clorox gets about 20% of its revenues overseas.
Share price: $70.85
Market capitalization: $20.8 billion
Yield: 3.7%
Headquarters: New York, NY
Down market total returns:
2000-02 bear market: 61.3%
2007-09 bear market: -25.6%
2011 correction: 10.8%
You won't have to worry about overseas exposure for Consolidated Edison ( ED ). The holding company derives 100% of its revenues from two utilities that supply electric and gas service to millions of customers in and around New York City. The vast majority of the company's business is regulated, which helps Con Ed earn steady profits. So during the financial crisis, the firm was able to keep raising its dividend. In fact, Con Ed has increased its payout for 41 consecutive years.
Rising interest rates could put pressure on the utility's stock, but Con Ed's investments in solar energy projects and system upgrades should help spur modest growth, by 1.3% in 2015, if analysts are correct with their forecasts. The stock's hefty yield is nearly twice that of the S&P 500, providing extra protection should the bear strike.
Share price: $54.08
Market capitalization: $32.7 billion
Yield: 3.0%
Headquarters: Minneapolis, Minn.
Down market total returns:
2000-02 bear market: 34.8%
2007-09 bear market: -11.9%
2011 correction: -0.8%
General Mills ( GIS ) owns a pantryful of iconic brands, including Cheerios, Häagen-Dazs and Yoplait. So it may come as no surprise that in the fiscal year that ended in May 2009, when consumers were keeping a tight grip on their wallets, sales at General Mills expanded 8% from the previous year. The stock couldn't escape the market's sell-off during the financial crisis, but the loss was dramatically smaller than the S&P 500's 55% rout.
Today, General Mills is struggling to appeal to health-conscious consumers, but the firm is making changes, including offering high-protein Cheerios. The company "has proven able to adjust over time to consumers," says investment bank RBC Capital Markets. In the quarter that ended in November, 28% of General Mills' sales came from abroad.
Share price: $52.40
Market capitalization: $13.8 billion
Yield: 1.9%
Headquarters: Austin, Minn.
Down market total returns:
2000-02 bear market: 59.7%
2007-09 bear market: -15.0%
2011 correction: -9.4%
During hard times, households eat more Spam, the precooked canned meat. That helps Hormel Foods ( HRL ), which makes Spam and other processed foods, such as deli meats, bacon and Skippy peanut butter. One particularly bright spot is Hormel's Jennie-O Turkey Store division, which saw sales climb 11% in the August-October quarter of 2014 from the same period a year earlier. In the latest quarter, Hormel generated a mere 5% of its sales overseas.
The stock's yield isn't huge, but Hormel has raised its dividend for 49 consecutive years, including a 25% hike in November. One short-term negative: The stock trades at 21 times estimated earnings for the fiscal year that ends in October, near the high end of its range for the past two decades.
Share price: $71.86
Market capitalization: $9.3 billion
Yield: 2.2%
Headquarters: Sparks, Md.
Down market total returns:
2000-02 bear market: 71.5%
2007-09 bear market: -14.2%
2011 correction: -8.0%
When the going gets tough, smart investors spice up their portfolios with McCormick ( MKC ). Consumer purchases account for roughly 60% of sales at the giant spice maker. Food manufacturers and restaurants make up the rest, so even as fewer people eat out during hard times, demand from home cooks helps prop up business. For example, in the fiscal year that ended in November 2008, which occurred during the Great Recession, McCormick's earnings expanded 12% from the previous year.
McCormick is not without its challenges. It faces increased competition from private-label firms, and a strong U.S. dollar could hurt results--overseas sales account for about one-third of total revenues. The stock trades at 20 times estimated earnings for the fiscal year that ends in November, compared with its average 10-year forward price-earnings ratio of 18, according to Citi Research. On the plus side, McCormick has raised its dividend for 29 straight years, most recently in November, with a hike of 8%.
Share price: $93.66
Market capitalization: $19.5 billion
Yield: 0.9%
Headquarters: Dublin, Calif.
Down market total returns:
2000-02 bear market: 79.2%
2007-09 bear market: 10.1%
2011 correction: 4.3%
A bear market killer, Ross ( ROST ) is the only stock on our list that was in the black in each of the past three downturns, a remarkable accomplishment. Plus, Ross, the largest off-price apparel and home-goods chain in the U.S., is a pure domestic play. The company has been doing brisk business as budget-conscious consumers hunt for deals. Over the past decade, earnings have increased by an annualized 18.2%. And since initiating a dividend in 1994, Ross has boosted it every year.
Analysts at Canaccord Genuity, a Canadian investment bank, believe Ross's sales and earnings growth will start to slow in coming years. But lower gasoline prices could give Ross shoppers more spending power, and analysts on average still expect profits to climb a comfortable 10% in the fiscal year that ends in January 2016.
Share price: $52.17
Market capitalization: $46.9 billion
Yield: 4.0%
Headquarters: Atlanta, Ga.
Down market total returns:
2000-02 bear market: 137.9%
2007-09 bear market: -22.7%
2011 correction: 8.9%
Like Con Ed, this utility derives all of its profits and revenues in the U.S. Southern ( SO ) provides power services to more than 4.4 million customers in Alabama, Florida, Georgia and Mississippi. Strong economic performance in the South is helping boost earnings, which are projected to grow by 3.3% annually for the next few years. Although two projects, a nuclear power plant in Georgia and a clean-coal facility in Mississippi, are pressuring earnings over the short term because of cost overruns, they should boost Southern's results down the road. Meanwhile, says Argus Research, dividends should climb 3% to 3.5% a year over the next few years, helping to prop up Southern's generous yield.
Share price: $86.82
Market capitalization: $279.8 billion
Yield: 2.2%
Headquarters: Bentonville, Ark.
Down market total returns:
2000-02 bear market: -4.0%
2007-09 bear market: 7.4%
2011 correction: -4.2%
Wal-Mart's ( WMT ) low prices look especially appealing when the economy is stumbling. For the fiscal year that ended in January 2009, the discount retailer's sales grew 3.5% at U.S. locations open at least a year. In comparison, same-store sales at Target ( TGT ), a higher-end competitor, fell 2.9% for the same period. In the quarter that ended last October, Wal-Mart generated 29% of its sales outside of the U.S.
Wal-Mart must defend its turf from a growing number of online retailers and discount chains. But low gas prices will pad the wallets of shoppers and help boost Wal-Mart's earnings, which analysts estimate will expand by 4.8% in the fiscal year that ends in January 2016. That's up from an estimated 2.2% increase for the current fiscal year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Share price: $43.41 Market capitalization: $65.4 billion Yield: 2.2% Headquarters: Abbott Park, Ill. Down market total returns: 2000-02 bear market: 26.0% 2007-09 bear market: -11.6% 2011 correction: -2.8% Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. And although a strong dollar could hurt overseas profits in the near term, company execs believe the market in China alone for in-vitro diagnostics (tests to detect health conditions and diseases) could grow by an average of more than 15% annually through 2018. Rising interest rates could put pressure on the utility's stock, but Con Ed's investments in solar energy projects and system upgrades should help spur modest growth, by 1.3% in 2015, if analysts are correct with their forecasts. | Share price: $43.41 Market capitalization: $65.4 billion Yield: 2.2% Headquarters: Abbott Park, Ill. Down market total returns: 2000-02 bear market: 26.0% 2007-09 bear market: -11.6% 2011 correction: -2.8% Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. Share price: $107.10 Market capitalization: $13.9 billion Yield: 2.8% Headquarters: Oakland, Calif. Down market total returns: 2000-02 bear market: 28.6% 2007-09 bear market: -22.9% 2011 correction: -6.6% During a market downturn, stocks of companies that make essential consumer goods tend to do better than most. Share price: $52.40 Market capitalization: $13.8 billion Yield: 1.9% Headquarters: Austin, Minn. Down market total returns: 2000-02 bear market: 59.7% 2007-09 bear market: -15.0% 2011 correction: -9.4% During hard times, households eat more Spam, the precooked canned meat. | Share price: $43.41 Market capitalization: $65.4 billion Yield: 2.2% Headquarters: Abbott Park, Ill. Down market total returns: 2000-02 bear market: 26.0% 2007-09 bear market: -11.6% 2011 correction: -2.8% Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. Share price: $107.10 Market capitalization: $13.9 billion Yield: 2.8% Headquarters: Oakland, Calif. Down market total returns: 2000-02 bear market: 28.6% 2007-09 bear market: -22.9% 2011 correction: -6.6% During a market downturn, stocks of companies that make essential consumer goods tend to do better than most. Share price: $93.66 Market capitalization: $19.5 billion Yield: 0.9% Headquarters: Dublin, Calif. Down market total returns: 2000-02 bear market: 79.2% 2007-09 bear market: 10.1% 2011 correction: 4.3% A bear market killer, Ross ( ROST ) is the only stock on our list that was in the black in each of the past three downturns, a remarkable accomplishment. | Share price: $43.41 Market capitalization: $65.4 billion Yield: 2.2% Headquarters: Abbott Park, Ill. Down market total returns: 2000-02 bear market: 26.0% 2007-09 bear market: -11.6% 2011 correction: -2.8% Health care needs are growing steadily, and Abbott Labs ( ABT ), a diagnostics, medical-device and nutritional-formula company, is profiting. And since initiating a dividend in 1994, Ross has boosted it every year. Share price: $52.17 Market capitalization: $46.9 billion Yield: 4.0% Headquarters: Atlanta, Ga. Down market total returns: 2000-02 bear market: 137.9% 2007-09 bear market: -22.7% 2011 correction: 8.9% Like Con Ed, this utility derives all of its profits and revenues in the U.S. Southern ( SO ) provides power services to more than 4.4 million customers in Alabama, Florida, Georgia and Mississippi. |
34080.0 | 2015-01-30 00:00:00 UTC | Company News for January 30, 2015 - Corporate Summary | ABT | https://www.nasdaq.com/articles/company-news-for-january-30-2015-corporate-summary-2015-01-30 | nan | nan | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68
• Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents
• Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09
• Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
BAXTER INTL (BAX): Free Stock Analysis Report
TIME WARNER CAB (TWC): Free Stock Analysis Report
NORTHROP GRUMMN (NOC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68 • Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents • Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09 • Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report TIME WARNER CAB (TWC): Free Stock Analysis Report NORTHROP GRUMMN (NOC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68 • Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents • Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09 • Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report TIME WARNER CAB (TWC): Free Stock Analysis Report NORTHROP GRUMMN (NOC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68 • Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents • Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09 • Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report TIME WARNER CAB (TWC): Free Stock Analysis Report NORTHROP GRUMMN (NOC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Shares of Abbott Laboratories ( ABT ) climbed 4.3% after announcing fourth quarter adjusted earnings per share of $0.71, beating the Zacks Consensus Estimate of $0.68 • Baxter International Inc.'s ( BAX ) shares rose 1.7% after declaring fourth quarter adjusted earnings per share of $1.34, outpacing the Zacks Consensus Estimate by 3 cents • Shares of Time Warner Cable Inc. ( TWC ) declined 1% after reporting fourth quarter adjusted earnings per share of $2.03, missing the Zacks Consensus Estimate of $2.09 • Northrop Grumman Corporation's ( NOC ) shares gained 3.8% after posting fourth quarter adjusted earnings of $2.26 per share, higher than the Zacks Consensus Estimate of $2.22 Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report TIME WARNER CAB (TWC): Free Stock Analysis Report NORTHROP GRUMMN (NOC): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
34081.0 | 2015-01-30 00:00:00 UTC | Zacks Rank #5 Additions for Friday - Tale of the Tape | ABT | https://www.nasdaq.com/articles/zacks-rank-5-additions-for-friday-tale-of-the-tape-2015-01-30 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abbott Laboratories ( ABT )
Antero Resources Corp ( AR )
Blackhawk Network Holdings Inc ( HAWK )
Bristow Group Inc ( BRS )
Cameron International Corporation ( CAM )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ANTERO RESOURCE (AR): Free Stock Analysis Report
BLACKHAWK NETWK (HAWK): Free Stock Analysis Report
BRISTOW GROUP (BRS): Free Stock Analysis Report
CAMERON INTL (CAM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Antero Resources Corp ( AR ) Blackhawk Network Holdings Inc ( HAWK ) Bristow Group Inc ( BRS ) Cameron International Corporation ( CAM ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANTERO RESOURCE (AR): Free Stock Analysis Report BLACKHAWK NETWK (HAWK): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Antero Resources Corp ( AR ) Blackhawk Network Holdings Inc ( HAWK ) Bristow Group Inc ( BRS ) Cameron International Corporation ( CAM ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANTERO RESOURCE (AR): Free Stock Analysis Report BLACKHAWK NETWK (HAWK): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Antero Resources Corp ( AR ) Blackhawk Network Holdings Inc ( HAWK ) Bristow Group Inc ( BRS ) Cameron International Corporation ( CAM ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANTERO RESOURCE (AR): Free Stock Analysis Report BLACKHAWK NETWK (HAWK): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report To read this article on Zacks.com click here. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Antero Resources Corp ( AR ) Blackhawk Network Holdings Inc ( HAWK ) Bristow Group Inc ( BRS ) Cameron International Corporation ( CAM ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ANTERO RESOURCE (AR): Free Stock Analysis Report BLACKHAWK NETWK (HAWK): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report To read this article on Zacks.com click here. Want the latest recommendations from Zacks Investment Research? |
34082.0 | 2015-01-29 00:00:00 UTC | Abbott Labs (ABT) Earnings up Y/Y, Stent Sales Decline - Tale of the Tape | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-earnings-up-y-y-stent-sales-decline-tale-of-the-tape-2015-01-29 | nan | nan | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. On Jan 1, 2013, Abbott Labs separated its pharmaceutical business into a new company called AbbVie.
Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutritionals.
We note that Abbott Labs agreed to sell its developed markets generics pharmaceutical business to Mylan, Inc. in Jul 2014. Hence, investors will mainly focus on Abbott Labs' business strategy going forward given the impending divestiture. The sale of branded generics business is expected to positively impact the top line and bottom line as Abbott Labs will now focus primarily on the branded generics pharmaceuticals business in emerging markets. However, vascular business continues to be weak.
Abbott Labs has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 6.59%. However, estimate revisions have gone down for 2015.
Currently, Abbott Labs has a Zacks Rank #4 (Sell). We have highlighted some of the key stats from this just-revealed announcement below:
Earnings : Abbott Labs reported earnings from continued operations of $0.62, up 29.2% y/y. Including results of discontinued operations, total earnings were $0.71. Our consensus called for EPS of $0.68.
Revenue : Revenues missed expectations. Abbott Labs posted revenues of $5.4 billion, compared to our consensus estimate of $5.6 billion but were up on y/y basis.
Key Stats: Currency headwinds continue to adversely impact sales. The vascular business is particularly dismal in the U.S. as a competitive environment in the drug-eluting stent business continues to negatively impact the company's quarterly sales.
Moreover, the guidance for 2015 was below expectations.
Stock Price: Shares are trending down in pre-market trading following the release.
Check back later for our full write up on this Abbott Labs earnings report later!
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs reports its diversified business in four segments - namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutritionals. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. The sale of branded generics business is expected to positively impact the top line and bottom line as Abbott Labs will now focus primarily on the branded generics pharmaceuticals business in emerging markets. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. The sale of branded generics business is expected to positively impact the top line and bottom line as Abbott Labs will now focus primarily on the branded generics pharmaceuticals business in emerging markets. | Abbott Laboratories ( ABT ), discovers, develops, manufactures and sells a diversified line of healthcare products. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. On Jan 1, 2013, Abbott Labs separated its pharmaceutical business into a new company called AbbVie. |
34083.0 | 2015-01-29 00:00:00 UTC | Health Care Sector Update for 01/29/2015: ABT, CAH, ALXN | ABT | https://www.nasdaq.com/articles/health-care-sector-update-01292015-abt-cah-alxn-2015-01-29 | nan | nan | Top Health-care stocks:
JNJ: -0.2%
PFE: +0.2%
ABT: flat
MRK: +0.2%
AMGN: +0.1%
Health-care shares were higher in pre-market trade Thursday.
In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. The company reported Q4 adjusted EPS of $0.71, up from $0.58 in the same period a year ago and topping analyst estimates of $0.68.
Shares in the company were down 0.02% at $43.40 during pre-market trading. Over the past 52 weeks, the company has traded between $35.65 and $46.50.
Meanwhile Cardinal Health ( CAH ) reported Q2 earnings and revenue that beat the Street view on Thursday.
Cardinal reported earnings of $1.20 per share versus the analyst consensus of $1.10 per share, according to Thomson Reuters.
Shares in the company were unchanged at $85.39 during the pre-market trading session. Over the past 52 weeks, the company has traded between $63.06 and $87.33.
And Alexion Pharmaceuticals ( ALXN ) reported Q4 results that beat the Street view on both EPS and total revenues.
The company reported Q4 adjusted EPS of $1.30, up from $0.87 in the same period a year ago and beating analyst estimates of $1.27.
Shares in the company were 2.1% lower at $174 in pre-market trade. Over the past 52 weeks, the company has traded between $128.89 and $203.30.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. ABT: flat Meanwhile Cardinal Health ( CAH ) reported Q2 earnings and revenue that beat the Street view on Thursday. | ABT: flat In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. The company reported Q4 adjusted EPS of $0.71, up from $0.58 in the same period a year ago and topping analyst estimates of $0.68. | In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. ABT: flat Shares in the company were down 0.02% at $43.40 during pre-market trading. | In health-care stocks news, Abbott Laboratories ( ABT ), a healthcare product developer, reported Q4 results that exceeded Street projections on EPS but missed on total revenues. ABT: flat Meanwhile Cardinal Health ( CAH ) reported Q2 earnings and revenue that beat the Street view on Thursday. |
34084.0 | 2015-01-29 00:00:00 UTC | Abbott Labs' (ABT) Q4 Earnings Up, Guides Below Estimates - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-q4-earnings-up-guides-below-estimates-analyst-blog-2015-01-29 | nan | nan | Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter.
We note that Abbott Labs agreed to sell its developed markets generics pharmaceutical business to Mylan ( MYL ) in Jul 2014. The company has also decided to sell its animal health business. Hence, both these businesses have been reported as discontinued operations.
Including the discontinued operations, earnings came in at 71 cents, up 22.4% year over year. The Zacks Consensus Estimate was 68 cents.
Abbott Labs generated sales of $5.4 billion in the fourth quarter of 2014, up 5.6% year over year (on a reported basis). Sales were impacted unfavorably by foreign exchange movements to the tune of 4.6% during the quarter. Quarterly sales were below the Zacks Consensus Estimate of $5.6 billion.
Fourth Quarter in Detail
Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
EPD sales were up 26.9% to $922 million including the negative impact of 8.5% due to currency fluctuations. Sales in key emerging markets climbed 10.6% on an operational basis (excluding foreign currency fluctuations) driven by growth in India, China and Russia.
We note that Abbott Labs completed the CFR Pharmaceuticals acquisition in Sep 2014, thereby more than doubling its branded generics pharmaceuticals presence in Latin America. In Dec 2014, the company completed its acquisition of Russia-based Veropharm.
The Medical Devices business generated sales of $1.4 billion, down 3.9% year over year (up 0.4% on an operational basis). Diabetes Care sales were down 9.6%. The Vascular business was down 2.5%, impacted by a decline in drug-eluting stent sales in the U.S. The Medical Optics business was down 0.9%. Cataract sales, accounting for almost 70% of total Medical Optics sales, increased in high-single digits, being partially offset by market declines in the refractive and corneal businesses.
The Nutrition business improved 6% year over year to $1.8 billion. Pediatric Nutrition sales were up 11.4% during the quarter fueled by market uptake of recently launched products. However, Adult Nutrition sales were weak in the U.S. due to a decline in performance nutrition along with dynamics in the institutional market segment.
Diagnostics business sales increased 3.2% year over year to $1.2 billion. Core Laboratory sales increased 2.5%, while Point of Care Diagnostics rose 13.6% year over year. Worldwide sales of Molecular Diagnostics were up 0.6%.
2014 Results
Abbott Labs reported total sales of $20.2 billion, up 3% from 2013. Earnings per share of $1.98 recorded an increase of 20.7% year over year.
2015 Outlook
Abbott Labs expects earnings per share in the range of $2.10 to $2.20 in 2015. The Zacks Consensus Estimate currently stands at $2.23. For the first quarter, earnings are projected in 41 to 43 cents. The Zacks Consensus Estimate of 42 cents is well within the guidance.
Our Take
Abbott Labs currently carries a Zacks Rank #4 (Sell). Unfavorable currency exchange rate movements continue to dampen results along with the decline in drug-eluting stents sales. The guidance disappointed expectations as well.
Some better-ranked stocks in the broader health care sector include Allergan ( AGN ) and AbbVie ( ABBV ). Both carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Abbott Labs agreed to sell its developed markets generics pharmaceutical business to Mylan ( MYL ) in Jul 2014. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter. Abbott Labs generated sales of $5.4 billion in the fourth quarter of 2014, up 5.6% year over year (on a reported basis). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter. Abbott Labs generated sales of $5.4 billion in the fourth quarter of 2014, up 5.6% year over year (on a reported basis). | Abbott Laboratories ( ABT ) reported fourth-quarter 2014 earnings of 62 cents per share, up 29.2% from the year-ago quarter. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Including the discontinued operations, earnings came in at 71 cents, up 22.4% year over year. |
34085.0 | 2015-01-28 00:00:00 UTC | Zacks Rank #5 Additions for Wednesday - Tale of the Tape | ABT | https://www.nasdaq.com/articles/zacks-rank-5-additions-for-wednesday-tale-of-the-tape-2015-01-28 | nan | nan | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Abbott Laboratories ( ABT )
Baytex Energy Corp ( BTE )
BRS Resources Ltd ( BRS )
Cameron International Corporation ( CAM )
Chart Industries, Inc. ( GTLS )
View the entire Zacks Rank #5 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
BAYTEX ENERGY (BTE): Free Stock Analysis Report
BRISTOW GROUP (BRS): Free Stock Analysis Report
CAMERON INTL (CAM): Free Stock Analysis Report
CHART INDUSTRIE (GTLS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Baytex Energy Corp ( BTE ) BRS Resources Ltd ( BRS ) Cameron International Corporation ( CAM ) Chart Industries, Inc. ( GTLS ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYTEX ENERGY (BTE): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report CHART INDUSTRIE (GTLS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Baytex Energy Corp ( BTE ) BRS Resources Ltd ( BRS ) Cameron International Corporation ( CAM ) Chart Industries, Inc. ( GTLS ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYTEX ENERGY (BTE): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report CHART INDUSTRIE (GTLS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Baytex Energy Corp ( BTE ) BRS Resources Ltd ( BRS ) Cameron International Corporation ( CAM ) Chart Industries, Inc. ( GTLS ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYTEX ENERGY (BTE): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report CHART INDUSTRIE (GTLS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: Abbott Laboratories ( ABT ) Baytex Energy Corp ( BTE ) BRS Resources Ltd ( BRS ) Cameron International Corporation ( CAM ) Chart Industries, Inc. ( GTLS ) View the entire Zacks Rank #5 List . Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report BAYTEX ENERGY (BTE): Free Stock Analysis Report BRISTOW GROUP (BRS): Free Stock Analysis Report CAMERON INTL (CAM): Free Stock Analysis Report CHART INDUSTRIE (GTLS): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
34086.0 | 2015-01-28 00:00:00 UTC | Pre-Market Earnings Report for January 29, 2015 : CELG, COP, EPD, ABT, OXY, CL, F, EMC, DOW, TMO, TWC, PSX | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-january-29-2015-celg-cop-epd-abt-oxy-cl-f-emc-dow-tmo-twc-psx | nan | nan | The following companies are expected to report earnings prior to market open on 01/29/2015. Visit our Earnings Calendar for a full list of expected earnings releases.
Celgene Corporation ( CELG ) is reporting for the quarter ending December 31, 2014. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.88. This value represents a 31.34% increase compared to the same quarter last year. CELG missed the consensus earnings per share in the 4th calendar quarter of 2013 by -2.9%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CELG is 37.53 vs. an industry ratio of -7.60, implying that they will have a higher earnings growth than their competitors in the same industry.
ConocoPhillips ( COP ) is reporting for the quarter ending December 31, 2014. The oil company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.62. This value represents a 55.71% decrease compared to the same quarter last year. In the past year COP has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 10.26%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for COP is 12.09 vs. an industry ratio of -11.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Enterprise Products Partners L.P. ( EPD ) is reporting for the quarter ending December 31, 2014. The oil/gas company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.36. This value represents a 10.00% decrease compared to the same quarter last year. EPD missed the consensus earnings per share in the 2nd calendar quarter of 2014 by -8.11%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for EPD is 23.24 vs. an industry ratio of 36.40.
Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. The large cap pharmaceutical company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.68. This value represents a 17.24% increase compared to the same quarter last year. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60.
Occidental Petroleum Corporation ( OXY ) is reporting for the quarter ending December 31, 2014. The oil company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.68. This value represents a 60.47% decrease compared to the same quarter last year. OXY missed the consensus earnings per share in the 3rd calendar quarter of 2014 by -5.39%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for OXY is 13.53 vs. an industry ratio of -11.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Colgate-Palmolive Company ( CL ) is reporting for the quarter ending December 31, 2014. The cleaning company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.75. This value represents a no change for the same quarter last year. In the past year CL has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for CL is 22.49 vs. an industry ratio of 19.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Ford Motor Company ( F ) is reporting for the quarter ending December 31, 2014. The auto (domestic) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.22. This value represents a 29.03% decrease compared to the same quarter last year. F missed the consensus earnings per share in the 1st calendar quarter of 2014 by -21.87%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for F is 13.38 vs. an industry ratio of -82.20, implying that they will have a higher earnings growth than their competitors in the same industry.
EMC Corporation ( EMC ) is reporting for the quarter ending December 31, 2014. The computer storage company's consensus earnings per share forecast from the 6 analysts that follow the stock is $0.59. This value represents a 13.46% increase compared to the same quarter last year. The last two quarters EMC had negative earnings surprises; the latest report they missed by -2.7%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for EMC is 17.92 vs. an industry ratio of -7.50, implying that they will have a higher earnings growth than their competitors in the same industry.
Dow Chemical Company ( DOW ) is reporting for the quarter ending December 31, 2014. The chemical company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.68. This value represents a 4.62% increase compared to the same quarter last year. In the past year DOW has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 7.46%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for DOW is 14.97 vs. an industry ratio of 15.80.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending December 31, 2014. The medical instruments company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.94. This value represents a 35.66% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 3rd calendar quarter where they beat the consensus by 1.18%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for TMO is 18.07 vs. an industry ratio of 2.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Time Warner Cable Inc ( TWC ) is reporting for the quarter ending December 31, 2014. The cable tv company's consensus earnings per share forecast from the 11 analysts that follow the stock is $2.10. This value represents a 15.38% increase compared to the same quarter last year. The last two quarters TWC had negative earnings surprises; the latest report they missed by -2.11%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for TWC is 18.90 vs. an industry ratio of -5.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Phillips 66 ( PSX ) is reporting for the quarter ending December 31, 2014. The oil refining company's consensus earnings per share forecast from the 9 analysts that follow the stock is $1.33. This value represents a 0.75% decrease compared to the same quarter last year. PSX missed the consensus earnings per share in the 2nd calendar quarter of 2014 by -10.65%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for PSX is 11.08 vs. an industry ratio of 15.00.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60. | Abbott Laboratories ( ABT ) is reporting for the quarter ending December 31, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 19.33 vs. an industry ratio of 22.60. |
34087.0 | 2015-01-27 00:00:00 UTC | 3 Stocks to Sell as Greece Concerns Intensify Euro Slide - Analyst Blog | ABT | https://www.nasdaq.com/articles/3-stocks-to-sell-as-greece-concerns-intensify-euro-slide-analyst-blog-2015-01-27 | nan | nan | It's not a sweet 16th birthday for the euro as the currency continues to face headwinds. A slew of incidents -- including Greece's anti-austerity party winning general elections, the European Central Bank's (ECB) aggressive stimulus measures and the Swiss National Bank's (SNB) surprise decision to drop its long-standing exchange rate of the Swiss franc against the euro -- have dragged the currency lower.
The euro hit an 11-year low against the dollar before recovering on Monday after Greece's anti-austerity party, Syriza, won the election. The euro dropped to $1.1098, its lowest level since Sep 2003. However, the currency rebounded to pre-election levels on Monday. Nevertheless, the currency has depreciated 7.8% against the dollar since the beginning of this year.
Greece's Anti-Austerity Party Sweeps Election
A possible standoff between the new radical leftwing government in Greece and the European Union dragged the euro down. Leftist leader Alexis Tsipras had opposed the bailout conditions imposed by the European Union and the International Monetary Fund. Alexis Tsipras wants to renegotiate the 240 billion euro bailout debt. His decision to renegotiate with other Eurozone governments raised speculation that Greece could do away with euro and leave the European Union.
Meanwhile, Euro finance chief Jeroen Dijsselbloem warned Greece: "The most important thing is that if you remain in the Eurozone you stick to the rules we have. That's true for all countries." He added: "There has been a lot of easing of the debt already. In the coming years the interest for Greece will be very low. They get a lot of time to pay back loans so the question is whether more has to be done there." The Eurozone's biggest economy, Germany, also wanted Greece to respect the terms and conditions of its 240 billion euro bailout.
ECB Stimulus Measures
The euro has already been under pressure following the ECB's announcement of implementing aggressive quantitative easing. The ECB unveiled a large-scale asset-purchasing program to boost Eurozone's fragile economy. Last week, the euro fell more than 3% against the greenback.
The ECB announced a quantitative easing program worth about 1.1 trillion euro to address the risks of deflation in Eurozone. ECB President Mario Draghi had said the bank will buy 60 billion euros a month in assets -- including both government and private sector bonds, and securities issued by European organizations. The bond-buying program will begin in March and is expected to continue at least until Sep 2016.
Draghi said the asset purchasing program could extend further provided ECB fails to meet its inflation target of just below 2%. Eurozone had moved closer to deflation after consumer prices dropped 0.2% annually in December.
ECB's stimulus measures have boosted the euro in the past. However, in this case the euro remained weak as the bond-buying program is open-ended as it is subject to inflation failing to achieve its target rate by Sept 2016. This may lead to bond-buying of more than 1.1 trillion euros.
Swiss National Bank's Surprise Decision
The Swiss National Bank's (SNB) decision to do away with its long-standing resolution of fixing the exchange rate of the Swiss franc against the euro had a negative impact. The SNB decided to remove its three-year-old policy of maintaining minimum exchange rate of 1.20 Swiss francs to 1 euro. The Swiss franc was facing huge pressure due to this minimum exchange rate policy as the euro was becoming weaker against major currencies due to sluggish economic conditions in the Eurozone.
Meanwhile, sentiments in the options market regarding euro are bearish as evident from the following chart:
Source: FOREX.com
In the diagram, a rise in implied volatility (blue line) along with bearish risk reversal (red line) suggests that traders have taken a view that the euro will fall further. According to the thumb rule, implied volatility increases when the market is bearish, and vice versa. Similarly, a negative risk reversal means that more market participants are putting their bets on a fall in currency rather than rise in it.
Further, analysts predict that there could be further weakness and wild swings. Goldman Sachs ( GS ) forecasted that the euro will reach parity with the dollar by Jan 2017. It is expected to further fall to 90 cents by Jan 2018. Goldman Sachs predicts the dollar will show strength as the U.S. economy continues to expand ahead of the impending hike in key interest rates by the Federal Reserve.
Given this weakness in the euro and the strength in the dollar; it will be a prudent idea to stay away from U.S. companies having high exposure in European markets. Possible currency fluctuations between the two currencies may hamper their earnings results and guidance for this year. Below we present some of the biggest S&P 500 companies by market capitalization that draw a minimum 20% of its sales from overseas regions, including Europe.
3 Stocks to Dump
Philip Morris International, Inc. ( PM ) manufactures and sells cigarettes and other tobacco products. The company owns various cigarette brands throughout the world. Notable European brands are Diana, f6, Assos and Petra. The company was incorporated in 1987 and is headquartered in New York.
In the past two months, the Zacks Consensus Estimate for the current year was revised slightly lower for the company. This year's expected earnings growth rate for this Zacks Rank #5 (Strong Sell) stock is a negative 6.3%, in contrast to the industry growth rate of 0.3%. The stock plunged 0.4% in the last four weeks. Also, it has a Zacks Industry Rank in the bottom 34%.
The Coca-Cola Company ( KO ) manufactures and distributes soft drinks worldwide. The company was founded in 1886 and is headquartered in Atlanta, Georgia.
Over the past two months, the Zacks Consensus Estimate for the current year was revised almost 1% lower for this Zacks Rank #4 (Sell) company. Further, it has a Zacks Industry Rank in the bottom 30%.
Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
This Zacks Rank #4 (Sell) stock is part of an industry which is expected to grow at a negative rate of 8.8% this year. The stock dropped 3.7% in the last four weeks. It has a Zacks Industry Rank in the bottom 17%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PHILIP MORRIS (PM): Free Stock Analysis Report
COCA COLA CO (KO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. Click to get this free report PHILIP MORRIS (PM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. ECB President Mario Draghi had said the bank will buy 60 billion euros a month in assets -- including both government and private sector bonds, and securities issued by European organizations. | Click to get this free report PHILIP MORRIS (PM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. A slew of incidents -- including Greece's anti-austerity party winning general elections, the European Central Bank's (ECB) aggressive stimulus measures and the Swiss National Bank's (SNB) surprise decision to drop its long-standing exchange rate of the Swiss franc against the euro -- have dragged the currency lower. | Click to get this free report PHILIP MORRIS (PM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. A slew of incidents -- including Greece's anti-austerity party winning general elections, the European Central Bank's (ECB) aggressive stimulus measures and the Swiss National Bank's (SNB) surprise decision to drop its long-standing exchange rate of the Swiss franc against the euro -- have dragged the currency lower. | Abbott Laboratories ( ABT ) manufactures and sells health care products worldwide. Click to get this free report PHILIP MORRIS (PM): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A slew of incidents -- including Greece's anti-austerity party winning general elections, the European Central Bank's (ECB) aggressive stimulus measures and the Swiss National Bank's (SNB) surprise decision to drop its long-standing exchange rate of the Swiss franc against the euro -- have dragged the currency lower. |
34088.0 | 2015-01-24 00:00:00 UTC | This Stock Could Become the Next Johnson & Johnson | ABT | https://www.nasdaq.com/articles/stock-could-become-next-johnson-johnson-2015-01-24 | nan | nan | There's little debate that healthcare goliath Johnson & Johnson has become the de facto gold standard among healthcare companies. J&J's Tylenol and Band-Aid brands are household staples, its prescription drugs are among the most widely used on the planet, and its medical devices are common in hospital surgical rooms everywhere. But J&J wasn't always as big as it is today, and that suggests that investors may be well served by keeping an eye on these three companies that our Motley Fool contributors believe could be J&J's in the making.
Source: Novartis.
Cheryl Swanson : If you're looking for a megacap healthcare stock with a solid-gold dividend track record and the kind of steady-Eddy performance that lets you sleep well at night, you can't do better than Johnson & Johnson.
But if you'd prefer a megacap with more tailwinds heading into 2015, thanks to an abundance of late-pipeline potential blockbusters, you might want to look on other side of the pond at Swiss-based Novartis AG .
Of course, no pharma company compares with Johnson & Johnson in terms of diversity. But Novartis' fast-growing consumer eye-care business, as well as a generics business, Sandoz, gives it some cross-segment synergies and helps reduce its earnings volatility.
Where Novartis may have an edge over Johnson & Johnson is in its late pipeline. The biggest near-term opportunity is LCZ696, which Cyde Yancy , former American Heart Association president, called one of the biggest potential advances against heart failures in more than a decade. Novartis' personalized CAR-T cancer therapy is also barreling toward commercialization, with drug CTL019 getting a rare breakthrough status from the FDA.
On the dividend side, Novartis yields 2.85%, and the company has raised its dividend every year since it launched in 1996. That doesn't match Johnson & Johnson's 52-year track record, but hey, we're talking a teenager compared with a hundred-plus-year-old company. Give the kid some time.
LeoSun :Pfizer , which had a rough three years since the patent expiration of its blockbuster cholesterol drug Lipitor in 2011, could eventually post the same steady growth that J&J is known for.
Between fiscal 2011 and 2013, Pfizer's annual revenue dropped 21%, but it aggressively shielded its bottom line by cutting jobs, spinning off and selling business units, and raising prices. As a result, Pfizer's annual EPS improved 213% over those three years. After slashing its dividend in 2009, Pfizer raised its dividend annually and now pays a forward annual yield of 3.5%. Meanwhile, two experimental drugs -- the breast cancer drug palbociclib and cholesterol drug bococizumab -- are potential blockbusters that might offset its Lipitor losses.
Last year, Pfizer reorganized its business into three main segments: global innovative pharmaceuticals, or GIP; vaccines, oncology, and consumer healthcare, or VOC; and global established pharmaceuticals, or GEP. There has been speculation that Pfizer could spin off or sell its sluggish GEP segment and make a massive acquisition (like its failed AstraZeneca deal) to enhance its GIP segment. Last year, Pfizer closed its acquisition of Baxter International 's vaccine portfolio to enhance its VOC business.
I believe that Pfizer's aggressive protection of its bottom line, its pipeline of potential blockbusters, and the reorganization and growth of its business segments could eventually make it a solid healthcare investment with steady growth on par with J&J.
George Budwell : Johnson & Johnson is a top healthcare stock because management has consistently been ahead of the curve when it comes to identifying new growth opportunities and richly rewarding shareholders via share buybacks, dividend increases, and the like. AbbVie , in many ways, is following in J&J's giant footsteps.
Since becoming an independent company in January 2013, AbbVie's executives have raised the dividend on three occasions, keeping the payout well above the sector average (3.04% at current levels) and earning the coveted title of "Dividend Aristocrat" in the S&P 500 Dividend Aristocrat Index (with help from its Abbott Laboratories history). Management has also been aggressive in terms of buying back shares, instituting a new $5 billion repurchase program last October.
Perhaps most importantly, though, AbbVie has been extremely active in its search for future avenues of growth. Last September, for example, the Illinois-based drugmaker signed an agreement with Infinity Pharmaceuticals to develop duvelisib, a Class I PI3K-delta and gamma inhibitor, for treatment of a host of blood cancers. And in a separate agreement, AbbVie agreed to act as the marketing partner for Google 's highly speculative venture into the biotech arena, Calico, which is a clinically-oriented company investigating age-related diseases such as cancer and neurodegeneration.
All told, AbbVie has all the hallmarks of a great dividend stock to buy and hold for the long term.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that could revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article This Stock Could Become the Next Johnson & Johnson originally appeared on Fool.com.
Cheryl Swanson owns shares of Baxter International. George Budwell owns shares of AbbVie. Leo Sun owns shares of Pfizer. The Motley Fool recommends Baxter International, Google (A and C shares), and Johnson & Johnson and owns shares of Google (A and C shares) and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Between fiscal 2011 and 2013, Pfizer's annual revenue dropped 21%, but it aggressively shielded its bottom line by cutting jobs, spinning off and selling business units, and raising prices. And in a separate agreement, AbbVie agreed to act as the marketing partner for Google 's highly speculative venture into the biotech arena, Calico, which is a clinically-oriented company investigating age-related diseases such as cancer and neurodegeneration. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. | Last year, Pfizer reorganized its business into three main segments: global innovative pharmaceuticals, or GIP; vaccines, oncology, and consumer healthcare, or VOC; and global established pharmaceuticals, or GEP. I believe that Pfizer's aggressive protection of its bottom line, its pipeline of potential blockbusters, and the reorganization and growth of its business segments could eventually make it a solid healthcare investment with steady growth on par with J&J. The Motley Fool recommends Baxter International, Google (A and C shares), and Johnson & Johnson and owns shares of Google (A and C shares) and Johnson & Johnson. | I believe that Pfizer's aggressive protection of its bottom line, its pipeline of potential blockbusters, and the reorganization and growth of its business segments could eventually make it a solid healthcare investment with steady growth on par with J&J. George Budwell : Johnson & Johnson is a top healthcare stock because management has consistently been ahead of the curve when it comes to identifying new growth opportunities and richly rewarding shareholders via share buybacks, dividend increases, and the like. The Motley Fool recommends Baxter International, Google (A and C shares), and Johnson & Johnson and owns shares of Google (A and C shares) and Johnson & Johnson. | On the dividend side, Novartis yields 2.85%, and the company has raised its dividend every year since it launched in 1996. The Motley Fool recommends Baxter International, Google (A and C shares), and Johnson & Johnson and owns shares of Google (A and C shares) and Johnson & Johnson. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34089.0 | 2015-01-23 00:00:00 UTC | Notable ETF Outflow Detected - VIG, QCOM, MDT, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-vig-qcom-mdt-abt-2015-01-23 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25. Comparing the most recent | Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25. | Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25. | Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25. | Among the largest underlying components of VIG, in trading today Qualcomm, Inc. (Symbol: QCOM) is off about 0.2%, Medtronic, Inc. (Symbol: MDT) is up about 1.8%, and Abbott Laboratories (Symbol: ABT) is lower by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $57.0 million dollar outflow -- that's a 0.3% decrease week over week (from 262,818,849 to 262,118,903). For a complete list of holdings, visit the VIG Holdings page » The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $69.60 per share, with $82.53 as the 52 week high point - that compares with a last trade of $81.25. |
34090.0 | 2015-01-20 00:00:00 UTC | Can AbbVie Inc. Overcome Humira’s Looming Patent Expiration? | ABT | https://www.nasdaq.com/articles/can-abbvie-inc-overcome-humiras-looming-patent-expiration-2015-01-20 | nan | nan | Since its spin off from Abbott Laboratories in Jan. 2013, AbbVie has been on the fast track growth-wise. The double-digit sales growth of its flagship anti-inflammatory drug Humira, and shareholder friendly management, have caused shares to blow away the broader market, shown by the chart below.
Despite this amazing return on investment, management has had to repeatedly reassure investors lately that this growth profile is indeed sustainable for the long-term. At the recent JP Morgan Healthcare Conference, for instance, AbbVie's CFO Bill Chase specifically discussed the company's prospects as a "sustainable growth business" by taking a rather deep dive into its clinical pipeline -- not exactly a normal course of action for a big pharma executive overseeing double-digit revenue growth.
Source: AbbVie
What's keeping AbbVie's shareholders awake at night, of course, is the looming patent expiration for Humira. Humira presently accounts for a highly disproportionate 62% of total sales (via the first nine months of 2014), and more than half of the company's total profits. However, the drug is set to lose patent protection in the U.S. by December 2016.
Are investors right to worry about this event now in 2015?
Humira's patent expiration should be a nonevent
Humira's patent expiration would be a seriously detrimental event if it was accompanied by the typical loss of revenue that has befallen so many former blockbusters. But unlike most of its predecessors, Humira has a competitive moat against generics because it is a biologic, not a small-molecule drug like previous top-selling drugs Lipitor and Plavix.
What this means is that Humira probably won't face any significant generic competition in the form of so-called "biosimilars" until 2019 or perhaps later. The issue is that the legislation outlining the process for creating a biosimilar, and subsequently gaining an approval with the Food and Drug Administration, set an extremely high standard. As such, you shouldn't expect much, if any, revenue drop off from Humira when 2017 rolls around.
Source: Amgen
It took almost five years for the first biosimilar, Novartis ' EP2006 -- a proposed biosimilar for Amgen 's Neupogen -- to even receive a positive opinion from the agency, with many reviewers noting that they only did so because EP2006 has been on the European market for years at this point, making them feel comfortable with the drug's clinical profile.
No biosimilar for Humira currently exists in Europe because the drug's patent won't expire in most EU countries until 2018, making it impossible for a similar scenario to play out.
What's key to understand is that biosimilars can't by their nature be identical copies of an approved drug due to differences in source materials. The approval process is thus a judgement on a company's manufacturing processes, as much as anything, making it particularly costly to pursue a biosimilar. In short, you have to invest heavily in the drug's commercial production before a regulatory review can be undertaken, creating yet another barrier to the entry of generic biologics in general.
Why 2019?
Because Humira is the world's best-selling drug, multiple companies are lining up to develop biosimilars once the drug goes off of patent protection. And indeed, India's Cadila Healthcare has already launched a biosimilar for Humira dubbed "Exemptia" that it hopes can gain worldwide acceptance down the road.
That said, Cadila's own management has conceded that 2019 is probably the earliest the U.S. would grant an approval for a Humira biosimilar due to the initial legwork involved. And the better equipped European biosimilar manufacturers can't throw their hat in the ring until 2018, meaning that Humira should enjoy three to four years of exclusivity in the U.S. past its patent expiration.
Foolish takeaways
AbbVie's management hasn't spent much time talking or writing about Humira's patent expiration for these very reasons. Instead, they have tried to focus investor enthusiasm on the company's top-notch clinical pipeline that should be ready to handle falling Humira revenues by 2019. All told, this simply isn't an issue investors should be concerned about at present -- that is, unless something fundamentally and unforeseen changes with the approval process for biosimilars in the U.S. by the end of 2016. Stranger things have happened, but don't count on it -- I expect AbbVie to continue being a top growth stock for years to come.
For more Foolish coverage of the JP Morgan Healthcare Conference, click here .
The article Can AbbVie Inc. Overcome Humira's Looming Patent Expiration? originally appeared on Fool.com.
George Budwell owns shares of AbbVie Inc. The Motley Fool owns shares of JPMorgan Chase. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The double-digit sales growth of its flagship anti-inflammatory drug Humira, and shareholder friendly management, have caused shares to blow away the broader market, shown by the chart below. The issue is that the legislation outlining the process for creating a biosimilar, and subsequently gaining an approval with the Food and Drug Administration, set an extremely high standard. And the better equipped European biosimilar manufacturers can't throw their hat in the ring until 2018, meaning that Humira should enjoy three to four years of exclusivity in the U.S. past its patent expiration. | At the recent JP Morgan Healthcare Conference, for instance, AbbVie's CFO Bill Chase specifically discussed the company's prospects as a "sustainable growth business" by taking a rather deep dive into its clinical pipeline -- not exactly a normal course of action for a big pharma executive overseeing double-digit revenue growth. No biosimilar for Humira currently exists in Europe because the drug's patent won't expire in most EU countries until 2018, making it impossible for a similar scenario to play out. And the better equipped European biosimilar manufacturers can't throw their hat in the ring until 2018, meaning that Humira should enjoy three to four years of exclusivity in the U.S. past its patent expiration. | Humira's patent expiration should be a nonevent Humira's patent expiration would be a seriously detrimental event if it was accompanied by the typical loss of revenue that has befallen so many former blockbusters. No biosimilar for Humira currently exists in Europe because the drug's patent won't expire in most EU countries until 2018, making it impossible for a similar scenario to play out. Because Humira is the world's best-selling drug, multiple companies are lining up to develop biosimilars once the drug goes off of patent protection. | Humira's patent expiration should be a nonevent Humira's patent expiration would be a seriously detrimental event if it was accompanied by the typical loss of revenue that has befallen so many former blockbusters. And the better equipped European biosimilar manufacturers can't throw their hat in the ring until 2018, meaning that Humira should enjoy three to four years of exclusivity in the U.S. past its patent expiration. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. |
34091.0 | 2015-01-20 00:00:00 UTC | March 20th Options Now Available For Abbott Laboratories (ABT) | ABT | https://www.nasdaq.com/articles/march-20th-options-now-available-abbott-laboratories-abt-2015-01-20 | nan | nan | Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new March 20th contracts and identified one put and one call contract of particular interest.
The put contract at the $43.00 strike price has a current bid of 94 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $43.00, but will also collect the premium, putting the cost basis of the shares at $42.06 (before broker commissions). To an investor already interested in purchasing shares of ABT, that could represent an attractive alternative to paying $44.02/share today.
Because the $43.00 strike represents an approximate 2% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 62%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract . Should the contract expire worthless, the premium would represent a 2.19% return on the cash commitment, or 13.53% annualized - at Stock Options Channel we call this the YieldBoost .
Below is a chart showing the trailing twelve month trading history for Abbott Laboratories, and highlighting in green where the $43.00 strike is located relative to that history:
Turning to the calls side of the option chain, the call contract at the $45.00 strike price has a current bid of 91 cents. If an investor was to purchase shares of ABT stock at the current price level of $44.02/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $45.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.29% if the stock gets called away at the March 20th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red:
Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 61%. On our website under the contract detail page for this contract , Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 2.07% boost of extra return to the investor, or 12.80% annualized, which we refer to as the YieldBoost .
The implied volatility in the put contract example is 19%, while the implied volatility in the call contract example is 20%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $44.02) to be 15%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABT shares really soar, which is why looking at the trailing twelve month trading history for Abbott Laboratories, as well as studying the business fundamentals becomes important. Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. | Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new March 20th contracts and identified one put and one call contract of particular interest. | Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new March 20th contracts and identified one put and one call contract of particular interest. | At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new March 20th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABT's trailing twelve month trading history, with the $45.00 strike highlighted in red: Considering the fact that the $45.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Abbott Laboratories (Symbol: ABT) saw new options become available today, for the March 20th expiration. |
34092.0 | 2015-01-14 00:00:00 UTC | DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-declares-preliminary-q4-14-revenues-guides-15-analyst-blog-2015-01-14 | nan | nan | Developer of continuous glucose monitoring systems, DexCom Inc. ( DXCM ), recently announced preliminary product revenues for fourth quarter and full year 2014.
DexCom anticipates fourth quarter product revenues to surge an impressive 64% on a year-over-year basis to $84 million. The stated figure is higher than the current Zacks Consensus Estimate which is pegged at $82 million.
Notably, product revenues have grown over 60% on a year-over-year basis for six consecutive quarters. The company's average year-over-year quarterly revenue growth has been 65% since the launch of G4 PLATINUM.
For 2014, revenues are estimated to soar 64% on a year-over-year basis to $257 million, in line with the current Zacks Consensus Estimate. According to DexCom's estimates, the company's patient base in the U.S. grew by more than 50% in 2014.
DexCom is riding high on the back of a number of FDA approvals as well as a robust pipeline. DexCom has received clearances from the FDA for G4 Platinum Continuous Glucose Monitoring (CGM) system and the CGM remote mobile communications device - DexCom SHARE. The company also remains focused on introducing a steady stream of innovative products related to its sensor technology.
DexCom's revenues have been outperforming the Zacks Consensus Estimate for quite some time now and going by the preliminary estimations, we hope to see another beat.
For 2015, DexCom expects product revenues in the range of $340-$360 million. The current Zacks Consensus Estimate for the year is pegged at $350 million, which lies within the company's guidance range.
We believe DexCom will continue to generate significant top-line growth on the back of strong performance by G4 Platinum coupled with innovative product launches.
Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind.
Currently, DexCom carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DEXCOM INC (DXCM): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Developer of continuous glucose monitoring systems, DexCom Inc. ( DXCM ), recently announced preliminary product revenues for fourth quarter and full year 2014. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. Developer of continuous glucose monitoring systems, DexCom Inc. ( DXCM ), recently announced preliminary product revenues for fourth quarter and full year 2014. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. For 2014, revenues are estimated to soar 64% on a year-over-year basis to $257 million, in line with the current Zacks Consensus Estimate. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Nevertheless, the company continues to face stiff competition from Johnson and Johnson ( JNJ ), Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a potent headwind. For 2014, revenues are estimated to soar 64% on a year-over-year basis to $257 million, in line with the current Zacks Consensus Estimate. |
34093.0 | 2015-01-12 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for January 13, 2015 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-january-13-2015-2015-01-12 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 13, 2015. A cash dividend payment of $0.24 per share is scheduled to be paid on February 13, 2015. Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 9.09% increase over the prior quarter.
The previous trading day's last sale of ABT was $45.2, representing a -2.8% decrease from the 52 week high of $46.50 and a 26.79% increase over the 52 week low of $35.65.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). ABT's current earnings per share, an indicator of a company's profitability, is $1.27. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 12.65%, compared to an industry average of -9.1%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares Dow Jones US Medical Devices Index Fund ( IHI )
Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF )
Schwab U.S. Large-Cap Value ETF ( SCHV )
iShares iBonds Mar 2020 Corporate Term ETF ( IBDC )
Schwab Fundamental U.S. Large Company Index ( FNDX ).
The top-performing ETF of this group is IHI with an increase of 13.05% over the last 100 days. It also has the highest percent weighting of ABT at 9.37%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 12.65%, compared to an industry average of -9.1%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares Dow Jones US Medical Devices Index Fund ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ( FNDX ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 13, 2015. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $45.2, representing a -2.8% decrease from the 52 week high of $46.50 and a 26.79% increase over the 52 week low of $35.65. The following ETF(s) have ABT as a top-10 holding: iShares Dow Jones US Medical Devices Index Fund ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ( FNDX ). | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. Abbott Laboratories ( ABT ) will begin trading ex-dividend on January 13, 2015. The previous trading day's last sale of ABT was $45.2, representing a -2.8% decrease from the 52 week high of $46.50 and a 26.79% increase over the 52 week low of $35.65. |
34094.0 | 2015-01-12 00:00:00 UTC | Alere (ALR) Closes Alere Health Sale to Optum for $600M - Analyst Blog | ABT | https://www.nasdaq.com/articles/alere-alr-closes-alere-health-sale-to-optum-for-%24600m-analyst-blog-2015-01-12 | nan | nan | Global rapid diagnostic tests company, Alere Inc. ( ALR ), has recently completed another divestiture. This time, Alere has divested Alere Health and its subsidiaries to Optum - the health services business unit of Minneapolis, MN-based UnitedHealth Group ( UNH ). The two companies had signed the $600 million cash deal in Oct 2014.
The sale of Alere Health is part of the company's key strategic objective to divest its non-core operations. With the continued divestment of non-core assets, the company intends to focus on core areas like rapid diagnostics and improve balance sheet strength.
Following the sale of Alere Health to Optum, Alere intends to use the net proceeds from this transaction to reduce the company's debt. We note that Alere's total long-term debt (including current portions) stood at $3.79 billion as of Sep 30, 2014. Though this figure is lower than the total debt of $3.84 billion recorded at the beginning of this year, Alere's debt-to-equity ratio is on the rise. Markedly, the ratio increased to 2:1 as of Sep 30, 2014 from 1.85:1 as of Dec 31, 2013.
Along with accelerating Alere's progress toward its deleveraging target, the deal with Optum expands the latter's population health management footprint to improve care delivery.
Alere Health, a subsidiary of Waltham, MA-based Alere, is a $3 billion technology company that provides leading condition management, case management, and wellbeing and wellness services to insurers, employers and health care payers. The addition of Alere's offerings will complement Optum's consumer-wellness businesses, enabling the delivery of more innovative and comprehensive population health management solutions.
Alere has of late been following a divestment strategy to get rid of non-core assets and focus more on developing its core operations. Apart from paying off debt, Alere expects the divestitures to boost the top line and improve cost structure going forward.
Notably, Alere sold off the Alere ACS unit - its health information exchange system - which accounted for around half of the company's total expenses in Connected Health. Alere also sold 40% of its stake in Vedalab for roughly $10 million in the third quarter of 2014.
In addition, the company recently divested its vet business unit - Bionote, for around $45 million. Proceeds from all these transactions are being used by management to de-leverage the company.
Alere also boasts a diversified and strong product portfolio. Notably, Alere's Influenza i A & B Test and HIV Combo Test were both recently granted a waiver by the U.S. Food and Drug Administration (FDA). With the Clinical Laboratory Improvement Amendments, Alere's tests can now be used across a wide variety of healthcare settings. Given the company's focus onglobal marketdevelopment in addition to its diverse product portfolio, we believe that Alere is positioned to perform well going forward.
However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others.
Currently, Alere carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
UNITEDHEALTH GP (UNH): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others. Click to get this free report UNITEDHEALTH GP (UNH): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. With the continued divestment of non-core assets, the company intends to focus on core areas like rapid diagnostics and improve balance sheet strength. | Click to get this free report UNITEDHEALTH GP (UNH): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others. This time, Alere has divested Alere Health and its subsidiaries to Optum - the health services business unit of Minneapolis, MN-based UnitedHealth Group ( UNH ). | Click to get this free report UNITEDHEALTH GP (UNH): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others. Alere Health, a subsidiary of Waltham, MA-based Alere, is a $3 billion technology company that provides leading condition management, case management, and wellbeing and wellness services to insurers, employers and health care payers. | However, Alere faces significant competition from large diagnostic companies like Becton, Dickinson ( BDX ) and Abbott Laboratories ( ABT ) among others. Click to get this free report UNITEDHEALTH GP (UNH): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. This time, Alere has divested Alere Health and its subsidiaries to Optum - the health services business unit of Minneapolis, MN-based UnitedHealth Group ( UNH ). |
34095.0 | 2015-01-07 00:00:00 UTC | Alere's (ALR) Influenza Test Gets CLIA Waiver from the FDA - Analyst Blog | ABT | https://www.nasdaq.com/articles/aleres-alr-influenza-test-gets-clia-waiver-from-the-fda-analyst-blog-2015-01-07 | nan | nan | Global rapid diagnostic tests company, Alere Inc. ( ALR ), has received a waiver from the U.S. Food and Drug Administration (FDA) which makes way for the company's i Influenza A & B test to be used in a greater variety of health care settings. The Alere i Influenza A & B is a molecular test designed to allow rapid influenza diagnosis.
Alere's Influenza test was earlier available only for use in certain laboratories. As the FDA waiver has been granted under the Clinical Laboratory Improvement Amendments (CLIA), the Alere i Influenza A & B test can now be used across a wide variety of clinical settings, including doctors' chambers, emergency rooms, clinics and other healthcare facilities.
The FDA had first approved the test in June as a prescription-only device, categorizing it as moderately complex and therefore not to be used widely. However, the regulatory body allowed a wider use of the test after the company submitted data demonstrating its ease of use and low risk of false results when used by untrained operators.
Influenza affects millions of people in the U.S. each year. According to the Centers for Disease Control and Prevention, more than 200,000 people in the U.S. are hospitalized for seasonal flu-related complications annually. As per a Reuters report, the current flu season has already recorded 21 deaths so far.
Additionally, influenza poses significant economic burden, which includes medical care expenses and loss of productivity. Thus, rapid diagnosis of the disease can help reduce length of hospital stays, secondary complications and hospital care expenses.
The Alere i Influenza A & B test delivers timely and lab-accurate results on a user-friendly platform. The test uses a nasal swab sample of the patient with signs and symptoms of flu infection and provides results in as little as 15 minutes.
By providing an efficient molecular technology, this Waltham, MA-based company intends to deliver clinically meaningful and actionable results to clinicians - enabling a quicker and appropriate treatment for influenza patients.
Alongside its effort to improve influenza treatment, Alere is also taking steps to advance HIV screening and diagnosis. Notably, Alere's HIV Combo Test was granted a CLIA waiver by the FDA last month. With the CLIA waiver, Alere's HIV test is now available for broader use in HIV screening, facilitating accurate and early detection.
However, competition for rapid diagnostic testing products is intense and is primarily based on price, quality, breadth of product line, technology and distribution capabilities. As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others.
Currently, Alere carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BECTON DICKINSO (BDX): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ALERE INC (ALR): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others. Click to get this free report BECTON DICKINSO (BDX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the regulatory body allowed a wider use of the test after the company submitted data demonstrating its ease of use and low risk of false results when used by untrained operators. | As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others. Click to get this free report BECTON DICKINSO (BDX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report BECTON DICKINSO (BDX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others. Global rapid diagnostic tests company, Alere Inc. ( ALR ), has received a waiver from the U.S. Food and Drug Administration (FDA) which makes way for the company's i Influenza A & B test to be used in a greater variety of health care settings. | Click to get this free report BECTON DICKINSO (BDX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ALERE INC (ALR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. As such, Alere counters significant competition from large diagnostic companies like Becton, Dickinson ( BDX ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ) among others. The Alere i Influenza A & B is a molecular test designed to allow rapid influenza diagnosis. |
34096.0 | 2015-01-02 00:00:00 UTC | IWV, USB, FOXA, ABT: Large Outflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iwv-usb-foxa-abt-large-outflows-detected-etf-2015-01-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $55.0 million dollar outflow -- that's a 0.9% decrease week over week (from 51,550,000 to 51,100,000). Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average:
Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $55.0 million dollar outflow -- that's a 0.9% decrease week over week (from 51,550,000 to 51,100,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60. | Among the largest underlying components of IWV, in trading today U.S. Bancorp (Symbol: USB) is off about 0.3%, Twenty-First Century Fox Inc (Symbol: FOXA) is down about 0.7%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Russell 3000 ETF (Symbol: IWV) where we have detected an approximate $55.0 million dollar outflow -- that's a 0.9% decrease week over week (from 51,550,000 to 51,100,000). For a complete list of holdings, visit the IWV Holdings page » The chart below shows the one year price performance of IWV, versus its 200 day moving average: Looking at the chart above, IWV's low point in its 52 week range is $104.30 per share, with $124.27 as the 52 week high point - that compares with a last trade of $122.60. |
34097.0 | 2014-12-30 00:00:00 UTC | Billionaires Are Gobbling Up These Stocks Right Now | ABT | https://www.nasdaq.com/articles/billionaires-are-gobbling-these-stocks-right-now-2014-12-30 | nan | nan | The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market.
According to recent 13F filings submitted to the SEC, we have learned that billionaire superinvestors have started gobbling up AbbVie , , Celladon Corp. , and Kite Pharma . So let's consider why these stocks are attracting some of the world's best investors right now.
AbbVie is also considered a "dividend aristocrat" because of Abbott's long history of raising its dividend, a tradition AbbVie extended last quarter by raising its dividend 17%, from $0.42 to $0.49 per share, starting in the first quarter of 2015.
The key to AbbVie's rapid rise has been its flagship anti-inflammatory drug Humira, which was the world's best-selling drug in 2013, posting $11 billion in sales.
But it hasn't exactly been smooth-sailing AbbVie or Humira. Because of the drug's nearly unmatched growth profile (double-digit sales growth in every quarter since AbbVie has been an independent company), competitors have raced to reach the market.
In 2012, Humira faced perhaps its biggest threat with Pfizer 's Xeljanz. Management has more than proved its worth, though, by securing favored reimbursement status for Humira with leading pharmacy benefits managers such as Express Scripts. Xeljanz, on the other hand, was excluded from Express Scripts' formulary this year.
Last December, we saw this same scenario play out with AbbVie's new hepatitis C therapy Viekira Pak. After Gilead Sciences refused to lower the price on its market-leading hep C drugs Sovaldi and Harvoni, AbbVie's management was able to negotiate a multiyear agreement with Express Scripts for genotype 1 patients, effectively excluding Gilead's offerings for the most common form of the disease.
We'll have to wait and see how this deal translates into market share and how other pharmacy benefits managers will react to Viekira Pak's approval. But AbbVie looks like an excellent long-term buy for all the reasons I've mentioned.
Baker Brothers take out a big position in Celladon
Billionaires Felix and Julian Baker snapped up 375,000 shares of the clinical-stage biotech Celladon Corp., through their Baker Bros. hedge fund, in the third quarter.
Riding the renewed interest in the field of gene therapy of late, Celladon specializes in diseases associated with so-called SERCA enzymes. These enzymes help regulate intra-cellular calcium in human cells and are believed to be medically important in a diversity of diseases, such as heart failure, vascular disease, and diabetes, among others.
Why did the Baker Brothers jump into Celladon now? This small-cap biotech is expected to announce top-line results in April for its mid-stage study for Mydicar, a gene therapy that targets an enzyme, SERCA2a, that's associated with advanced heart disease.
Put simply, the market would more than likely radically revalue the company if this trial reports positive results. Not only would a positive result allow Celladon to advance Mydicar into a pivotal late-stage trial, but it would also go a long way toward validating the company's therapeutic platform in general.
On the flip side, Celladon's shares have been surging higher in anticipation of this clinical catalyst, meaning that a failure would probably result in a huge drop in share price.
Source: Flickr user Insider Monkey.
George Soros likes Kite Pharma
Hedge-fund guru George Soros has never been afraid to dabble on the speculative side of investing, and he proved as much by gobbling up roughly 660,000 shares of Kite Pharma through its IPO .
Kite Pharma has seen its shares blast higher since its IPO, largely because investors have become enamored with the field of immuno-oncology in general. Even so, Kite's move northward was initially triggered by encouraging early-stage results for KTE-C19 as a potential treatment for aggressive non-Hodgkin's lymphoma. Since these results were made public and the company decided to advance KTE-C19 into mid-stage testing, shares have nearly doubled:
Before investors decide to follow in Soros' footsteps, though, I think there are a few points to consider. First, Kite is probably years away from having a commercial product generating revenue, and as such, the company will have to rely heavily on public offerings to fund its growing clinical activities. Next, Soros is well known for taking profits after a huge run-up like the one Kite has experienced. I therefore wouldn't be surprised to find out next quarter if he already sold most, if not all, of his Kite shares.
Are any of these billionaire picks right for retail investors?
Of these three stocks, AbbVie sticks out as the only compelling buy for the little guy. With strong cash flows, a history of raising its dividend, and a great management team, AbbVie should continue to be a top healthcare stock for a long time.
Celladon and Kite Pharma, on the other hand, might turn out to be better picks because of their huge upside potential. But their risks are simply too high for my taste.
Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted that this emerging technology is threatening his biggest cash cow. Buffett's fear can be your gain. Only a few investors are embracing this new market, which experts say will be worth over $2 trillion . Find out how you can cash in on this technology before the crowd catches on, by jumping on to one company that could get you the biggest piece of the action. Click here to access a free investor alert on the company we're calling the brains behind the technology.
The article Billionaires Are Gobbling Up These Stocks Right Now originally appeared on Fool.com.
George Budwell owns shares of AbbVie and Gilead Sciences. The Motley Fool recommends and owns shares of Berkshire Hathaway, Express Scripts and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days . We Fools don;t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. This small-cap biotech is expected to announce top-line results in April for its mid-stage study for Mydicar, a gene therapy that targets an enzyme, SERCA2a, that's associated with advanced heart disease. With strong cash flows, a history of raising its dividend, and a great management team, AbbVie should continue to be a top healthcare stock for a long time. | AbbVie is also considered a "dividend aristocrat" because of Abbott's long history of raising its dividend, a tradition AbbVie extended last quarter by raising its dividend 17%, from $0.42 to $0.49 per share, starting in the first quarter of 2015. Warren Buffett: This new technology is a "real threat" At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted that this emerging technology is threatening his biggest cash cow. The Motley Fool recommends and owns shares of Berkshire Hathaway, Express Scripts and Gilead Sciences. | AbbVie is also considered a "dividend aristocrat" because of Abbott's long history of raising its dividend, a tradition AbbVie extended last quarter by raising its dividend 17%, from $0.42 to $0.49 per share, starting in the first quarter of 2015. Baker Brothers take out a big position in Celladon Billionaires Felix and Julian Baker snapped up 375,000 shares of the clinical-stage biotech Celladon Corp., through their Baker Bros. hedge fund, in the third quarter. George Soros likes Kite Pharma Hedge-fund guru George Soros has never been afraid to dabble on the speculative side of investing, and he proved as much by gobbling up roughly 660,000 shares of Kite Pharma through its IPO . | The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. Celladon and Kite Pharma, on the other hand, might turn out to be better picks because of their huge upside potential. The Motley Fool recommends and owns shares of Berkshire Hathaway, Express Scripts and Gilead Sciences. |
34098.0 | 2014-12-30 00:00:00 UTC | Omnicare (OCR) Faces Another Kickback Allegation - Analyst Blog | ABT | https://www.nasdaq.com/articles/omnicare-ocr-faces-another-kickback-allegation-analyst-blog-2014-12-30 | nan | nan | Healthcare services company Omnicare Inc. ( OCR ) is facing charges of receiving kickbacks from a pharmaceutical company. The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote.
Depakote is usually used to control the behavior of elderly nursing home residents suffering from dementia. This use, incidentally, has not been approved by the FDA.
However, the news did not have significant on share price movement which was fairly stable over the last 7 days. Nevertheless, this kind of allegation most certainly raises uncertainties regarding the company's long-term financial and liquidity position. Hence, more often than not, investor confidence takes a downturn.
The Department of Justice apparently stated that Omnicare accepted kickbacks disguised as grants and educational funding. The civil complaint alleges that Omnicare's consultant pharmacists recommended the drug in return for tens of millions of dollars in kickbacks between 1998 and 2008. It has been claimed that the sales of the drug increased from $3 million to $92 million during the same time frame.
This is not the first time that Omnicare has found itself caught in legal troubles. Earlier this year, it was alleged that the company paid kickbacks in order to secure contracts to supply drugs to nursing homes with Medicare and Medicaid patients.
The Department of Justice holds that this conduct violates the federal Anti-Kickback Statute and has resulted in the submission of false claims to the Kentucky Medicaid program. Consequently, Omnicare had agreed to a $124 million settlement to resolve the allegations.
Though the company reported an impressive third quarter of 2014 and also recently rewarded its investors with a dividend hike, we feel the kick-back allegations may tarnish Omnicare's image. Since this kind of lawsuits generally take a long time to settle, we believe that it will remain an overhang on the stock.
Zacks Rank
Currently, Omnicare carries a Zacks Rank #2 (Buy). Some other stocks that warrant a look in the Medical Services sector are AMN Healthcare Services ( AHS ) and Catamaran Corp ( CTRX ). These two stocks hold the same rank as Omnicare.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OMNICARE INC (OCR): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
AMN HLTHCR SVCS (AHS): Free Stock Analysis Report
CATAMARAN CORP (CTRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote. Click to get this free report OMNICARE INC (OCR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report CATAMARAN CORP (CTRX): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this year, it was alleged that the company paid kickbacks in order to secure contracts to supply drugs to nursing homes with Medicare and Medicaid patients. | Click to get this free report OMNICARE INC (OCR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report CATAMARAN CORP (CTRX): Free Stock Analysis Report To read this article on Zacks.com click here. The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote. Some other stocks that warrant a look in the Medical Services sector are AMN Healthcare Services ( AHS ) and Catamaran Corp ( CTRX ). | The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote. Click to get this free report OMNICARE INC (OCR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report CATAMARAN CORP (CTRX): Free Stock Analysis Report To read this article on Zacks.com click here. The civil complaint alleges that Omnicare's consultant pharmacists recommended the drug in return for tens of millions of dollars in kickbacks between 1998 and 2008. | The U.S. Justice Department has alleged that Omnicare received unauthorized money from Abbott Laboratories ( ABT ) for recommending the latter's prescription drug, Depakote. Click to get this free report OMNICARE INC (OCR): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AMN HLTHCR SVCS (AHS): Free Stock Analysis Report CATAMARAN CORP (CTRX): Free Stock Analysis Report To read this article on Zacks.com click here. Healthcare services company Omnicare Inc. ( OCR ) is facing charges of receiving kickbacks from a pharmaceutical company. |
34099.0 | 2014-12-30 00:00:00 UTC | Health Care Sector Update for 12/30/2014: NDRM,BGMD,CTSO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12302014-ndrmbgmdctso-2014-12-30 | nan | nan | Top Health Care Stocks
JNJ +0.10%
PZE +0.19%
MRK +0.31%
ABT +0.01%
AMGN -1.12%
Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group.
In company news, NeuroDerm Ltd. ( NDRM ) rallied Tuesday, with shares of the recently minted biotech company more than doubling today after Phase IIa testing of its experimental drug combination for Parkinson's disease indicates it could be an effective alternative to current treatments requiring surgery.
Using a belt-worn pump to provide continuous, subcutaneous delivery of the company's proprietary liquid levodopa and carbidopa drug candidates, the combination resulted in clinically-significant plasma levodopa levels in Parkinson's patients, also reducing fluctuations observed with oral dosing.
NDRM shares were up nearly 194% at $18.16 apiece in late trade after earlier racing to a new record high of $19.07 a share. Since pricing its initial public offering of 4.5 million shares at $10 apiece Nov. 14, the stock had declined more than 38% through yesterday's close, touching an all-time low of $5.67 less than two weeks ago on Dec. 19.
In other sector news,
(+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer.
(-) CTSO, Submits Investigational Device Exemption application to begin clinical testing of its CytoSorb filter in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. In company news, NeuroDerm Ltd. ( NDRM ) rallied Tuesday, with shares of the recently minted biotech company more than doubling today after Phase IIa testing of its experimental drug combination for Parkinson's disease indicates it could be an effective alternative to current treatments requiring surgery. Since pricing its initial public offering of 4.5 million shares at $10 apiece Nov. 14, the stock had declined more than 38% through yesterday's close, touching an all-time low of $5.67 less than two weeks ago on Dec. 19. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. | In other sector news, (+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. In company news, NeuroDerm Ltd. ( NDRM ) rallied Tuesday, with shares of the recently minted biotech company more than doubling today after Phase IIa testing of its experimental drug combination for Parkinson's disease indicates it could be an effective alternative to current treatments requiring surgery. | In other sector news, (+) BGMD, FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Top Health Care Stocks Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.